



OF CATALYTIC ENZYME ACTIVITY
Dissertation
for the award of the degree
"Doctor rerum naturalium"
of the Georg-August-Universität Göttingen
within the doctoral program Chemistry







Prof. Dr. Ulf Diederichsen
Institute of Organic and Biomolecular Chemistry, University of Göttingen
Prof. Dr. Kai Tittmann
Department of Molecular Enzymology, University of Göttingen
Members of the Examination Board
Referee:
Prof. Dr. Ulf Diederichsen
Institute of Organic and Biomolecular Chemistry, University of Göttingen
2nd Referee:
Prof. Dr. Kai Tittmann
Department of Molecular Enzymology, University of Göttingen
Further Members of the Examination Board
Prof. Dr. Manuel Alcarazo
Institute of Organic and Biomolecular Chemistry, University of Göttingen
Prof. Dr. Claudia Steinem
Institute of Organic and Biomolecular Chemistry, University of Göttingen
Dr. Sebastian Kruss
Institute of Physical Chemistry, University of Göttingen
Dr. Michael John
Institute of Organic and Biomolecular Chemistry, University of Göttingen
Date of oral examination: September 25, 2019
The work described in this thesis was carried out under the supervision of Prof.
Dr. Ulf Diederichsen at the Institute of Organic and Biomolecular Chemistry of the
Georg-August University of Göttingen between November 2015 and August 2019 in
close cooperation with Prof. Dr. Kai Tittmann at the Department of Molecular Enzy-
mology of the Georg-August University of Göttingen.
Parts of Chapter 2 of this thesis have been published as:
S. Johansson, P. Neumann, A. Wulff, L.M. Welp, H.-D. Gerber, M. Krull, U. Diederich-
sen, H. Urlaub, R. Ficner, "Structural insights into the stimulation of S. pombe Dnmt2
catalytic efficiency by the tRNA nucleoside queuosine", Scientific Reports, 2018,
8:8880.
Declaration of Authorship
Hereby, I declare that I prepared the doctoral thesis entitled "Synthesis of rare
nucleobases and artificial nucleotides for investigation of catalytic enzyme activity"








1. Mechanistic study of orotidine-5’-monophosphate-deca rboxylase 5
1.1. Motivation and objectives . . . . . . . . . . . . . . . . . . . . . . . . . 5
1.2. Orotidine-5’-monophosphate-decarboxylase (OMPD) . . . . . . . . . . 7
1.2.1. Structure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
1.2.2. Substrate binding . . . . . . . . . . . . . . . . . . . . . . . . . . 9
1.3. Possible decarboxylation mechanisms . . . . . . . . . . . . . . . . . . 12
1.4. Synthesis of OMPD Inhibitors . . . . . . . . . . . . . . . . . . . . . . . 15
1.4.1. OMP (1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
1.4.2. BMP (3) and 6-aza-UMP (4) . . . . . . . . . . . . . . . . . . . . 20
1.4.3. 6-Amido-UMP (8) . . . . . . . . . . . . . . . . . . . . . . . . . . 21
1.4.4. 6-Isopropyl-UMP (9) . . . . . . . . . . . . . . . . . . . . . . . . 22
1.4.5. Dithio-OMP (6) . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
1.4.6. 6-Nitro-UMP (5) . . . . . . . . . . . . . . . . . . . . . . . . . . 30
1.5. Examination of hOMPD-inhibitor complexes using cryo-crystallography 35
1.5.1. hOMPD-BMP complex . . . . . . . . . . . . . . . . . . . . . . . 36
1.5.2. hOMPD-6-Aza-UMP complex . . . . . . . . . . . . . . . . . . . 37
1.5.3. hOMPD-6-Amido-UMP complex . . . . . . . . . . . . . . . . . 40
1.5.4. hOMPD-6-Thiocarboxamido-UMP complex . . . . . . . . . . . 42
1.5.5. hOMPD-6-Isopropyl-UMP complex . . . . . . . . . . . . . . . . 44
1.5.6. hOMPD-6-Methyl-UMP complex . . . . . . . . . . . . . . . . . 46
1.5.7. hOMPD-6-Isopropenyl-UMP complex . . . . . . . . . . . . . . 48
1.5.8. hOMPD314AcK-OMP complex . . . . . . . . . . . . . . . . . . . 50
1.5.9. hOMPD314AcK-BMP complex . . . . . . . . . . . . . . . . . . . 53
1.6. Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
1.6.1. New insights into enzyme substrate interactions . . . . . . . . 55
1.6.2. Mechanistic implications . . . . . . . . . . . . . . . . . . . . . . 59
1.7. Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
1.8. Outlook . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
2. Stimulation of S. pombe Dnmt2 by the micronutrient queuine 67
2.1. Motivation and objectives . . . . . . . . . . . . . . . . . . . . . . . . . 67
2.2. Dnmt2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
2.3. Queuosine biosynthesis . . . . . . . . . . . . . . . . . . . . . . . . . . 70
2.4. Chemical synthesis of queuine and queuosine . . . . . . . . . . . . . 72
2.4.1. Synthetic strategies for queuosine . . . . . . . . . . . . . . . . 72
2.4.2. Synthetic strategies for queuine . . . . . . . . . . . . . . . . . . 76
2.4.3. Improved syntheses for the cyclopentylamino building block 63 78
2.4.4. Recent synthetic strategies for queuine . . . . . . . . . . . . . 80
2.5. New synthesis of (1R,2S,3S)-1-bromo-2,3-O-isopropylidene-
cyclopent-4-ene (122) . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
2.6. Stimulation of S. pombe Dnmt2 by queuine . . . . . . . . . . . . . . . 89
2.7. Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
3. Experimental section 95
3.1. General Equipment and Methods . . . . . . . . . . . . . . . . . . . . . 95
3.2. Characterization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96
3.3. X-ray diffraction data collection and processing . . . . . . . . . . . . . 97
3.4. Synthesis of orotidine analogues . . . . . . . . . . . . . . . . . . . . . 98
3.4.1. 2’,3’-O-Isopropylidene-uridine (11) . . . . . . . . . . . . . . . . 98
3.4.2. 5’-O-Tertbutyldimethylsilyl-2’,3’-O-isopropylidene-
uridine (12) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
3.4.3. 5’-O-Tertbutyldimethylsilyl-2’,3’-O-isopropylidene-
orotidine (13) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100
3.4.4. Orotidine (14) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
3.4.5. Orotidine-5’-monophosphate (1) . . . . . . . . . . . . . . . . . 102
3.4.6. 2,4,6-tris-trimethylsilyloxy-pyrimidine (16) . . . . . . . . . . . . 103
3.4.7. 2’,3’,5’-Tri-O-benzoyl-6-hydroxyuridine (18) . . . . . . . . . . . 104
3.4.8. 6-Hydroxyuridine (19) . . . . . . . . . . . . . . . . . . . . . . . 105
3.4.9. Barbituric-acid-ribonucleoside-5’-monophosphate (3) . . . . . . 106
3.4.10. 6-Azauridine-5’-monophosphate (4) . . . . . . . . . . . . . . . 107
3.4.11. 5’-O-Tertbutyldimethylsilyl-2’,3’-O-isopropylidene-
orotidinemethylester (21) . . . . . . . . . . . . . . . . . . . . . 108
3.4.12. 5’-O-Tertbutyldimethylsilyl-2’,3’-O-isopropylidene-
6-amidouridine (22) . . . . . . . . . . . . . . . . . . . . . . . . 109
3.4.13. 6-Amidouridine (23) . . . . . . . . . . . . . . . . . . . . . . . . 110
3.4.14. 6-Amidouridine-5’-monophosphate (8) . . . . . . . . . . . . . . 111
3.4.15. Orotidinemethylester (24) . . . . . . . . . . . . . . . . . . . . . 112
3.4.16. 5-Iodouridine (26) . . . . . . . . . . . . . . . . . . . . . . . . . 113
3.4.17. 5’-O-Tertbutyldimethylsilyl-2’,3’-O-isopropylidene-
5-iodouridine (27) . . . . . . . . . . . . . . . . . . . . . . . . . 114
3.4.18. 5’-O-Tertbutyldimethylsilyl-2’,3’-O-isopropylidene-
6-cyanouridine (28 . . . . . . . . . . . . . . . . . . . . . . . . . 115
3.4.19. 5’-O-Tertbutyldimethylsilyl-2’,3’-O-isopropylidene-
6-isopropyluridine (29) . . . . . . . . . . . . . . . . . . . . . . . 116
3.4.20. 6-Isopropyluridine (30) . . . . . . . . . . . . . . . . . . . . . . . 117
3.4.21. 6-Isopropyl-UMP (9) . . . . . . . . . . . . . . . . . . . . . . . . 118
3.4.22. 5’-O-Tertbutyldimethylsilyl-2’,3’-O-isopropylidene-
dithioorotidinebenzylester (35) . . . . . . . . . . . . . . . . . . 119
3.4.23. Dithioorotidinebenzylester (36) . . . . . . . . . . . . . . . . . . 121
3.4.24. Dithioorotidine-5’-monophosphatebenzylester (37) . . . . . . . 122
3.5. Synthesis of queuine . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123
3.5.1. Methyl-6-deoxy-6-iodo-3,4-O-isopropylidene-
α-D-galactopyranoside (139) . . . . . . . . . . . . . . . . . . . 123
3.5.2. Methyl-6-deoxy-6-iodo-3,4-O-isopropylidene-2-O-tertbutyl-
dimethylsilyl-α-D-galactopyranoside (140) . . . . . . . . . . . . 125
3.5.3. (2R,3S,4S)-3,4-O-Isopropylidene-2-O-tertbutyl-
dimethylsilyl-hex-5-en-1-al (141) . . . . . . . . . . . . . . . . . 126
3.5.4. (2R,3S,4S)-3,4-O-Isopropylidene-2-O-tertbutyl-
dimethylsilyl-hepta-1,5-diene (142) . . . . . . . . . . . . . . . . 127
3.5.5. (1S,2S,3S)-1-O-tertbutyldimethylsilyl-2,3-O-isopropylidene-
cyclopent-4-ene (145) . . . . . . . . . . . . . . . . . . . . . . . 128
3.5.6. (2R,3S,4S)-2-Hydroxy-3,4-O-isopropylidene-
hepta-1,5-diene (143) . . . . . . . . . . . . . . . . . . . . . . . 129
3.5.7. (1S,2S,3S)-1-Hydroxy-2,3-O-isopropylidene-
cyclopent-4-ene (130) . . . . . . . . . . . . . . . . . . . . . . . 130
3.5.8. (1R,2S,3S)-1-Bromo-2,3-O-isopropylidene-
cyclopent-4-ene (122) . . . . . . . . . . . . . . . . . . . . . . . 131
3.5.9. 2’,3’-O-Isopropylidene-queuine (144) . . . . . . . . . . . . . . . 132
3.5.10. Queuine (95) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133
3.5.11. Benzyl-β-D-galactopyranoside (132) . . . . . . . . . . . . . . . 134
3.5.12. Benzyl-6-O-tertbutyldimethylsilyl-β-D-galactopyranoside (133) 135
Bibliography 136
Appendix 145
A. Abbreviations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 145
B. Crystal data collection and refinement data . . . . . . . . . . . . . . . 147
Introduction
In 1828 Friedrich Wöhler synthesized urea by heating of ammoniumcyanate. This
experiment proved that organic compounds can be synthesized in vitro from inor-
ganic materials without the necessity of a vital force (lat. vis vitalis), as it was con-
viction in those days. Based on this discovery, biochemistry developed from the
three disciplines of natural science (physics, chemistry and biology) in the second
half of the 19th century. Structure elucidation of biochemical compounds was very
expensive, time consuming and often not successful at first. With the development
of new methods for structure analysis in the 20th century, biochemistry made a fast
development. Two events are especially noteworthy. The finding of desoxyribonu-





















































































































































Figure 0.1. Simple model of a DNA double
strand.[2]
Nucleic acids are an important class
of biomolecules. In 1943 Avery iden-
tified the deoxyribonucleic acid (DNA)
as the carrier of genetic information.[3]
In 1953 Watson and Crick decrypted
the structure of DNA. They introduced
a model of four nucleotides (adenine,
guanine, cytosine and thymine) which
build up polymers with random se-
quences. The result of the sequence
is a code which contains the genetic in-
formation. In pairs of two, each duo
is able to form two or three hydrogen
bonds between each other. Due to
these bonds, two complementary strands
can assemble to one double strand and




Furthermore, base pairing ensures replication of genetic information by synthe-
sizing copies of complementary strands, which enables cell division and transfer of
genetic information from mother cells to daughter cells. Moreover, base sequences
in DNA can be transcripted into RNA sequences, which act as a templates for amino





















































































































































Figure 0.2. Models of protein secondary struc-
tures.[6]
Beside nucleic acids, proteins have ex-
ceptional value in organisms due to their
broad range of tasks. They can act as
signal transmitters, catalytic active en-
zymes or form structural stability in cells.
This complexity is achieved by the inner
structure of proteins. They consist of up
to 20 amino acids, which bind together
to build up polymers. The variability in
the sequence of amino acids result in a
huge number of combinatorial possibili-
ties, which lead to their broad range of
tasks. With the knowledge that enzymes
act as bio catalysts researchers took an
interest in the mechanisms with which this class of proteins achieves their tasks.
The introduction of x-ray diffraction in the 1930’s, opened the field of protein analyt-
ics as a new discipline in biochemistry. In 1934 Bernal and Hodgkin used this new
method to prove that proteins show defined structures in solution.[7] In 1951 Pauling
and Corey identified the α-helix and β-sheet as the central secondary structures in
proteins. (figure 0.2).[8]
Enzymes are also involved in replication, transcription and translation of DNA, as
well as the synthesis of nucleobases. The roles and mechanisms for many of these
enzymes stay broadly unknown until today. The herein presented projects are based
on the research of the enzymatic activity of selected enzymes, which are important
for the synthesis and modification of nucleobases.
Chapter 1 describes the synthesis of uridine-derivatives for co-crystallization with
orotidine-5’-monophosphatedecarboxylase (OMPD). This enzyme catalyzes the last
2
step in the de novo biosynthesis of pyrimidine-nucleotides and shows an extreme
high catalytic activity. Therefore, investigation of the natural enzyme-substrate com-
plex is impossible with currently available methods. By decreasing the catalytic ac-
tivity with suitable substrate-derivatives, a targeted investigation of the mechanism
should be possible.
Chapter 2 describes the development of a new synthetic route for the rare nucle-
obase queuine, with focus on the cyclopentadiene part. Via in vitro introduction of




1. Mechanistic study of orotidine-5’-
monophosphate-decarboxylase
1.1. Motivation and objectives
Cell division is one of the essential biochemical processes and of exceptional im-
portance for the survival and reproduction of all organisms from protozoic bacterium
right up to high developed multicellular animals and humans. To transfer the genetic
information from the mother cell to the daughter cell, the DNA has to be duplicated
prior to cell division. For this process, large amounts of nucleotides are required, in
relation to the rate of division. As for most eukaryotes, humans are able to obtain
most of the required nucleotides via a salvage pathway, by degradation of nucleic
acids. This is the preferred pathway due to its energetic efficiency.[9] Some cells like
hair roots, liver cells and skin cells, but also malignant tumor cells show an extremely
high division rate and therefore need more nucleotides than the salvage pathway is
able to produce. These cells need to synthesize nucleotides from the ground up via
the de novo pathway (scheme 1.1). Inhibition of this pathway might be an interesting
target for the development of new therapies against cancer. Like most in vivo syn-
theses the de novo pathway is a cascade of many single steps. To develop specific
therapies it is necessary to understand the mechanism of the de novo pathway in
general and the mechanisms of the involved enzymes in particular.
The most interesting enzyme involved in the de novo pathway is orotidine-5’-
monophosphate-decarboxylase (OMPD 6©), which catalyzes the last step in the de
novo synthesis of pyrimidine nucleotides by decarboxylation of orotidine-5’-mono-
phosphate (1) to uridine-5’-monophosphate (2). OMPD shows one of the highest
catalytic activities of all known enzymes, especially regarding the fact that it works
without metal ions or other co-factors. The decryption of the mechanism of OMPD
has been the topic of many studies in past years. However, aside of postulates and
proposals, no verified mechanism has been published until today.
5
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Scheme 1.1. Pathway of the de novo pyrimidine synthesis.
1© carbamylphosphate synthetase; 2© aspartate transcarbamylase; 3© dihydroorotase; 4© dihy-
droorotate dehydrogenase; 5© orotate phosphoribosyltransferase; 6© orotidine 5’-monophosphate
decarboxylase.[10]
As of now, no enzyme-substrate complex structure has been published, due to the
extreme acceleration of OMPD catalyzed decarboxylation. To understand how the
enzyme is able to be so proficient without usage of metal ions, prosthetic groups or
other cofactors, crystal structures are necessary to get more information of substrate
binding to the active site. Due to recent improvements of x-ray diffraction data collec-
tion, much better resolved structures are obtainable these days. Within this thesis,
new modified substrates were synthesized to act as inhibitors for OMPD. In order
to obtain new information about active site binding these modified substrates and
OMPD were cocrystallized and structures were measured via x-ray diffraction. All







In 2000 the first crystal structures of orotidine-5’-monophosphate-decarboxylase
from the organism B. subtilis, E. coli, M. thermoautotrophicum and S. cervisiae were
published and provided new insights into the general structure of OMPD.[11]–[14] Crys-
tal structures of OMPDs from other organisms followed a few years later, including
human OMPD.[15], [16] This new information lead to better understanding of the en-
zyme structure. The active OMPD is a homodimeric enzyme, consisting of two
identical subunits with two active sites (figure 1.1).[15] Differences between bacteria
and eukaryotes were identified. In bacteria OMPD appears in form of a single do-
main, whereas in eukaryotes OMPD is a part of the bifunctional enzyme complex
uridine-5’-monophosphate-synthetase (UMPS).[17] Beside OMPD which is located at
the C-terminal end, the UMPS complex includes orotate-phosphoribosyl-transferase





















































































































































Figure 1.1. Structure of the OMPD dimer from M. thermoautotrophicum complexed with BMP (PDB
entry: 4FX8).[18]
(BMP is not displayed), α-helices and β-sheets are colored in blue and green, respectively. The
phosphate gripper loop is coloured in yellow.
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1. Mechanistic study of orotidine-5’-monophosphate-decarboxylase
Each OMPD monomer forms a TIM barrel, which consist of eight parallel aligned
β-sheet structures, forming a β-barrel and an outer sphere consisting of multiple
α-helices.[19] The α and β motifs are connected in an alternating fashion by loop
regions (figure 1.2). The exact number of these structures vary among different
organisms. The OMPD monomers are stacked at the C-terminal end of the TIM
barrels to form the catalytic active OMPD dimer, induced by substrate binding or by
addition of NaCl to the buffer solution.[17], [20]–[22] Two active sites are formed at the
monomer interfaces. Part of the active site pockets is a flexible loop region, which
binds to the phosphate and ribose part of OMP. Due to the flexibility of this phosphate
gripper loop, binding of the substrate induces a conformational change of the OMPD
dimer.[12] For different organisms, the length of the gripper loop varies in a range
from 10 to 20 amino acid residues. The longer the loop, the higher the entropic cost,
when the loop closes around the substrate. However, this disadvantage in entropy





















































































































































Figure 1.2. Structure of the OMPD monomer from M. thermoautotrophicum (PDB entry: 4FX8).[18]
left: side-view, right: top-view, α-helices and β-sheets are colored in blue and green, respectively.
The phosphate gripper loop is coloured in yellow.
Opposite of the phosphate gripper loop the active site is located, which looks very
similar in all domains of life, ranging from bacteria to higher evolved eukaryotes, like
plants and mammals. The amino acid residues, which are part of the active site or
are located in close proximity, appear to be highly conserved.[24] The TIM barrels
form a rigid framework, which conserves the important catalytic active amino acid
residues, while also possess some flexibility due to the loop regions, allowing confor-
mational changes during substrate binding and decarboxylation.[25], [26] The central
part of these conserved residues consist of two alternating aspartates and lysines,
forming the catalytic tetrad (figure 1.3). Mutation at one of these residues lead to
significant loss of catalytic activity.[11] This tetrad is mostly part of one TIM barrel with


























































































































































Figure 1.3. Catalytic tetrad from the active site of M. thermoautotrophicum complexed with BMP.
(PDB entry: 4FX8).[18]
α-helices and β-sheets are colored in blue and green, respectively. The phosphate gripper loop is
coloured in yellow.
active site is surrounded by a cage of hydrophobic amino acid residues, shielding it
from solvent and keeping it nearly water free after substrate binding. Additionally, a
hydrophobic pocket is formed near to the C6 carboxy group of the substrate. This
pocket is considered to harbor the produced carbon dioxide. However, no CO2 could
be detected in the pocket yet.[15], [21], [28]
1.2.2. Substrate binding
Substrates are bound to the OMPD active site via a complex network of hydrogen
bonds from the phosphate, ribose and pyrimidine part of the substrate to the amino
acid side chains from the phosphate gripper loop, the pyrimidine umbrella and the
catalytic tetrad of OMPD (figure 1.4).[16] In human OMPD the phosphate part of sub-
strates forms two hydrogen bonds to Gly430 and Tyr432 of the phosphate gripper loop
and four additional bonds to the side chains and the backbone of Arg451 and Gly450.
The ribose part is bound to Asp259, Ser257, Thr’321, as well as Lys281 and Asp’317 of the
catalytic tetrad by six hydrogen bonds. Finally, the substrate pyrimidine is bound to
Ser372 from the pyrimidine umbrella at O4 and N3 and to Gln430 from the phosphate
9





























































































































































Figure 1.4. Binding of UMP to the active site of human OMPD (PDB entry: 3EX1).[16]
Hydrogen bonds are depicted as dashed yellow lines.
gripper loop at O2. Via coordination to the amino acid residues the pyrimidine ring
is forced into the energetically unfavored syn conformation, aligning C6 substituents
toward the catalytic tetrad.[11], [29]
However, the active site is considered rather small regarding the space needed
by the substrate bound in syn conformation. This results in a clash of the C6 sub-
stituent with Asp312 of the catalytic tetrad. In the case of OMP being the substrate,
Wu et al. assumed that ground state destabilization due to electrostatic repulsion
is a part of the decarboxylation mechanism. The repulsion leads to distortions at
the C6 substituent, showing rotation around the C6-C7 axis and bending out of the
pyrimidine plane.[15], [16], [30], [31] Nonetheless, C6 substrate distortion do not seem to






















































































































































Figure 1.5. Conformational change of OMPD from P. falciparum induced by ligand binding. (PDB
entries: 2ZA2, 2ZA3)[34]
α-helices and β-sheets are colored in blue and green, respectively. The phosphate gripper loop is
coloured in yellow.
was also observed.[30], [32] The necessary energy to force the syn conformation is
gained by phosphate and ribose binding.[33]
Upon substrate binding OMPD undergoes some conformational changes around
the active site. An open form, without bound substrate and a closed form with sub-
strate in the active site can be differentiated (figure 1.5). Mainly, the phosphate grip-
per loop is moving towards the active site, caused by hydrogen bonding of Gln430 to
the pyrimidine part of the ligand, closing the active site and resulting in exclusion of
solvent molecules.[14], [35] Additionally, movement of some α-helices closer the active
site causing rearrangement of some amino acid residues involved in substrate bind-
ing as well as a minor rearrangement of the catalytic tetrad.
Like mutations at the catalytic tetrad residues, mutations at the binding regions
also reduce catalytic activity, though in much lesser severity. Exchange of residues
involved in pyrimidine binding may enable the ligand to adopt anti conformation,
flipping the C6 substituent away from the catalytic tetrad.[27], [36] A similar effect was
observed for the ribose binding residues. Failures in the hydrogen bond network are
assumed to cause more flexibility of the ligand, which enables the C6 substituent to
evade the catalytic tetrad.[37]
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1.3. Possible decarboxylation mechanisms
The mechanism of OMPD catalyzed decarboxylation is a topic of discussion for al-
most 40 years now.[29], [38]–[40] Regarding the enormous efficiency of OMPD, it is very
difficult to obtain suitable data. NMR spectroscopy is not viable due to the size
of the enzyme. Moreover, the method is too slow for the reaction timescale. IR
spectroscopy is able to provide data but the results are very difficult to interpret.[41]
However, OMPD shows good expressibility and can be crystallized reliably. There-
fore, x-ray diffraction is the best suited method, although the reaction remains too
fast to be directly observable. To get insights into substrate binding, OMPD mutants
and substrate analogs were used and are the basis of the following mechanistic pro-
posals, alongside kinetic measurements. The possible mechanisms are manifold
and ranging from covalent bound intermediates, over concerted reactions to spon-















































































































































































































Scheme 1.2. Overview of proposed mechanisms of OMPD catalyzed decarboxylation.[29], [45], [46]
The first possible mechanism was proposed by Beak and Siegel. They suggested
a protonation at O2 leading to yilide formation and a positive charge located at N1
(scheme 1.3). Decarboxylation would lead to formation of a zwitterionic intermedi-
12
1.3. Possible decarboxylation mechanisms
ate which is stabilized by tautomerism. Their proposal is supported by observations
of an 108-fold increase of uncatalyzed decarboxylation velocity in C2 methylated 1-
methylorotate compared to unmodified 1-methylorotate.[43], [47] Additionally, Shostak
and Jones observed a significant loss of activity using 2-Thio-OMP and 4-Thio-OMP
as substrate analogs. However, it remains unclear if this effect is due to lower pro-
tonation at C2 and C4 position or worse fixation of the pyrimidine ring as a result
of weaker hydrogen bonding to the thiocarbonyl groups.[44], [48], [49] A similar mecha-
nism was proposed by Lee and Houk. They reported a protonation at O4 which gets
stabilized as a carbene at C6, following decarboxylation. However, no proton donor














































































































































































Scheme 1.3. Nitrogen-yilide mechanism postulated by Beak and Siegel.[43]
Silverman and Groziak proposed a covalent mechanism, although this reaction
type is very rare in enzyme catalysis.[42] In this proposal Lys314 acts as a nucleophile
attacking C5 of the pyrimidine ring in a Micheal-addition, followed by elimination of
CO2 with Lys314 as the leaving group (scheme 1.4). This mechanism is supported
by the finding that any mutation at Lys314 leads to almost complete loss of activity,
which can be regained by renaturation (Smiley and Jones).[20] However, Lys314 may
be the most important amino acid residue in other mechanisms as well. Therefore,















































































































































































Scheme 1.4. Covalent mechanism postulated by Silverman and Groziak.[42]
Kollman et al. proposed a protonation-elimination mechanism at C5 with a car-
bene intermediate at C6 (scheme 1.5). This mechanism is supported by out of
plane distortion of the C6-C7 bond, indicating a change of geometry at C5 by switch-
ing from sp2 to sp3 hybridization.[15], [32], [44] In this case, 5,6-dihydroorotidine should
be a strong inhibitor for OMPD. Yet, kinetic studies revealed 5,6-dihydroorotidine
13
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to bind very poorly to OMPD. Moreover, no crystal structures complexed with 5,6-


















































































































































































Scheme 1.5. C5 protonation mechanism postulated by Kollman et al.[44]
A concerted mechanism with release of CO2 and simultaneous protonation was
proposed by Appleby et al. (scheme 1.6) The reaction proceeds without change of
geometry at C6. Support for this proposal comes from computations suggesting no
geometrical change at N1, C5 and C6. Additionally, no secondary isotope effect was
observed.[11], [51]–[53] However, if the reaction is concerted the product UMP should
be 100% protonated in 50:50 v/v H2O, D2O due to the fact that protonation should















































































































































































Scheme 1.6. Concerted mechanism postulated by Appleby et al.[11]
Another possible mechanism was proposed by Wolfenden et al., suggesting a
spontaneous decarboxylation facilitated via ground state destabilization by electro-
static repulsion (scheme 1.7). The resulting negative charge remains located at C6







































































































































































Scheme 1.7. Direct decarboxylation mechanism postulated by Wolfenden et al.[37]
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1.4. Synthesis of OMPD Inhibitors
To get more insight into the mechanism of OMPD catalyzed decarboxylation, crys-
tal structures are a very useful tool. To obtain these structures, the substrate get
soaked into the precrystallized resting state enzyme and is then measured via x-ray
diffraction. Unfortunately, the decarboxylation is too fast in the OMP-OMPD complex
to obtain crystal structures using current methods. To get structural information, two
options are available. First, OMPD mutants can be used, which show decreased or
no activity. The other option to gain information is usage of substrate analogues,
which are similar to OMP in terms of geometry and electronic structure. Another
option, are transition state analogues, trapping the enzyme at the energy minimum.
However, the information gained by both options might belong to artificial structures
and are prone to be misinterpreted. In this work new substrate- and transition state
analogues were synthesized, which were designed to gain specific information about
the structure of the active site and its interactions with the substrate. Additionally,
some known inhibitors were synthesized in order to reevaluate published results with
higher resolved structures.
Studies from Miller and Wolfenden with the competitive inhibitor BMP (3) demon-
strated highly effective inhibition characteristics.[39] They proposed a deprotona-
tion at the C6-hydroxy group, forming a C6-hydroxylate anion, which mimics the C6
anion transition state and results in trapping the enzyme at the energy minimum.
This hypothesis should be verified using modern methods of crystallization and x-
ray diffraction to obtain new high resolution structures of the OMPD-BMP complex.
Therefore BMP should be synthesized following known protocols. Moreover, 6-aza-
UMP (4) was a synthetic target to evaluate the possibility of a carbene intermediate
at C6, which may result from shift of the negative charge to the O4 oxygen. In this
case the electron lone pair of the N6 nitrogen would mimic the carbene lone pair,























































































































































































Scheme 1.8. Transition state analogues: left: BMP (3); right: 6-aza-UMP (4)
15
1. Mechanistic study of orotidine-5’-monophosphate-decarboxylase
Earlier studies from Pai et al. revealed an out of plane distortion of the C6-C7 axis
from the pyrimidine ring plane.[32], [33] The reason for this distortion could not be veri-
fied exactly and remains unclear until today. In research community an electrostatic
repulsion between the carboxylate group at C6 and Asp312 of the catalytic tetrad is
the favored reason for this out of plane distortion. However, aside from OMPD mu-
tants, no OMP-OMPD-structure is known so far to support the electrostatic repulsion
hypothesis. The synthesis of OMP analogues, which are isoelectronic to OMP (1)
and posses identical geometric properties, should help to evaluate the interactions
of the catalytic tetrad with the C6 carboxy group. For this purpose new substrate
analogues should be synthesized (scheme 1.9). Best suitable are 6-nitro-UMP (5)
and 6-dithiocarboxy-UMP (6), which are isoelectronic and geometric identical to
OMP (1). Other geometric suitable analogues are 6-boryl-UMP (7) and 6-amido-
UMP (8). The latter should be synthesized to detect possible attractive interactions,
in case that the OMP-C6 carboxy group remains protonated. To evaluate the OMPD
active site with respect to steric tolerance and to determine how non-electrostatic



















































































































































































































Scheme 1.9. Substrate analogues: isoelectronic: 6-nitro-UMP (5), 6-dithiocarboxy-UMP (6); geo-
metric identical: 6-boryl-UMP(7), 6-amido-UMP (8); sterically demanding: 6-isopropyl-UMP (9).
Overall, modifications at C6 position are best tolerated by the active site, evi-
denced by relatively low Kd values of C6 modified UMP derivatives. Modifications
at O2 and O4, as well as at the phosphate result in much higher Kd values and
poor binding affinity to OMPD. Especially phosphate modification lead to signifi-
16
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cant loss of catalytic activity. In case of S. cervisiae the activity is decreased by
109, when 1-orotidyl-β-D-erythrofuranoside and phosphite anions are used as sub-
strate.[39], [54], [55] Moreover, co-crystallization experiments failed completely, when
nucleosides and phosphite were used instead of the corresponding well crystaliz-
able nucleotide inhibitors.[56]
For modifications at the pyrimidine, electrophilic aromatic substitution is suitable,
due to the aromatic character of the pyrimidine heterocycle. However, the dou-
ble bond between C5 and C6 possesses significant olefin character, enabling elec-
trophilic addition and, because of the conjugation to the O4 carbonyl, Michael addi-
tion. For aromatic heterocycles an alternating electron density at the carbon-atoms
is common. In the case of pyrimidine the C6 carbon possesses significant less elec-
tron density compared to the C5 carbon. This enables polarity inversion at C6 via
lithiation with strong bases, followed by reaction with electrophiles as another syn-






















































 E   = F, Cl, Br, I, NO2
 X   = Br, I
Nu  = CN, NR2 (soft nucleophiles)

























































































































































Scheme 1.10. Suitable synthetic strategies for uridine functionalisation.
a) electrophilic aromatic substitution; b) electrophilic addition; c) polarity inversion at C6 and subse-
quent reaction with an electrophile; d) Michael addition at C6 followed by elimination at C5.[50]
In order to avoid any side reactions at the ribose unit during pyrimidine modi-
fication, the hydroxy groups at C2’, C3’ and C5’ had to be protected prior to C6
functionalisation. Suitable protecting groups need to be stable under harsh basic
17
1. Mechanistic study of orotidine-5’-monophosphate-decarboxylase
conditions and should be cleavable under slightly acidic conditions. Starting from
uridine (10) full protection was achieved in two steps (scheme 1.11). Due to the
syn configuration of the hydroxy groups at C2’ and C3’ an isopropylidene protecting
group was chosen, which can be attached easily by reaction with acetone under
slightly acidic conditions. The resulting C2’-C3’ protected uridine 11 was used in
the next step after chromatographic purification. The remaining hydroxy group at
C5’ was protected using tert-butyldimethylsilylchloride (TBDMSCl) and imidazole in
DMF. After purification by column chromatography the fully protected uridine 12 was
obtained with 85% yield over two steps in multi gramm scale and was used as the











































































































































































Scheme 1.11. Protection of uridine (10) to obtain compound 12.
1.4.1. OMP (1)
In order to test the overall reaction conditions for protection and deprotection, as
well as phosphorylation and purification of the crude nucleotides, OMP (1) was syn-
thesized following the protocol from D. Heinrich.[50] To apply a shorter synthesis
sequence and purification by HPLC, the reaction process was modified. Aside from
testing conditions the synthesized OMP (1) was used by the Tittmann group as the
ligand for the human OMPD mutant 314AcK and to optimize soaking condition with
wild type OMPD.
Starting from fully protected uridine 12, polarity inversion and lithiation at C6 was
applied by slow addition of two equivalents of LDA in THF at -78 ◦C to avoid un-
wanted deprotonation at C5. Two equivalents of LDA were necessary, due to the
acidic proton at N3. However, the resulting deprotonated N3 nitrogen is not nu-
cleophilic enough to cause any side reactions with most electrophiles. Following
deprotonation, CO2 gas was introduced as the electrophile to obtain protected oro-
tidine 13. After purification via column chromatography, deprotection was applied
18
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by stirring 13 in a mixture of TFA and water (50:50 v/v ) for 2 h. The resulting oro-
tidine (14) was phosphorylated with POCl3 in (MeO)3PO. Removal of the solvent
yielded crude OMP (1), containing significant amounts of (MeO)3PO and phosphate




























































































































































































Scheme 1.12. Synthesis of OMP (1) starting from compound 12.
Due to the strong affinity of the phosphate group to silica, standard column chro-
matography with silica gel is not applicable for purification of nucleotides. Follow-
ing the purification procedure of D. Heinrich, using DEAE-Sephadex GL-25 ion-
exchange gel yielded unsatisfying results in regard of remaining (MeO)3PO impuri-
ties. In order to improve the purification high pressure liquid chromatography (HPLC)
was applied. Attempts to apply reversed phase chromatography failed completely.
Both water/acetonitrile and 1 M TEAA buffer/acetonitrile gradients provided no sep-
aration of the nucleotide from any impurities. However, successful purification of
OMP (1) was achieved by using strong anion binding ion exchange chromatography
applying a water/0.5 M TEAA buffer gradient. Remaining excess of buffer could be
removed by lyophilization multiple times. The pure OMP (1) was obtained as the
triethylammonium salt.
19
1. Mechanistic study of orotidine-5’-monophosphate-decarboxylase
1.4.2. BMP (3) and 6-aza-UMP (4)
In order to reevaluate the crystal structures of OMPD complexed with BMP (3)
and 6-aza-UMP (4) by high resultion structures, these inhibitors were synthesized
(scheme 1.13). For BMP (3) synthesis the silyl-Hilbert-Johnson reaction was ap-
plied, which is also known as Vorbruggen nucleosidation. Here, a preactivated het-
erocyclic base is connected to a Lewis acid activated sugar derivative, which acts
as an electrophile. Activation of the heterocycle is done by silylation.[57] Barbituric
acid (15) and a catalytic amount of TMSCl were stirred in HMDS under reflux to
obtain tris-TMS activated pyrimidine 16, which was bound to SnCl4 activated 1-O-
Acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose (17) via stereochemical controlled nu-









































































































































































































Scheme 1.13. Synthesis of BMP (3) using Vorbruggen nucleosidation.
Due to the symmetry of barbituric acid (15) regioselectivity of N1 and N3 can be
neglected. However, double nucleosidation at N1 and N3 occur with high sugar
concentration. Saponification of benzoyl groups with NaOMe in methanol yielded 6-
hydroxyuridine (19), which was phosphorylated with POCl3 in trimethylphosphate to
20
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obtain BMP (3). Similar phosphorylation method was applied to convert commercial
available 6-azauridine (20) into 6-aza-UMP (4) (scheme 1.14). Purification was done










































































































































































Scheme 1.14. Phosphorylation of 6-azauridine (20).
1.4.3. 6-Amido-UMP (8)
To evaluate the possibility of attractive interactions between the active site and pro-
tonated OMP (1), 6-Amidouridine was synthesized as an substrate analogue repre-
senting protonated OMP. In a first approach protected orotidine 13 was synthesized
by deprotonation of protected uridine 12 and subsequent reaction with CO2. 13
should then be activated by either isobutyl-chloroformate or thionylchloride in the
presence of NEt3 to neutralize developing HCl. Reaction with ammonia solution in
THF should yield protected 6-amidouridine (22) (scheme 1.15). Unfortunately, no
reaction could be detected and protected orotidine 13 was re-isolated, as indicated














































































































































































Scheme 1.15. First approach to synthesize 6-amidouridine (22) by activation of orotidine 13.
a) 1. isobutyl-chloroformate, NEt3, 45 min, -78 ◦C, 2. NH3, THF, 2 h, rt;
b) 1. SOCl2, NEt3, 1 h, rt, 2. NH3, THF, 2 h, rt.
In a second approach, 6-amidouridine (23) was synthesized successfully, via
aminolysis of protected orotidinemethylester 21. Starting from protected uridine 12,
protected orotidinemethylester 21 was obtained via deprotonation with LDA and sub-
sequent reaction with methyl-chloroformate. Stirring of 21 in 7 m methanolic ammo-
21
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nia solution for 20 h yielded protected 6-amidouridine (22) which was deprotected in
0.5 M methanolic hydrogenchloride solution to obtain 6-amidouridine (23). However,
phosphorylation failed using POCl3 in trimethylphosphate. Changing conditions to
a mixture of POCl3, pyridine and water in acetonitrile worked out, yielding 6-amido-
UMP (8) after purification by ion exchange chromatography. The full synthesis is
shown in scheme 1.16
POCl3, pyridine, H2O










































































































































































































Scheme 1.16. Successful synthesis of 6-amido-ump (8) via aminolysis of orotidinemethylester 21.
The successful synthesis of protected orotidinemethylester 21 made methyl-OMP
(25) another appealing substrate analogue, which should be easily available by de-
protection and phosphorylation. However, both POCl3 in trimethylphosphate and
the mixture of POCl3, pyridine and water in acetonitrile failed to synthesize methyl-
OMP (25) (scheme 1.17). OMP (1) was obtained in both attempts, indicating es-
ter hydrolysis is the problem preventing a successful synthesis. Because methyl-
OMP (25) was no prioritized target no further attempts were done.
1.4.4. 6-Isopropyl-UMP (9)
To evaluate how other than electrostatic interactions play a role in ground state
destabilization and substrate distortion, 6-isopropyl-UMP (9) was synthesized. Al-
though, the C7 carbon is sp3 hybridized, which lead to a slightly deviated geometry
22

































































































































































































Scheme 1.17. Synthesis of orotidinemethylester 21. Phosphorylation failed due to ester hydrolysis.
a) POCl3, trimethylphosphate, 6 h, 0 ◦C
b) POCl3, pyridine, H2O, acetonitrile, 20 min, 0 ◦C
compared to OMP (1) this analogue is an interesting target to investigate sterical
contribution to the catalytic mechanism.
In a first approach, the isopropyl group should be attached at 6-position via elec-
trophilic addition to C6 deprotonated uridine 12. Following the standard procedure
for deprotonation with LDA, polarity inversion at C6 was achieved. Subsequent ad-
dition of isopropyliodide should yield protected 6-isopropyluridine 29 (scheme 1.18).
However, only starting material 12 was isolated from the reaction mixture. Presum-
ably, isopropyliodide is not electrophilic enough, due to the relatively good stabiliza-


































































































































































Scheme 1.18. First approach to synthesize 6-isopropyluridine 29 via lithiation and reaction with
isopropyliodide.
23
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bulky character of the isopropyl group might be another problem, which prevent suc-
cessful conversion.
Due to the weak electrophilicity of the isopropyl group, the reaction was done with
strong nucleophilic Grignard reagent isopropylmagnesiumbromide in the second ap-
proach. Applying a protocol from Chien et al., nucleophilic substitution of protected
6-cyanouridine 28 should yield compound 29.[58] Compound 28 was synthesized
following modified protocols from Fujihashi and Torrence.[59], [60] Starting from uri-
dine (10), 5-iodouridine 26 was obtained by reaction with NIS in DMF. The product 26























THF, 3 h, rt


















    3 h, rt
2. TBDMSCl, Imidazole,














































































































































































Scheme 1.19. Synthesis of 6-isopropyl-UMP (9) via nucleophilic substitution of 6-cyanouridine 28
with isopropylmagnesiumbromide.
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with TBDMSCl in the presence of imidazole to yield protected 5-iodouridine 27. After
purification, 27 was converted to protected 6-cyanouridine 28 via Michael addition of
KCN in DMF and subsequent elimination of KI. To enhance the solubility of KCN in
DMF, 18-crown-6 was added as a potassium chelating agent. Nucleophilic substitu-
tion of the cyano group with isopropylmagnesiumbromide in THF yielded protected
6-isopropyluridine 29. Addition of catalytic amounts of ZnCl2 enhance the reactivity
of 6-cyanouridine 28 for nucleophilic substitution by activating the carbonyl group
at C4. 6-Isopropyl-UMP (9) was obtained by deprotection with 0.5 M methanolic
HCl solution and phosphorylation with POCl3, pyridine and water in acetonitrile. The
complete synthetic sequence is shown in scheme 1.19.
1.4.5. Dithio-OMP (6)
In order to synthesize an OMPD inhibitor with nearly identical steric and electronic
properties as OMP (1), dithio-OMP (6) was a promising target as it is identical to
OMP except substitution of the carboxylic oxygen atoms against sulfur. In a first
approach the synthesis was designed similar to the synthesis of OMP, but CO2 was
exchanged by CS2 as the electrophile. However, dithioacid 31 turned out to be un-
stable in acidic media producing only unidentifiable products upon deprotection in













































































































































































Scheme 1.20. Approach to synthesize dithioorotidine (32). Dithioacid 31 decomposes in acidic
media.
a) TFA/water 50:50, v/v, 2 h, rt
b) 0.5 M HCl in methanol, 30 min, rt
To avoid acidic conditions during deprotection, the isopropylidene group was ex-
changed by two additional silyl ether groups. Protection of uridine (10) with 4 equiv-
alents of TBDMSCl and 5-fold excess of imidazole in DMF provided tris-TBDMS-
uridine 33 in excellent yield. However, subsequent electrophilic substitution with
CS2 showed no conversion of the starting material. Steric hindrance was assumed
25
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to be an issue. In order to reduce the size of the silyl groups, tris-TES protected
uridine 34 was synthesized, applying the same reaction conditions used for TBDMS
protection. However, no conversion was observed during electrophilic substitution









DMF, 24 h, rt
TESCl, imidiazole


































    2 h, -78 °C
2. CS2
1. LDA, THF,





















































































































































Scheme 1.21. Synthesis of tris-silyl ether protected uridines 33 and 34. Electrophilic substitution
with CS2 was unsuccessful in both cases.
To stabilize the dithiocarboxy group against acidic conditions, the acid was pro-
tected as a dithiobenzylester, which is more stable against aqueous media and
acids. Cleavage of the benzyl group should be achieved by selective catalytic hy-
drogenation of the benzyl position (scheme 1.22). Synthesis of dithioorotidineben-
zylester 35 was achieved similar to dithioacid 31 by lithiation at C6 and reaction
with CS2, followed by quenching with benzylbromide. After purification, deprotection
of 35 to dithioester 36 was achieved successfully in TFA/water 50:50 v/v without
any decomposition. Subsequent phosphorylation with POCl3 in trimethylphosphate
delivered pure dithio-OMP-benzylester 37 after ion exchange chromatography. Al-
though, the syntheses of 37 was proven to be successful, cleavage of the benzyl
group provided major problems. Originally considered catalytic hydration with pal-
ladium on carbon turned out to produce no conversion at atmospheric H2 pressure
as well as higher pressure up to 5 bar. Using Pd(OH)2 on carbon and palladium on
CaCO3 provided the same results. The reason might be coordination of palladium
by the resulting dithioacid, which lead to intoxication of the catalyst. Another expla-
26
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1. LDA, THF, 30 min -78 °C
2. CS2, 30 min, -78 °C to rt





































Pd(OH)2/C, 5 bar H2






































































































































































Scheme 1.22. Synthesis of dithio-OMP-benzylester 37. Cleavage of the benzyl group was unsuc-
cessful.
nation could be that the benzyl position reacts in another way compared to common
carbon-acid benzylesters. Either way the benzyl group turned out to be not suitable
as a protecting group for the dithioacid.
Another attempt to protect the dithioacid was to synthesize the dithioacidmethyl-
ester 38. Deprotection should be performed via ester thiolysis with potassium hy-
drogensulfide in water free media (scheme 1.23). Because dithiobenzylester 35
proved to be stable under acidic deprotection conditions and during phosphoryla-
tion it was assumed that is also the case for other dithioesters. Therefore cleavage
of the methylester was tested using 38 without prior deprotection and phosphory-
lation. Synthesis of 38 was performed similar to 35 using methyliodide instead of
27
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1. LDA, THF, 30 min -78 °C
2. CS2, 30 min, -78 °C to rt















































































































































































Scheme 1.23. Synthesis of dithioorotidinemethylester 38. Thiolysis failed in DCM, THF, DMF, DMSO
and MeOH.
benzylbromide. Ester thiolysis was tested using 6-fold excess of KHS in various sol-
vents and stirring the mixtures for 24 h. However, no reaction could be observed in
any mixture. Obviously, dithioesters are more stable than expected, protecting the
dithioacid well against decomposition but are hardly cleavable.
In order to facilitate dithioester thiolysis, dithiophenylester 39 was tested in an-
other attempt. Due to the higher pKa value, compared to thiobenzylalcohol and
thiomethanol, thiophenol should provide a better leaving group. Synthesis of 39
was not performable similar to dithiobenzylester 35 and dithiomethylester 38 be-
cause unlike benzylbromide and methyliodide, phenylbromide does not undergo
nucleophilic substitution. Therefore, a synthesis similar to orotidinemethylester 24
was chosen, using phenyl-chlorodithioformate as the electrophile. The resulting
dithiophenylester 39 was stirred with 5-fold excess of KHS in DMF for 24 h. The
dithiophenylester turned out to be reactive against thiolysis, leading to complete
cleavage of thiophenol. However, the resulting dithioacid 31 undergoes nucleophilic
substitution in the presence of KHS yielding 6-thio-BMP 40 as the final product
(scheme 1.24), which was proven by NMR spectroscopy and ESI massspectrom-
etry.
28
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1. LDA, THF, 30 min -78 °C






















































































































































































Scheme 1.24. Synthesis of dithiophenylester 39. Thiolysis yielded 6-thio-BMP 40 instead of
dithioorotidine 31.
Another possible strategy is using photolabile protecting groups, which can be
cleaved via irradiation by light of certain wavelength. By using this strategy no further
reagents are necessary to deprotect the dithioacid, which minimize possible side re-
actions. However, all following steps have to be done under exclusion of light to avoid
any undesired cleavage of the protecting group. For esters ortho-nitrobenzylesters
are known to be cleavable by light irradiation in the UV range (350-400 nm), en-
abling the established synthesis of dithioesters to be applicable for the photocleav-
able protecting strategy.[61] However, in case of using ortho-nitrobenzylbromide to
obtain dithio-ortho-nitrophenylester 41 only unidentified side products were formed
(scheme 1.25).
1. LDA, THF, 30 min -78 °C
2. CS2, 30 min, -78 °C to rt




































































































































































Scheme 1.25. Failed synthesis of dithio-ortho-nitrobenzylester 41.
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Another possibility to stabilize dithiocarboxylic acids is to oxidize them to obtain
dithiocarboxylic acids disulfides, which can be reduced later on to gain back the
dithiocarboxylic acid. In order to obtain dithioacid-disulfide 42 the dithioacid was
synthesized via lithiation and reaction with CS2 as previously described. Subsequent
oxidations with either oxygen and iodine were applied but failed to produce in both
cases (scheme 1.26).
1. LDA, THF, 30 min -78 °C














































































































































































Scheme 1.26. Attempted synthesis of dithioacid-disulfide 42.
a) O2, 24 h, rt; b) I2, AcOH, 2 h, rt
1.4.6. 6-Nitro-UMP (5)
Another isoelectronic and isosteric OMP analogue is 6-nitro-UMP (5). First synthetic
attempts were made by Daniel Heinrich and Julian Strohmeier. These attempts fol-
lowed the strategy to oxidize 6-aminouridine 43 to obtain 6-nitrouridine 44, which
would then be converted to 6-nitro-UMP 5 by standard deprotection, phosphoryla-
tion procedure. Several oxidants were tested, but all failed to produce the desired
product. Ozone on solid support, as well as in solution produced unidentified side
products, likely due to oxidation of the double bond. The same results were obtained
when OsO4, KMnO4 and DMDO were used. On the other hand, TBHP and mCPBA
were to mild and only starting material was recovered (scheme 1.27).[50], [62]
An alternative to the oxidation of 6-aminouridine 43 might be well established C6
lithiation, followed by subsequently reaction with an electrophile. While this meth-
ods works very well for most electrophiles, in case of nitronium kations some issues
occur. First, nitronium ions are highly unstable and therefore are generated in situ
by mixing concentrated nitric and sulfonic acid. In the case of C6 lithiation the addi-
tion of acids would reprotonate at C6. Fortunately, nitronium ions can be stabilized
by forming NO2BF4 and NO2PF6 salts. Another barrier for using nitronium ions are
30


































































































































































Scheme 1.27. Attempted oxidations of 6-aminouridine 43 by Heinrich and Strohmeier.[50], [62]
a) O3 on SiO2, 5 min, -78 ◦C; b) O3, DCM, 2 min, -78 ◦C; c) OsO4 ∗THF, DCM, 1 h, -78 ◦C; d) KMnO4,
DCM, 30 min, -78 ◦C; e) DMDO, DCM, 1 h, 0 ◦C; f) TBHP, Zr(OtBu)4, DCM, 4 Å molecular sieves,
20 h, rt; g) mCPBA, DCM, 22 h, 0 ◦C
their high reactivity, which lead to reactions with most solvents. Testing the lithiation
method with standard procedure, following change of solvent for the nitration step
with NO2BF4 lead to reaction with solvent in case of THF, Et2O and DCM or to no
















1. LDA, THF, -78 °C, 30 min
2. NO2BF4, solvent




















































































































































Scheme 1.28. Testing direct of lithiation nitration method with NO2BF4 in THF, Et2O, DCM, DMF,
DMA and MeCN.
In an attempt to stabilize the nitronium ion a method developed by Cupas and
Pearson was applied.[63] In this method, the nitronium ion is bound to pyridine by an
N-N bond delocalizing the positive charge in the aromatic plane. N-nitro-pyridinium-
tetrafluoroborate (46) was obtained by reaction of NO2BF4 with pyridine (45) in ace-
tonitrile. Unfortunately, addition of N-nitro-pyridinium-tetrafluoroborate (46) to lithi-
ated uridine 12 lead to no reaction again (scheme 1.29).
Another possibility to obtain aromatic nitro compounds is ipso-nitration of suitable
6-nitrouridine 44 precursors. Prakash and Mathew developed a catalytic method to
convert aryl halides into nitro aryls.[64] The reaction is done via palladium catalyst
and the BRETTPHOS ligand. Although being a reliable method for aryl halides, no
experimental data for heteroaryls are available. To evaluate if this reaction is suitable
31
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Scheme 1.29. Attempted stabilization of NO2+ in form of N-nitro-pyridinium-tetrafluoroborate (46)
and subsequent reaction with lithiated uridine 12.
for uridine, 6-iodouridine 47 was synthesized from protected uridine 12 by lithiation
and subsequent reaction with iodine. Catalytic ipso-nitration via nucleophilic sub-
stitution was attempted following the protocol from Prakash.[64] Unfortunately no
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Scheme 1.30. Attempted catalytic ipso-nitration of 6-iodouridine 47.
The main problem might occur from the significantly lower electron density at
the uracil C6 position compared to the aryl compounds converted in the work of
Prakash. In order to evaluate this assumption and to enhance the electron density,
6-chloro-2,4-dimethoxy-pyrimidine (48) was chosen as a suitable model compound.
Same reaction conditions for the palladium mediated ipso-nitration were applied in
order to obtain 6-nitro-2,4-dimethoxy-pyrimidine (49) (scheme 1.31). Unfortunately,
again only starting material was recovered from the reaction mixture, indicating a
more general problem using this nitrating method for heterocyclic compounds.
32
































































































































































Scheme 1.31. Attempted catalytic ipso-nitration of model compound 6-chloro-2,4-dimethoxy-
pyrimidine (48).
Another method to synthesize nitro compounds is conversion of α-carboxy-olefins
into α-nitro-olefins by decarboxylation-nitration mechanism. One possibility is to
achieve decarboxylation in the presence of a catalytic amount of silver carbonate,
which was discovered by Natarajan et al.[65] The resulting anion at C6 would then re-
act with NO2BF4 in DMA. While, the silver catalyzed decarboxylation was successful
no reaction of the intermediate anion with NO2+ was observed. Instead, protona-
tion upon aqueous workup was achieved. Additionally, deprotection of the silylether
seem to be a side reaction, providing acetal protected uridine 11 as the only product
(scheme 1.32). Silylether cleavage might be the reason for the protonation as well.













































































































































































Scheme 1.32. Silver catalyzed decarboxylation of protected orotidine 13 to acetal protected uri-
dine 11. No reaction of the intermediate anion with NO2+ was observed.
A second mechanism for decarboxylation-nitration is the nitro-Hunsdieker reac-
tion, which was invented by Das et al.[66] Here, the decarboxylation is done via a
radical mechanism, started by AIBN. The resulting acyloxy radical is attacked by a
33
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NO2 radical, resulting in the nitro product. However, in case of orotidine 13 only






































































































































































Scheme 1.33. Attempted nitro-hunsdieker reaction to obtain 6-nitrouridine 44.
34
1.5. Examination of hOMPD-inhibitor complexes using cryo-crystallography
1.5. Examination of hOMPD-inhibitor complexes
using cryo-crystallography
In order to obtain more insights into the structure of the hOMPD-substrate com-
plex, enzyme-inhibitor structures were measured, using the in section 1.4 success-
fully synthesized OMP analogues BMP (3), 6-aza-UMP (4), 6-amido-UMP (8) and
6-isopropyl-UMP (9), which were soaked into precrystallized hOMPD resting state
crystals.
To compare the obtained structures with similar analogues, 6-thiocarboxamido-UMP
(50) and 6-methyl-UMP (51), which were synthesized by Tobias Schmidt as part
of his Ph.D. work and 6-isopropylene-UMP (52), which was synthesized by Moritz
von Geyso in his bachelor thesis (scheme 1.34), were soaked into hOMPD resting






















































































































































































Scheme 1.34. 6-thiocarboxamido-UMP (50), 6-methyl-UMP (51) and 6-isopropylene-UMP (52),
which were synthesized and provided by Tobias Schmidt and Moritz von Geyso.
The work concerning protein expression and purification as well as crystalliza-
tion and x-ray diffraction was done by our close cooperation partner Sören Rind-
fleisch from the Tittmann group.1 His6-GST-hOMPD was expressed in E.coli strain
SoluBL21. Purification was achieved via Ni-affinity chromatography and the His6-
GST-tag was cleaved by protein protease ULP1, followed by a second Ni-affinity
chromatography. hOMPD crystals were obtained using the hanging drop method
from Wittmann et al., which was improved by Sören Rindfleisch.[15], [24], [67] Crystal-
lization was done in ammonium sulfate buffer in the presence of gluthation, providing
hOMPD resting state crystals at a resolution of 0.95 Å in space group C2221 with
one monomer in the asymmetric unit.
1AG Prof. K. Tittmann, Georg-August-Universität Göttingen, Dept. of Molecular Enzymology
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1.5.1. hOMPD-BMP complex
The hOMPD-BMP complex was obtained by co-crystallization of BMP and hOMPD
via the hanging drop method. Diffraction data of the crystals were obtained with
the same resolution like the resting state crystals at 0.95 Å. The data were pro-
cessed in space group C2221 with one monomer in the asymmetric unit. The model
was built and refined to fit the experimental data with Rwork = 9.9% and Rfree = 11.2%.
The enzyme was found to be in closed conformation completely with the phos-
phate gripper loop closing the active site. The catalytic tetrad is arranged in the
known alternating arrangement, with Lys314 being the center of a hydrogen bond
network involving Asp’317, Asp312, Lys281 and O6 of BMP. The diffraction data indi-
cate no alternative positions for the catalytic tetrad residues (figure 1.6).
Due to its extremely high binding affinity with Kd = 9·10−12 M, BMP is expected
to be a transition state analogue of the OMPD-OMP complex.[68], [69] This analogue
is believed to be formed via deprotonation of the C6 hydroxy group resulting in an
O6 oxyanion, which mimics the C6 carbanion formed as the intermediate in the pro-
posed mechanism from Wolfenden et al.[12], [37] This assumption is supported by the
fact that the enol form is the thermodynamically favored tautomer and the pKa value
of barbituric acid being approximately 4.5 enabling for easy deprotonation.[68], [70]
However, the experimental data obtained via x-ray diffraction of the hOMPD-BMP
complex dissent the formation of an O6 oxyanion. The electron density map with
higher contour level show equivalent delocalized electron densities for the C2-O2,
C4-O4 and C6-O6 bonds, indicating the existence of carbonyl double bonds. The
bond length were determined at 1.24±0.01 Å, 1.26±0.01 Å and 1.25±0.01 Å for
the C2-O2, C4-O4 and C6-O6 bond respectively. These length further support a
carbonyl bond between C6-O6 instead of a hydroxylate, which should show localized
electron density and a C-O distance around 1.45 Å. Likewise, localized electron
density at C5 indicates a single bond between C5-C6 and sp3 hybridized C5, which
is in contradiction to an enolate tautomer and further support the existence of a
carbonyl bond between C6-O6. Side view of the BMP nucleobase in close distance
to the catalytic tetrad show an out of plane distortion of the C6-O6 carbonyl bond by
4.9◦ (figure 1.7).
36

































































































































































Figure 1.6. Structure of the hOMPD-BMP complex.
A: Binding of BMP at the active site of hOMPD with focus on the interactions with the catalytic
tetrad and His283. The structure is determined at a resolution of 0.95 Å. Possible hydrogen bonds
are indicated as dashed yellow lines with distances of maximal 3.0 Å.
B: 2mFO-DFC electron density map (blue meshes) and mFO-DFC difference electron density maps
(pos: green meshes, neg: red meshes) with a contour level of 1.5 and ±3.0 σ, respectively.
1.5.2. hOMPD-6-Aza-UMP complex
Another good inhibitor for OMPD is 6-aza-UMP (4) with a Kd value of 6.4·10−9 M,
which is used as an anticancer drug.[69], [71], [72] Due to the strong binding affinity
6-aza-UMP might also mimic the transition state. Two different conformers can be
transition state analogues for two types of mechanism. The syn-conformation was
found in OMPD from E. coli and M. thermoautotrophicum.[32], [33], [35] In this conformer
the carbene lone pair, which occurs as the intermediate of the O4 protonation mech-
anism from Kollmann et al., is exchanged by the lone pair of the N6 nitrogen. In the
anti-conformation, which was found in S. cerevisiae,[35] the pyrimidine ring is rotated
by 180◦, exposing the C2-O2 carbonyl to the catalytic tetrad. This causes an envi-
ronment, similar to the OMPD-BMP complex.
37























































































































































Figure 1.7. Out of plane distortion and focused electron density map of the hOMPD-BMP complex.
A: Side view of the BMP nucleobase. Ribose-phosphate is not displayed for better clarity.
B: 2mFO-DFC electron density map (gray meshes) with a contour level of 4 σ.
The hOMPD-6-aza-UMP complex was obtained via soaking of 6-aza-UMP into
hOMPD resting state crystals. Diffraction data were measured at a resolution of
1.0 Å in space group C2221 with one monomer in the asymmetric unit. The model
was built and refined to fit the experimental data with Rwork = 11.7% and Rfree = 13.4%.
The enzyme was found to be in closed conformation completely with the phos-
phate gripper loop closing the active site. The catalytic tetrad residues and His283
are in similar position like in the hOMPD-BMP complex. 6-Aza-UMP occupies the
active site in the anti-conformation, leading to the formation of a hydrogen bond net-
work, similar to the BMP complex with Lys314 in the center, forming bonds to Asp’317,
Asp312, Lys281 and O2 of 6-aza-UMP (figure 1.8). The rotation of the pyrimidine ring
causes loss of interactions to Gln430 and Ser372, which are substituted by hydrogen
bonds to water molecules.
38

































































































































































Figure 1.8. Structure of the hOMPD-6-aza-UMP complex.
A: Binding of 6-aza-UMP at the active site of hOMPD with focus on the interactions with the catalytic
tetrad and His283. The structure is determined at a resolution of 1.0 Å. Possible hydrogen bonds
are indicated as dashed yellow lines with distances of maximal 3.0 Å.
B: 2mFO-DFC electron density map (blue meshes) and mFO-DFC difference electron density maps
(pos: green meshes, neg: red meshes) with a contour level of 1.5 and ±3.0 σ, respectively.
In difference to the hOMPD-BMP complex, examination of the bond length of
the C2-O2 bond and the C4-O4 bond revealed different distances, indicating non
equal binding. While the C2-O2 bond has a length of 1.24±0.01 Å and shows de-
localized electron density in the electron density map with higher contour level, the
C4-O4 bond has a length of 1.31±0.01 Å and more localized electron density. This
indicates clearly a carbonyl bond at C2-O2, whereas the C4-O4 bond has both car-
bonyl and single bond character. Side view of the 6-aza-UMP nucleobase in close
distance to the catalytic tetrad show a slight out of plane distortion of the C2-O2
carbonyl bond by 4.3◦ (figure 1.9).
39























































































































































Figure 1.9. Out of plane distortion and focused electron density map of the hOMPD-6-aza-UMP
complex.
A: Side view of the 6-aza-UMP nucleobase. Ribose-phosphate is not displayed for better clarity.
B: 2mFO-DFC electron density map (blue meshes) with a contour level of 4 σ.
1.5.3. hOMPD-6-Amido-UMP complex
In order to gain more insight into the hOMPD-substrate complex, the isosteric sub-
strate analogue 6-amido-UMP was used to examine interactions with the active site,
assuming OMP is bound in protonated C6-COOH form. The protonated C6-carboxy
group is mimicked by the C6-amido group, being a proton donor for potential hydro-
gen bonds.
The hOMPD-6-amido-UMP complex was obtained via soaking of 6-amido-UMP
into hOMPD resting state crystals. Diffraction data were measured at a resolution
of 1.2 Å in space group C2221 with one monomer in the asymmetric unit. The
model was built and refined to fit the experimental data with Rwork = 11.9% and
Rfree = 14.7%.
40

































































































































































Figure 1.10. Structure of the hOMPD-6-amido-UMP complex.
A: Binding of 6-amido-UMP at the active site of hOMPD with focus on the interactions with the
catalytic tetrad and His283. The structure is determined at a resolution of 1.2 Å. Possible hydrogen
bonds are indicated as dashed yellow lines with distances of maximal 3.0 Å.
B: 2mFO-DFC electron density map (blue meshes) and mFO-DFC difference electron density maps
(pos: green meshes, neg: red meshes) with a contour level of 1.5 and ±3.0 σ, respectively.
The enzyme was found to be in closed conformation completely with the phos-
phate gripper loop closing the active site. 6-Amido-UMP is bound in syn-confor-
mation, exposing the amido group to the catalytic tetrad, which was found to be
present in a slightly different arrangement, compared to the BMP and 6-aza-UMP
complexes. Lys314 adopts another position, sliding out from between Asp’317 and
Asp312. The new position is located between Asp’317 and His281. The latter is ro-
tated by 180◦ in order to enable potential hydrogen bonds from Lys314 towards both
residues. Except for Asp312 all catalytic tetrad residues occupy a second conforma-
tion by about 30%. Lys314 is pointing into the water channel which interconnects both
active sites. Asp’317 moves slightly towards the pyrimidine ring and Lys281 adopts a
conformation, oriented towards the amido-carbonyl, potentially enabling a hydrogen
bond. The amido protons forms a second hydrogen bond to Asp312. The amido
41
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group show an out of plane distortion by 8.9◦ and a torsion angle with respect to the
























































































































































Figure 1.11. Out of plane distortion and torsion of the amido group of the hOMPD-6-amido-UMP
complex.
A: Side view of the 6-amido-UMP nucleobase. Ribose-phosphate is not displayed for better clarity.
B: Torsion of the amido group with respect to the pyrimidine ring plane.
1.5.4. hOMPD-6-Thiocarboxamido-UMP complex
To further evaluate the structure of the hOMPD-6-amido-UMP complex, the struc-
tural similar inhibitor 6-thioamido-UMP (provided by Tobias Schmidt) was soaked
into hOMPD resting state crystals to obtain the hOMPD-6-thioamido-UMP complex.
Diffraction data were measured at a resolution of 1.2 Å in space group C2221 with
one monomer in the asymmetric unit. The model was built and refined to fit the ex-
perimental data with Rwork = 12.1% and Rfree = 15.2%.
42
































































































































































Figure 1.12. Structure of the hOMPD-6-thioamido-UMP complex.
A: Binding of 6-thioamido-UMP at the active site of hOMPD with focus on the interactions with the
catalytic tetrad and His283. The structure is determined at a resolution of 1.2 Å. Possible hydrogen
bonds are indicated as dashed yellow lines with distances of maximal 3.0 Å.
B: 2mFO-DFC electron density map (blue meshes) and mFO-DFC difference electron density maps
(pos: green meshes, neg: red meshes) with a contour level of 1.5 and ±3.0 σ, respectively.
As expected, the enzyme was found in a similar situation like it was measured for
the hOMPD-6-amido-UMP complex, being in closed conformation completely, with
the phosphate gripper loop closing the active site and the ligand positioned in syn-
conformation, exposing the C6 substituent to the active site. The hydrogen bond
network between Asp’317, Lys314, Asp312, Lys281 and His283 remains almost the same
like in the hOMPD-6-amido-UMP complex with a few exceptions. First, the hydro-
gen bond between the thioamido-amine and Asp312 is formed to the other oxygen
atom of the Asp312 carboxylate, making the bond slightly shorter at 2.86 Å compared
to the 6-amido-UMP bond at 2.93 Å. An additional bond between the thioamido-
amine and Asp’317 is formed. Second, The additional conformer of Lys281, which is
bound the amido-carbonyl in the hOMPD-6-amido-UMP complex does not exist in
the hOMPD-6-thioamido-UMP complex. Occupancy of both conformations remains
43
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like in the hOMPD-6-amido-UMP complex at about 70% for the higher occupied con-
formation and about 30% for the lower conformation. The thioamido group show an
out of plane distortion by 7.2◦ and a torsion angle with respect to the pyrimidine ring

























































































































































Figure 1.13. Out of plane distortion and torsion of the thioamido group of the hOMPD-6-thioamido-
UMP complex.
A: Side view of the 6-thioamido-UMP nucleobase. Ribose-phosphate is not displayed for better
clarity.
B: Torsion of the thioamido group with respect to the pyrimidine ring plane.
1.5.5. hOMPD-6-Isopropyl-UMP complex
In order to evaluate, how hOMPD reacts if no electrostatic or polar interactions with
the C6-substituent are possible the hOMPD-6-isopropyl-UMP complex was investi-
gated. The isopropyl group resemble the carboxylate group in its steric properties,
while being completely hydrophobic. The complex was obtained via soaking of 6-
isopropyl-UMP into resting state hOMPD crystals. Diffraction data were measured
44
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at a resolution of 1.3 Å in space group C2221 with one monomer in the asymmetric
unit. The model was built and refined to fit the experimental data with Rwork = 14.2%

































































































































































Figure 1.14. Structure of the hOMPD-6-isopropyl-UMP complex.
A: Binding of 6-isopropyl-UMP at the active site of hOMPD with focus on the interactions with the
catalytic tetrad and His283. The structure is determined at a resolution of 1.3 Å. Possible hydrogen
bonds are indicated as dashed yellow lines with distances of maximal 3.0 Å.
B: 2mFO-DFC electron density map (blue meshes) and mFO-DFC difference electron density maps
(pos: green meshes, neg: red meshes) with a contour level of 1.5 and ±3.0 σ, respectively.
Like in the 6-amido and 6-thioamido complexes, the phosphate gripper loop is
fully closed, indicating high ligand occupancy in the active site. 6-isopropyl-UMP
is bound in syn-conformation, exposing the isopropyl group to the catalytic tetrad.
The positioning of the catalytic tetrad residues resembles the positioning found in 6-
amido-UMP and 6-thiocarboxamido-UMP complexes. Lys314 occupies the position
between Asp’317, Asp312 and flipped His281 forming hydrogen bonds to each residue.
Asp’317 is dragged towards the pyrimidine ring. Alternative conformations were found
for Asp’317, Asp312 and His281 with occupancy of approximately 30%. The isopropyl
45
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group is rigidly positioned with the methyl groups pointing away from the ribose
toward a hydrophobic pocket. No indication for rotation was found. No hydrogen
bonds to the isopropyl group are possible, which is mainly due to its hydrophobic
character but also because Asp312 is not positioned close enough towards the methyl
groups. The isopropyl group show almost no out of plane distortion or distortion


























































































































































Figure 1.15. Out of plane distortion and tetrahedral angle of the isopropyl group of the hOMPD-6-
isopropyl-UMP complex.
A: Side view of the 6-isopropyl-UMP nucleobase. Ribose-phosphate is not displayed for better
clarity.
B: Angle between the methyl groups of the isopropyl substituent.
1.5.6. hOMPD-6-Methyl-UMP complex
To check how the enzyme reacts if the unpolar C6 substituent is smaller, the hOMPD-
6-Methyl-UMP complex was obtained via soaking of 6-methyl-UMP, which was pro-
46
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vided by Tobias Schmidt, into hOMPD resting state crystals. Diffraction data were
measured at a resolution of 1.4 Å in space group C2221 with one monomer in the
asymmetric unit. The model was built and refined to fit the experimental data with

































































































































































Figure 1.16. Structure of the hOMPD-6-methyl-UMP complex.
A: Binding of 6-methyl-UMP at the active site of hOMPD with focus on the interactions with the
catalytic tetrad and His283. The structure is determined at a resolution of 1.4 Å. Possible hydrogen
bonds are indicated as dashed yellow lines with distances of maximal 3.0 Å.
B: 2mFO-DFC electron density map (blue meshes) and mFO-DFC difference electron density maps
(pos: green meshes, neg: red meshes) with a contour level of 1.5 and ±3.0 σ, respectively.
As it is the case for the previous described inhibitors, the phosphate gripper loop
appears to be fully closed, which indicates a high occupancy of 6-methyl-UMP in the
active site. The arrangement of the catalytic tetrad residues resemble the arrange-
ment in the BMP- and 6-aza-UMP complexes. Lys314 is centered between Asp’317
and Asp312, forming hydrogen bonds to both residues. Asp312 is further connected
to Lys281 by a second hydrogen bond, formed by the other oxygen. No alternative
residue positions are present. Like in the 6-isopropyl complex, no polar interactions
47
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are observable to the C6 substituent. While the hydrophobic character exclude any
polar interactions, it would be also out of range from any residue to form potential






















































































































































Figure 1.17. Out of plane distortion of the hOMPD-6-methyl-UMP complex.
Side view of the 6-methyl-UMP nucleobase. Ribose-phosphate is not displayed for better clarity.
1.5.7. hOMPD-6-Isopropenyl-UMP complex
In order gather more information about sterical similar but unpolar inhibitors the
hOMPD-6-isopropenyl-UMP complex was investigated. The inhibitor was synthe-
sized and provided by Moritz von Geyso as part of his bachelor thesis. The iso-
propenyl group is isosteric the carboxylate group with its central sp2 hybridized car-
bon. The complex was obtained via soaking of 6-isopropenyl-UMP into resting state
hOMPD crystals. Diffraction data were measured at a resolution of 1.2 Å in space
group P21 with the dimer in the asymmetric unit. The model was built and refined to
fit the experimental data with Rwork = 13.6% and Rfree = 15.7%.
The electron density map revealed two ligand configurations bound to the active
site. In both cases the positioning of the catalytic tetrad residues is similar to the
arrangement found in the 6-amido 6-thioamido and isopropyl-UMP complexes, with
Lys314 centered between Asp’317, Asp312 and His283. Alternative arrangements for
Asp’317 and Lys314 were also found, but no indication for inversion of His283, which in
result has no polar interactions with Lys314. The high occupied first ligand conformer
48





































































































































































Figure 1.18. Structure of the hOMPD-6-isopropenyl-UMP complex.
A+B : Binding of two potential conformers of 6-isopropenyl-UMP at the active site of hOMPD with
focus on the interactions with the catalytic tetrad and His283. The structure is determined at a
resolution of 1.3 Å. Possible hydrogen bonds are indicated as dashed yellow lines with distances of
maximal 3.0 Å.
C: 2mFO-DFC electron density map (blue meshes) and mFO-DFC difference electron density maps
(pos: green meshes, neg: red meshes) with a contour level of 1.5 and ±3.0 σ, respectively.
is in the same position like the other inhibitors, showing a slight out of plane distor-
tion by 4.2◦ and a torsion angle with respect to the pyrimidine ring plane of 73.7◦
49
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(figures 1.18 A, 1.19 A, B). The second ligand conformer adopts a more relaxed
structure, with the ribose refolded and a small tilt of the pyrimidine plane. The iso-
propenyl group shows almost no out of plane distortion, but nearly twice the torsion


























































































































































Figure 1.19. Out of plane distortions and torsion angles of the isopropenyl group of the hOMPD-6-
isopropenyl-UMP complex conformers.
A: Side view of the 6-isopropenyl-UMP nucleobase of the first conformer. Ribose-phosphate is not
displayed for better clarity.
B: Torsion of the isopropenyl group of the first conformer with respect to the pyrimidine ring plane.
C: Side view of the 6-isopropenyl-UMP nucleobase of the second conformer. Ribose-phosphate is
not displayed for better clarity.
D: Torsion of the isopropenyl group of the second conformer with respect to the pyrimidine ring
plane.
1.5.8. hOMPD314AcK-OMP complex
For evaluate how the original substrate interacts with the catalytic tetrad the mostly
inactive mutant hOMPD314AcK was expressed by Sören Rindfleisch and the complex
was obtained via soaking of OMP into hOMPD314AcK resting state crystals. Diffrac-
tion data were measured at a resolution of 1.2 Å in space group P2221 with one
monomer in the asymmetric unit. The model was built and refined to fit the experi-
50
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Figure 1.20. Structure of the hOMPD314AcK-OMP complex.
A: Binding of OMP at the active site of hOMPD314AcK with focus on the interactions with the catalytic
tetrad and His283. The structure is determined at a resolution of 1.2 Å. Possible hydrogen bonds
are indicated as dashed yellow lines with distances of maximal 3.0 Å.
B: 2mFO-DFC electron density map (blue meshes) and mFO-DFC difference electron density maps
(pos: green meshes, neg: red meshes) with a contour level of 1.5 and ±3.0 σ, respectively.
Like in the wild type enzyme complexes the phosphate gripper loop appeared
to be fully closed, indicating a high inhibitor occupancy for the hOMPD314AcK-OMP
complex as well. The OMP is bound in syn-conformation, forcing the carboxy group
in close proximity to Asp312 of the catalytic tetrad. The arrangemant of the catalytic
tetrad is similar to the hOMPDwt-inhibitor complexes, except for acetylated Lys314,
which adopts a new position beside Asp’317 with the acetyl group above the pyrim-
idine ring plane. The distance of the OMP C6-carboxy group and Asp312 at 2.45 Å
indicates the formation of a hydrogen bond. Asymmetric electron density at the
C6-carboxy group further support the possibility of a bond formation. The electron
density map with higher contour level of 4.0 show a clear distinction between a car-
51

























































































































































Figure 1.21. Out of plane distortion, torsion, and focused electron density map of the carboxy group
of the hOMPD314AcK-OMP complex.
A: Side view of the OMP nucleobase. Ribose-phosphate is not displayed for better clarity.
B: Torsion of the carboxy group with respect to the pyrimidine ring plane.
C: 2mFO-DFC electron density map (blue meshes) with a contour level of 4 σ, focused on the OMP
C6-carboxy group.
bonyl bond with delocalized density and a hydroxy group with density only around
the second oxygen atom. The carboxy group shows an out of plane distortion by
52
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16.3◦ and a torsion angle with respect to the pyrimidine ring plane of 36.6◦ (fig-
ures 1.20, 1.21).
1.5.9. hOMPD314AcK-BMP complex
In order to identify interaction differences of the catalytic tetrad of hOMPD314AcK and
hOMPDwt aside from Lys314, the hOMPD314AcK-BMP complex was crystallized and
compared with the hOMPDwt-BMP complex. The complex was obtained via soaking
of BMP into hOMPD314AcK resting state crystals. Diffraction data were measured at
a resolution of 1.1 Å in space group P2221 with one monomer in the asymmetric

































































































































































Figure 1.22. Structure of the hOMPD314AcK-BMP complex.
A: Binding of BMP at the active site of hOMPD314AcK with focus on the interactions with the catalytic
tetrad and His283. The structure is determined at a resolution of 1.2 Å. Possible hydrogen bonds
are indicated as dashed yellow lines with distances of maximal 3.0 Å.
B: 2mFO-DFC electron density map (blue meshes) and mFO-DFC difference electron density maps
(pos: green meshes, neg: red meshes) with a contour level of 1.5 and ±3.0 σ, respectively.
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and Rfree = 12.4%.
Like all other complexes, the hOMPD314AcK-BMP complex shows high occupancy,
by a fully closed phosphate gripper loop. The arrangement of the catalytic tetrade
closely resembles the hOMPD314AcK-OMP complex. Compared to the hOMPDwt-
BMP complex no hydrogen bond between O6 and Lys314 is possible as expected.
Instead a bond to Asp312 is possible due to moving of BMP towards the catalytic
tetrad by approximately 0.5 Å. The electron density map with a contour level of 4 σ
shows delocalized density at C2-O2, C4-O4 and C6-O6, indicating carbonyl bonds
























































































































































Figure 1.23. Out of plane distortion and focused electron density map of the hOMPD314AcK-BMP
complex.
A: Side view of the BMP nucleobase. Ribose-phosphate is not displayed for better clarity.





1.6.1. New insights into enzyme substrate interactions
hOMPD favors uncharged species
The mechanism of OMPD catalyzed decarboxylation is still under discussion, al-
though being investigated for more than 40 years. The scientific community tends to
favor the mechanism, first proposed by Wolfenden et al., which involves a carban-
ion with localized negative charge at C6.[25], [55], [73]–[77] This intermediate is stabilized
and then neutralized by protonated Lys314, acting as the proton donor. Proof for this
mechanism proposal is the extreme high binding affinity of BMP and 6-aza-UMP
to OMPD. These inhibitors are assumed to resemble the carbanion intermediate by
either formation of an oxyanion at O6 in case of BMP or by the N6 lone pair of 6-aza-
UMP, potentially acting as a hydrogen bond donor to the carbanion stabilizing Lys314.
However, the herein measured hOMPD-BMP complex did not confirm the forma-
tion of charged species. All C-O bonds of the pyrimidine ring are equal, matching
the bond length of carbonyl bonds at approximately 1.25 Å and showing evenly elec-
tron distribution. This indicates the existence of a carbonyl bond at C6 instead of an
oxyanion, as proposed by Wolfenden et al. The enzyme seems to prefer uncharged
species. BMP is bound and stabilized via formation of attractive dipol-dipol interac-
tion and hydrogen bonds as indicated by close distances of the C6 carbonyl to Lys314
and Asp312 of the catalytic tetrad. This binding mode is supported by the hOMPD-
6-aza-UMP complex. Against expectations, the pyrimidine ring is inverted by 180◦
and bound in anti-conformation. Thereby the C2 carbonyl replaces the C6 carbonyl
in the BMP complex. Due to the ring inversion, the hydrogen bonds of the pyrim-
idine umbrella, which are formed to the C2 carbonyl and N3 in syn-conformation
were broken in favor of carbonyl interactions with the catalytic tetrad. This further
indicates the preference of uncharged intermediates.
In general, no evidence for C6 charged transition state intermediates were found.
Investigation of the OMP and 6-aza-UMP complexes show strong interactions with
uncharged carbonyl bonds, suggesting the formation of a C6 neutral transition state
intermediate.
While a negative charge results from decarboxylation, its whereabouts remains
unknown. It might be delocalized in the pyrimidine ring plane and stabilized at O4.
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The 6-aza-UMP complex reveals a more distinguished electron density at C4-O4
with a slightly elongated bond length compared the the C4 carbonyl in the BMP
complex (figure 1.24). This might result from higher electron density in 6-aza-UMP
compared to BMP, which possibly mimic delocalized negative charge like it could be
exist in the transition state intermediate. This charge seems to be further stabilized
at O4, however no hydrogen bond donor in proximity to O4 is present. The exact






















































































































































Figure 1.24. Electron density map at 5 σ of the C4-O4 bond of the hOMPD-BMP complex (A) and
hOMPD-6-aza-UMP complex (B), respectively.
In the proposed mechanism from Wolfenden et al. out of plane distortion of C6
substituents is assumed to result mainly from electrostatic repulsion. The nega-
tively charged C6-carboxy group of OMP and Asp312 push off each other, resulting
in bend of the C6-C7 bond. Against expectations, OMP seems to be protonated
and not negatively charged in the hOMPD314AcK-OMP complex. The electron den-
sity map reveals asymmetric density distribution at the C6-carboxy group. While
electron density is delocalized at one C-O bond, indicating a carbonyl bond, there is
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sharply localized density at the other oxygen, indicating the existence of a hydroxy
group. Comparing the distance of the carboxy group to Asp312 with amido-group
and thioamido-group distances to Asp312 in the respective complexes, similar val-
ues were observed. Taking these results into account, repulsive interactions seem
unlikely and instead attractive dipole or hydrogen bond formation is more probable.
Size of C6 substituents is important
Due to the enormous catalytic proficiency of OMPD, no substrate complex has been
obtained until today, regardless of species. In order to gain information about sub-
strate interactions with the active site, stable substrate analogues were synthesized
and soaked into hOMPD resting state crystals. While closely resembling steric prop-
erties of OMP, the analogues differ in electronic properties. 6-Amido-UMP and
6-Thioamido-UMP could be bound similar to protonated OMP, acting as a hydro-
gen bond acceptor. The active site arrangement differ from that observed in the
BMP- and 6-aza-UMP complexes. Specifically, Lys314 adopts a new position be-
tween Asp’317 and Asp312. Asp’317 gets slightly shifted towards the pyrimidine plane
in order to make room for Lys314. This active site architecture was formerly ob-
served in the mutant hOMPDD312N in complex with 6-hydroxymethyl-UMP.[15] As ex-
pected a hydrogen bond is formed between Asp312 and the Amido- and Thioami-
dogroup, respectively. The new catalytic tetrad arrangement might be induced by a
distortion of the hydrogen bond network. In order to exclude non-polar interactions,
hOMPD crystal structures in complex with 6-methyl-UMP, 6-isopropyl-UMP and 6-
isopropenyl-UMP were investigated. All three inhibitors bound interestingly well to
the active site, which is indicated by a high occupancy of approximately 90%. Bind-
ing interactions seem to occur mainly at the phosphate gripper and the pyrimidine
umbrella region. Missing polar interaction did not disturb binding affinity significantly.
The inhibitors with unpolar C6 substituents differ in size and geometry, ranging from
6-methyl-UMP resembling BMP sterically, over 6-isopropenyl-UMP which is similar
to OMP and 6-amido-UMP to 6-isopropyl-UMP being the most sterically demand-
ing inhibitor. Interestingly, all three analogue complexes showed the same catalytic
tetrad arrangement compared to their sterical matching polar equivalents, indicating
that steric interactions being a significant factor for positioning of the tetrad residues
(figures 1.25 A, B).
Surprisingly, 6-methyl-UMP shows significantly greater out of plane distortion com-
pared to 6-isopropyl-UMP and 6-isopropenyl-UMP. Expectedly, bulky groups should
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Figure 1.25. Overlay of hOMPD crystal structures in complex with different inhibitors.
A: 6-amido-UMP, 6-thioamido-UMP, 6-isopropyl-UMP, 6-isopropenyl-UMP
B: BMP, 6-aza-UMP, 6-methyl-UMP
C: hOMPD314AcK in complex with OMP and BMP.
Ribose-phosphate is not displayed for better clarity.
show greater distortion, due to steric hindrance. However, the exact opposite was
observed from the crystal structures. Apparently, Lys314 is forced out of position,
which lead to formation of a new hydrogen bond network by shifting Asp’317 and flip-
ping His283. This create space for the substituents. Inhibitors with smaller groups at
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C6 does not seem to be able to force Lys314 out of its original position. In this case
it might be energetically favorable to bend the C6-C7 bond to avoid steric repul-
sion. In case of the hOMPD-isopropenyl-UMP complex, a second ligand conformer
was observed, which adopts a different arrangement of the ribose, allowing the iso-
propenyl group to adopt a greater torsion angle. The greater torsion create more
space between the isopropenyl group and Lys314 to avoid any out of plane distor-
tion. However, in BMP and 6-aza-UMP complexes almost no bending of the C6-O6
and C2-O2 bond respectively was observed, although Lys314 remains in original po-
sition. The higher stability of the carbonyl bond might prevent any bending. The
formation of a hydrogen bond to Lys314 further hold the carbonyl bond in plane. Ad-
ditionally, the a single oxygen atom at C6 or C2 in OMP and 6-aza-UMP respectively
is significantly smaller than the substituents of the other inhibitors.
Taking the hOMPD314AcK in complex with OMP and BMP into account, the impor-
tant role of Lys314 becomes even more obvious (figure 1.25 C). The obtained struc-
tures further support the assumption that Lys314 causes steric repulsion. Comparing
the hOMPD314AcK-BMP complex with the hOMPDwt-BMP complex, both structures
appear to be similar except of the Lys314 position, proving acylation only affects the
concerning residue. Interestingly, the alkyl backbone of Lys314 remains nearly in the
same position found in the hOMPDwt-BMP complex. Only the acylated Nǫ adopts a
new position above the pyrimidine ring plane. Like the catalytic tetrad, BMP remains
in position and show almost no out of plane distortion or different electron density
distribution compared to the hOMPDwt-BMP complex. On the other hand, OMP in
complex with hOMPDwt show significantly greater out of plane distortion compared
to hOMPDwt complexes with ligands of similar size and geometry. The only obvious
difference in these complexes is the position of Lys314, which is arranged closer to
the ligand, indicating a direct correlation between Lys314 arrangement and distortion
of the ligands C6 substituents (figures 1.26).
1.6.2. Mechanistic implications
Regarding the observation of attractive interactions between the ligand and Asp312
for 6-amido-UMP and 6-Thioamido-UMP in complex with hOMPDwt, as well as for
OMP in the hOMPD314AcK complex, electrostatic repulsion has to be excluded as
the driving force for decarboxylation. Instead, steric interaction concerning the C6-
substituents and the position of Lys314 seem to play a significant role in substrate
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Figure 1.26. Space filling models of Lys314 and Asp312 with 6-amido-UMP, 6-methyl-UMP and OMP,
respectively .
A: 6-amido-UMP in complex with hOMPDwt.
B: 6-methyl-UMP in complex with hOMPDwt.
C: OMP in complex with hOMPD314AcK.
Ribose-phosphate is not displayed for better clarity.
distortion, which lead to ground state destabilization. As observed for the best in-
hibitors BMP and 6-aza-UMP Lys314 occupies a position between Asp’317 and Asp312,
which is assumed to be the thermodynamically favored catalytic tetrad arrangement.
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However, upon binding of sterically demanding ligands such as 6-amido-UMP or 6-
isopropyl-UMP Lys314 is forced out of its favored arrangement into a new conforma-
tion. Via pushing Asp’317 towards the ligand and flipping of His283, Lys314 is stabilized
by an alternative hydrogen bond network. Rearrangement of Lys314 into its orig-
inal position might be the driving force for substrate destabilization. While Lys314
occupies its thermodynamically favored conformation, the OMP-carboxy group get
pushed out of the way, leading to C6-C7 bond bending and finally heterocyclic bond
fission. The resulting anion intermediate is then quenched by either Lys314 or Asp’317.
However, protonation mechanism remains elusive.
Currently, the proposed mechanisms favor a localized C6 carbanion as the reac-
tion intermediate.[20], [73], [78] However, this localized negative charge would be a very
reactive nucleophile with the produced CO2 being a good electrophile in close prox-
imity.[79] Assuming similar rates for bond dissociation ans re-association the overall
decarboxylation can’t be accelerated by the observed rate of 1017. Computational
studies support this assumption.[33], [80] To overcome this limitation other decarboxy-
lases developed specific strategies, like usage of cofactors, solvation or prelocal-
ization of catalytic acids.[81]–[83] These strategies prevent re-association of CO2, ac-
celerating decarboxylations up to 105.[84] However, formation of hydrogencarbonate
was ruled out for OMPD and the enzyme does not use any cofactors.[85] No catalytic
acid is prelocalized close to C6 in the enzyme complexes with OMP sterical similar
inhibitors, but Lys314 might change position close to C6 during the decarboxylation
process, enabling it to act as catalytic acid. Another factor to slow down CO2 re-
association might be delocalization of the negative charge by tautomerism, which
would reduce the reactivity of the intermediate, enabling the resulting CO2 to leave
the active site. However, stabilization of the negative charge could not be elucidated
and remains mostly unknown.
Mechanistic proposal
The catalytic decarboxylation starts with OMP entering the OMPD active site, which
triggers phosphate gripper closure and binding to the pyrimidine umbrella, as well as
hydrogen bond formation to Asp312. Steric repulsion with the carboxy group forces
Lys314 out of the energetically favored position between Asp’317 and Asp312, leading
to reorganization of the hydrogen network. Rearrangement to the thermodynamic
favored catalytic tetrad positioning lead to bending of the C6-C7 bond, resulting in
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out of plane distortion of the carboxy group and finally heterocyclic bond fission. The
carboxy proton remains at Asp312. Upon repositioning of Lys314 is in suitable distance
to protonate the negatively charged reaction intermediate at C6. Stabilization of the
negative charge might be achieved by delocalization over the O4 oxygen as indi-
cated by the hOMPD-6-aza-UMP complex. However, more experiments focusing
on the C4-O4 bond are necessary to verify this assumption. Besides, the origin of
protons remain unknown. Interconnection of both active sites by a water channel is
known. This channel might interchange protons between both active sites. Like for













































































































































































































Orotidine-5’-monophosphate-decarboxylase is a unique enzyme, which accelerates
the decarboxylation of orotidine-5’-monophosphate by the factor of 1017. While being
one of the most effective enzymes known, it is able to catalyze the reaction without
need for any metals or other cofactors. Although a huge number of crystal structures
were resolved from different organism and in complex with different inhibitors, the
reaction mechanism could not be identified and still remains under discussion.
In order to obtain new insights into the decarboxylation mechanism new substrate
analogues were designed and synthesized. To reveal possible positive interactions
between the substrate and the catalytic tetrad residues, 6-amido-UMP was syn-
thesized. Starting from uridine, 6-amido-UMP was obtained via aminolysis of oro-
tidinemethylester over a total of six steps. Additionally, 6-isopropyl-UMP was synthe-
sized to evaluate how the enzyme react to substrates with unpolar C6 substituents,
which possess similar size and geometry compared to OMP. Starting from uridine
again, 6-isopropyl-UMP was obtained via nucleophilic substitution of 6-cyanouridine.
Beside these two inhibitors, the isoelectronic substrate analogues 6-nitro-UMP and
dithio-OMP were attempted to synthesize. Unfortunately, all attempts failed. Addi-
tionally to the new substrate analogues the natural substrate OMP, as well as the
known inhibitors BMP and 6-aza-UMP were synthesized, following known proce-
dures.
The synthesized substrate- and transition state analogues were soaked into pre-
crystallized hOMPDwt resting state crystals or were cocrystallized with hOMPDwt.
In order to increase the obtained data, 6-thioamido-UMP, 6-methyl-UMP and 6-
isopropenyl-UMP were cocrystallized additionally.2 The obtained hOMPD-inhibitor-
crystals and hOMPD314AcK-OMP-crystals were analyzed via x-ray scattering to ob-
tain structural data.3
Structures of BMP and 6-aza-UMP in complex with hOMPDwt showed no indica-
tion for a localized negative charged reaction intermediate. Instead, the structure
revealed a carbonyl bond at C6-O6 in the OMP structure and 6-aza-UMP bound
in anti-conformation exposing the C2-O2 bond to the catalytic tetrad, which also
appear to be a carbonyl. 6-Amido-UMP and 6-thioamido-UMP in complex with
2Inhibitors were synthesized by Tobias Schmidt and Moritz von Geyso.
3Enzyme expression and purification, as well as x-ray scattering was done by Sören Rindfleisch.
63
1. Mechanistic study of orotidine-5’-monophosphate-decarboxylase
hOMPDwt, as well as OMP in complex with hOMPD314AcK indicated the formation
of short hydrogen bonds between the substrates C6 substituents and Asp312. These
results argue against the formation and stabilization of a localized charge at C6 and
electrostatic repulsion between the carboxy groups of OMP and Asp312 as the driv-
ing force of catalytic decarboxylation.
Comparison of the obtained structures revealed a direct relation of size of the C6
substituents and the arrangement of the catalytic tetrad. Structures with small sub-
stituents (BMP, 6-aza-UMP, 6-methyl-UMP) showed Lys314 in the expected position
between Asp’317 and Asp312. However, substituents with similar size to OMP (6-
amido-UMP, 6-thioamido-UMP, 6-isopropyl-UMP, 6-isopropenyl-UMP) seem to force
Lys314 out of its favored position, inducing a new catalytic tetrad arrangement with
Lys314 between slightly shifted Asp’317 and flipped His283. Interestingly, the smaller
substituents show significantly greater out of plane distortion with respect to the
pyrimidine ring plane, indicating a direct correlation of the position of Lys314 and
bending of the C6-C7 bond. Lsy314 forcing back in its favored position seem to push
the C6 substituents, which ultimately lead to heterolytic bond fission. Repositioning




Substrate analogues are indispensable to get new insights into substrate binding
and the reaction mechanism of OMPD. In this work the new analogues 6-amido-
UMP and 6-isopropyl-UMP were synthesized successfully. While these analogues
resemble the geometry of OMP well or are useful to investigate certain properties of
the active site, neither of them mimic the electronic properties of OMP. 6-nitro-UMP
or dithio-OMP are suitable synthetic targets but were not synthetically accessible in
this work. New developments for nitration and thiolation reactions might enable new
synthetic approaches. However, regarding the discovery of hydrogen bond forma-
tion between the C6 substituents and Asp312 6-nitro-UMP might not be a suitable
analogue anymore, due to assumed electrostatic repulsion.
An open question remains the distribution and stabilization of the resulting nega-
tive charge. New substrate analogues with modifications at C4 and C2 could change
electronic situations in the pyrimidine ring. Using electron withdrawing and donating
groups might stabilize and destabilize the intermediate negative charge by inducing
new mesomeric structures.
A missing key piece for understanding of the decarboxylation mechanism is ob-
servation of the natural hOMPD-OMP complex and early stages of the reaction. To
obtain these data photocleavable caging groups could be a possibility. Caged sub-
strates may get preorganized into the resting state crystals and bound to the active
site upon photoactivation. These groups can be attached at the carboxy group or
the phosphate of OMP. An important limitation is the time frame of photoactivated
decaging, which has to be in the microsecond range in order to get decaging done
some orders of magnitude faster than x-ray scattering is performed. Additionally, the
excitation wavelength has to be preferably low energetic to avoid structural damage
of the protein crystals. New caging groups would have to be designed and synthe-
sized, matching these requirements.
In the best case scenario, use of photocleavable caging groups might enable in-
sights into active site dynamics via time resolved x-ray scattering. Observation of
the process at different time points could generate new information about substrate
binding and interconnection of the active site units. Furthermore, the origin of pro-
tons and the protonation process of the reaction intermediate could be enlightened.
65

2. Stimulation of S. pombe Dnmt2 by
the micronutrient queuine
2.1. Motivation and objectives
In organisms gene regulation plays an important role for the adaption of changing
environmental conditions. A part of these regulations is achieved by the chemical
modification of nucleobases, to some extend in DNA and in either mRNA or tRNA
in particular. The latter is often achieved by methylation and demethylation of cyto-
sine, leading to deactivation and reactivation of gene activity. These processes are
related to antibiotic resistance in bacteria. In eukaryotic cells, errors in regulatory
processes might play a role in cancer growth. Therefore, insights of these mecha-
nisms on the level of microbiology and biochemistry will be useful in the development
of new therapeutic ways to treat diseases.[86]
The addition of methyl groups to DNA and RNA is catalyzed by DNA-methyltrans-
ferases (Dnmt) which use S-adenosyl-methionine (SAM) as the methyl source.[87]
Dnmt enzymes are expressed by a wide variety of organisms, ranging from mam-
mals over insects to plants.[88] The proteins are as diverse as their occurence in
different organisms. In mammals three major active Dnmts are identified, named
Dnmt1, Dnmt3a and Dnmt3b.[89] A fourth Dnmt enzyme exists in mammals, which
provides barely detectable DNA methylation activity. This enzyme is named Dnmt2
and although sharing a huge sequence homology to other Dnmts, it shows activity
in the methylation of tRNA.[90] It specifically methylates cytosine 38 in tRNAAsp and
is considered to play a role in gene regulation by protecting the tRNA from cleav-
ing enzymes and therefore increases overall translation (figure 2.1A).[90], [91] Until
recently, the mechanisms about how Dnmt2 gets activated and silenced was little
understood. In 2015 it was discovered that Dnmt2 of the fission yeast Schizosac-
charomyces pombe shows an increased in vivo activity, following incorporation of
the rare nucleoside and micronutrient queuosine in tRNAAsp (figure 2.1B).[92] Incor-
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poration of queuosine was discovered to be done via transglycosylation of guanine
to queuine at position 34 by the enzyme tRNA-guanine transglycosylase (TGT).[93]
Although it is evident that incorporation of queuine stimulates the methylation of
tRNAAsp, until recently no in vitro studies are published excluding other possible
stimulating factors. Given that queuine is very rare in organisms, a chemical synthe-
sis is necessary for in vitro studies. While there are some synthetic routes published
for the the synthesis of queuosine and queuine, these routes suffer from some dis-
advantages. In order to establish an in vitro method to proof the dependency of
Dnmt2 from queuine and to improve the chemical synthesis of queuine, a new syn-
thetic route should be developed and the synthesized queuine should be used in the






















































































































































Figure 2.1. Function of Dnmt2.





Dnmt2 enzymes were originally thought to be DNA-methyltransferases, based on
their structural similarity compared to other types of DNA-methyltransferases like
Dnmt1 or Dnmt3, which methylate cytosine in DNA at 5-position. However, closer
studies of Dnmt2 revealed no activity in DNA methylation, but indicated activity for
methylation of tRNAs, which was first reported by the Bestor group. They were able
to show that Dnmt2 catalyzes the methylation of tRNAAsp at the cytosine in position
38.[91] It is assumed that Dnmt2 evolved from a prokaryotic DNA methyltransferase
ancestor, which switched substrates from DNA to RNA.[90], [94] Clustering analysis
support this assumption by showing no evidence for a relationship to other RNA
methyltransferases. Moreover, Dnmt2 uses a catalytic mechanism, which is similar
to other DNA methylating enzymes.[95]
To date, several structures of Dnmt2 from different organisms are published. One
of the best resolved is the crystal structure of E. histolytica from the groups of Ficner
and Ankri (figure 2.2).[96] The crystal structure revealed monomeric enzymes with
the active site loop at residues 80 to 100 adopting a α-helical structure. Although
obtaining structures with good resolutions, no enzyme-substrate complexes could
be crystallized. Therefore, the published structures may be stabilized by crystal





















































































































































Figure 2.2. Crystal structure of Dnmt2 from E. histolytica.
α-helices and β-sheets are colored in blue and green, respectively. The active site loop and α-helix
are coloured in yellow.[96]
A complex mechanism enables Dnmts to methylate nucleobases at non nucle-
ophilic positions like the C5 carbon in cytosine. Thereby, formation of very stable
C-C bonds is accessible (scheme 2.1). In the first step the C5 position gets ac-
tivated by 1,4 addition of a cytosine residue, working as a helper nucleophile, to
create an enamine structure. Thereby, the C5 carbon becomes more nucleophilic
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and can be methylated by SAM. In the last step elimination of the cysteine residue





























































































































































































Scheme 2.1. Mechanism of cytosine C5 methylation by Dnmts and SAM.[86]
First hints that Dnmt2 activity might be stimulated by nutrient factors were ob-
served in the Ehrenhofer-Murray group. They detected extreme low Dnmt2 activity,
when S. pombe cells were grown on minimal medium.[92] The stimulating nutrient
was identified as the rare nucleobase queuine, which upon supplementation to the
cell medium increased the methylation of tRNAAsp from 6% to quantitative conver-
sion.[92] However, the exact mechanism of the stimulation and the question if other
factors play a role in increasing Dnmt2 activity remains unclear.
2.3. Queuosine biosynthesis
No full queuine or queuosine synthesis has been observed in cytoplasm to date.
Instead, PreQ1 (58) is synthesized in bacteria, gets incorporated into tRNA and is
then functionalized to queuosine (67) (scheme 2.2).[97]
First, queuine precursor PreQ1 (58) is synthesized in five steps. Starting from
guanine-5’-triphosphate (53), GCH1 cleaves the purine ring at C8 and the fura-
nose between C2’ and C3’. Following, rearrangement and cyclyzation lead to 7,8-
dihydropterine-triphosphate (54). Next, QueD cleaves acetaldehyde at the triphos-
phate resulting in 6-carboxy-5,6,7,8-tetrahydropterin (55), which undergoes ring con-
traction, catalyzed by QueE to generate 7-deaza-7-carboxyguanine (56). 7-deaza-
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7-carboxyguanine (56) is then converted into PreQ0 (57). This step is catalyzed by
QueC, converting the carboxy group into a nitrile using ammonia as the nitrogen
source. PreQ0 (57) is then reduced to PreQ1 (58) by QueF. After incorporation of
PreQ1 (58) into tRNA by TGT, QueA catalyzes a reaction cascade resulting in the
formation of epoxy-queuosine-tRNA 60, which is reduced in the last step by QueG







































































































































































































































Scheme 2.2. Biosynthesis of queuosine.[98]
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2.4. Chemical synthesis of queuine and queuosine
2.4.1. Synthetic strategies for queuosine
In 1975 Kasai discovered the structure of queuosine (67).[99] Only a few years later
the first chemical synthesis was published. It was developed by Ohgi in 1979 and
was achieved by coupling a dibromodeazaguanosine derivative 62 and a cylopenty-
lamino building block 63 by nucleophilic substitution to obtain 64. 64 was debromi-












































































































































































































Scheme 2.3. First synthesis of queuosine (67) by ohgi et al.[100]
a) diisopropylethylamine, benzene; b) Zn/CuCl2, dioxane; c) NH4OH, methanol; d) 2 N HCl
The dibromodeazaguanosine derivative 62 was synthesized following protocols
developed by Kondo, Ohgi and Goto (schemes 2.4, 2.5),[100], [101] starting from cyano-
acetale 68. In the first step, 68 was condensed with thiourea in the presence of
sodium ethoxide to obtain 2-methylthio-7-methyl-7-desazahypoxanthin (69). 69 was
then chlorinated with phosphorusoxychloride and the resulting product 70 was sub-
72
2.4. Chemical synthesis of queuine and queuosine
stituted with sodium methoxide to 71. Coupling of 71 to the benzyl protected chloro-
sugar 72 using Königs-Knorr nucleosidation yielded benzyl protected nucleoside 73













































































































































































Scheme 2.4. Synthesis of dibromodeazaguanosine derivative 62 part 1.[101]
a) thiourea, NaOEt, ethanol; b) NaOH, MeI, methanol; c) POCl3, N,N-dimethylaniline; d) NaOMe,
methanol, reflux; e) NaH
Nucleoside 73 was demethylated under acidic conditions in the presence of a
radical inhibitor to avoid oxidation of the mercaptoether and protected with MOM
afterwards to compound 74. The mercaptoether was substituted with acetamide to
produce deazaguanosine 75. To avoid side reactions, the benzyl protecting groups
were changed to acetyl and isopropylidene groups, producing deazaguanosine 77.
Bromination with an excess of NBS delivered the dibromodeazaguanosine deriva-
tive 62 over two steps.
The cylopentylamino building block 63 for both synthetic routes was produced
following protocols developed by Gaoni, Posternak, Goto and Ohgi (scheme 2.6).
Starting from cyclopentadiene (78), dibenzoyl cyclopentene 79 was synthesized by
electrophilic addition of silverbonzoate in diethylether. 79 was then brominated by
NBS in allylic position to yield 80. The bromine was then substituted by an azide
group to yield 81, which was deprotected under basic conditions and reprotected
with acetone under acidic condition to 82. In the last step the azide was reduced in
the presence of CrCl2 to yield 63.
Due to poor reproducibility of this synthetic procedure, an improved version was
published in 1986. In this version deazaguanine aldehyde 83 was coupled to the
73






































































































































































































Scheme 2.5. Synthesis of dibromodeazaguanosine derivative 62 part 2.[100]
a) 0.5 N HCl, dioxane; b) NaH, MOMCl, dimethoxyethane; c) NaH, acetamide; d) Pd/C, H2,
methanol; e) acetone, 2,2-dimethoxypropane, D,L-camphorsulfonic acid; f) Ac2O, pyridine; g) NBS,
kat. benzoylperoxide, benzene; h) NBS, kat. benzoylperoxide, K2CO3, CCl4, reflux
cylopentylamino building block 63 by reductive amination to obtain isopropylidene
and MOM protected queuosine 66. Acidic deprotection lead to queuosine (67)
(scheme 2.7).
The deazaguanine aldehyde 83 was synthesized from 2-methylthio-7-methyl-7-
desazahypoxanthin (69), with dibromodeazaguanosine 62 as an intermediate, fol-
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Scheme 2.6. Synthesis of the cylopentylamino building block 63.[100]
a) AgOBn, Et2O; b) NBS; c) LiN3, DMF; d) NaOMe, methanol; e) acetone, 2,2-dimethoxypropane,
H+; f) CrCl2
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Scheme 2.7. Improved synthesis of queuosine 67.[102]
a) benzene; b) NaBH4, ethanol; c) 2 N HCl, methanol
lowing a shorter protocol (scheme 2.8).[100] In the first step 2-methylthio-7-methyl-7-
desazahypoxanthin (69) was deprotonated with n-BuLi and protected with MOMCl to
obtain 3-methoxymethyl-2-methylthio-7-methyl-7-desazahypoxanthin (84). 84 was
coupled to trityl- and isopropylidene protected chlorosugar 85 using Königs-Knorr
nucleosidation. The product nucleoside 86 was obtained as a mixture of α and β
anomeres in a 1:2 ratio. Substitution of the mercaptomethyl group with acetamide
was performed prior to separation of anomers to obtain 87. 87 was detrylated
with HBr and reprotected with acetanhydride to avoid side reactions in the following
steps, yielding 77. Bromination with an excess of NBS delivered the dibromodeaza-

































































































































































































Scheme 2.8. Synthesis of deazaguanine aldehyde 83 part 1.[102]
a) nBuLi, MOMCl, DME; b) NaBr; c) acetamide; d) HBr, DCM; e) Ac2O, pyridine; f) NBS, kat. ben-
zoylperoxide, benzene; g) NBS, kat. benzoylperoxide, K2CO3, CCl4, reflux
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To obtain deazaguanine aldehyde 83, dibromodeazaguanosine derivative 62 was
hydrolyzed in the presence of Ag2CO3 and subsequently debrominated with Pd/C
and H2 to 89. The primary alcohol was oxidized with MnO2 to form an aldehyde and


















































































































































































Scheme 2.9. Synthesis of deazaguanine aldehyde 83 part 2.[102]
a) dioxane/H2O, Ag2CO3; b) Pd/C, H2, AcOK, methanol/H2O; c) MnO2, MeCN; d) NH4OH, methanol
2.4.2. Synthetic strategies for queuine
Beside the nucleotide queuosine (67) the corresponding nucleobase queuine (95)
was an important synthetic target for the investigation of the role of queuosine in
cells. In 1988 Akimoto et al. first published a convergent synthetic route to queuine
(95) (scheme 2.10).[103] The used cylopentylamino building block 63 was synthe-
sized following the protocol of Gaoni, Posternak, Goto and Ohgi (scheme 2.6).
Starting from 2,4-diamino-6-hydroxypyrimidin (90), 7-deazaguanine (92) was syn-
thesized by condensation with α-chloroacetaldehyde (91) in the presence of sodium
methoxide. 7-deazaguanine (92) was acylated with octanoyl chloride at the 2-amino
position to compound 93. The acylation affects the electronic properties of the 5-
carbon, favoring the Mannich-reaction at the 5-position instead of the 6-position,
which is favored for the unmodified amino group. Mannich-reaction with formalde-
hyde and dibenzylamine in 80% acetic acid yielded aminodeazaguanine 94. Using
bulky amines like dibenzylamine supports regioselective reaction at the 5-position
due to steric reasons. The last critical step was an amino substitution reaction with
cyclopentylamine 63 in methanol/THF. For this reaction a large excess of 63 (5 eq.)
is necessary to gain a satisfactory yield. Subsequently deprotection under basic and
mild acidic condition yielded queuine (95).
Another synthetic route to queuine (95) was developed by Barnett et al. in 2000.[104]
In this route, queuine (95) is built up in a linear synthesis starting from cyclopen-
76





























































































































































































Scheme 2.10. Convergent synthesis of queuine (95) by Akimoto et al.[103]
a) NaOMe, pyridine/H2O; b) ClCOC7H15, pyridine; c) Bn2NH, formaldehyde, AcOH; d) MeOH/THF;
e) KOH; f) H+
tenol 100. Following a protocol developed by Borchard et al. in 1987 (scheme 2.11),[105]
R-ribose (96) is protected with isopropylidene and methoxy groups to 97, which is
oxidized with a four times excess of PCC. By this oxidation, a C-C cleavage occurs
leading to the formation of lactone 98. By an intramolecular Wittig-reaction, the lac-
ton 98 is converted to the cyclopentenone 99 and subsequently reduced with NaBH4






























































































































































Scheme 2.11. Synthesis of cyclopentenol 100 by Borchard et al.[105]
a) DMP, HClO4 methanol; b) PCC, benzene; c) (MeO)2POCH2Li; d) NaBH4, CeCl3, methanol.
Under the conditions of a Mitsunobu-reaction, sulfonamide 101 was coupled to cy-
clopentenol 100, yielding protected sulfonamide 102. The TBDMS protecting group
was cleaved with TBAF und the resulting alcohol 103 was oxidized with TEMPO
to obtain aldehyde 104. After condensation of aldehyde 104 with 2,4-diamino-6-
hydroxypyri- midin (90) protected queuine 105 was obtained. Deprotection yielded
the final product queuine (95) (scheme 2.12).
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Scheme 2.12. Linear synthesis of queuine (95) by Barnett et al.[104]
a) DIAD, PPh3, THF; b) TBAF, THF; c) TEMPO, NaOCl, KBr, DCM; d) TMSBr, DMSO, MeCN;
e) NaOAc, H2O/MeCN; f) HSCH2CH2OH, DBU, DMF; g) HCl, methanol
2.4.3. Improved syntheses for the cyclopentylamino building
block 63
Since the early 2000’s, shorter and more effective syntheses for cyclopentylamine
63 have been published.[106]–[109] The main challenge in the synthesis of this molecule
is to build up the three stereocenters, with the two hydroxy groups in cis-configuration
to each other and the amide function in trans-position to the adjacent hydroxy group.
Trost et al. puplished a six step synthesis in 2003 (scheme 2.13).[106] Starting
from cyclopentadiene (78), epoxide 106 was obtained by epoxidation with peracetic
acid. Opening of the epoxide under retention of the configuration was achieved
by using the strong lewis acid BF3·Et2O. In the presence of acetone, acetal 107
was obtained. Oxidation with SeO2 in boiling dioxane delivered alcohol 108 as a
racemic mixture of diastereomers. Conversion of the alcohol 108 to the methyl car-
bonates 109 occurred with methyl chlorocarbonate and pyridine, setting the stage
for the asymmetric allylic alkylation. By a stereoselective palladium catalyzed sub-
stitution with the (R,R)-DACH-Phenyl Trost-ligand 110 optically pure pthalimide 111
was obtained. Reaction of 111 with ethylenediamine released the primary amine,
yielding the cyclopentylamine 63.
In 1998 Van Boom et al. published a linear synthesis, containing twice as many
reaction steps, but after optimization by Leumann et al. the synthesis was feasible in
a multi gramm scale.[107], [108] According to the protocol of Leumann et al., the synthe-
78
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Scheme 2.13. Synthesis of the cylopentylamino building block 63 by Trost et al.[106]
a) AcOOH, Na2CO3, DCM; b) 10 mol% BF3·Et2O, acetone; c) SeO2, NaHPO4, dioxane, reflux;
d) ClCOOMe, pyridine, DCM; e) potassiumpthalimide, kat. Pd2dba2, (Hex)2NBr DCM; f) ethylendi-
amine, phenol, reflux
sis was started from D-mannose (112), which was protected with isopropylidene and
acetyl groups to obtain protected mannose 113. The 5,6-isopropylidene group was
hydrolyzed and the intermediate 114 was transformed to methyl ortoformate 115
subsequently. Thermal rearrangement of 115 by treatment with neat acetic anhy-
dride at 130 ◦C yielded compound 116, which was saponified to yield 117. Wittig
reaction furnished diene 118, followed by ring closing metathesis catalyzed by 1st















































































































































































Scheme 2.14. Synthesis of cylopentenol 119 by Leumann et al.[108]
a) DMP, TsOH; b) Ac2O, pyridine; c) 64% HOAc; d) HC(OMe)3; e) reflux, Ac2O; f) tertBuOK, MeOH;
g) NaH, BrCH2P(Ph)3, DMSO; h) 0.05 mol% Grubb’s 1st gen., DCM
Cyclopentenol 119 was converted into acetimidate 120 by trichloroacetonitrile and
79
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thermal [3,3]-rearrangement lead to trichloroacetamide 121, which was deprotected































































































































































Scheme 2.15. Synthesis of the cylopentylamino building block 63 by Van Boom et al.[107]
a) trichloroacetonitrile; b) o-xylol, 150 ◦C; c) NaOH, MeOH
2.4.4. Recent synthetic strategies for queuine
In 2012 Gerber and Klebe published a new synthetic route for queuine (95) using
the building blocks PreQ1 (58) and bromocyclopentene 122 which were connected






































































































































































Scheme 2.16. Synthesis of queuine (95) by Gerber and Klebe.[109]
a) DBU, DMF, 65 ◦C, 5 h; b) 1.25 M HCl/MeOH, reflux, 5 h
Bromocyclopentene 122 was synthesized starting from ribose (96) following the
protocol of Borchard et al.[105] to obtain cyclopentenol 100 (scheme 2.11).
To get the right diastereomer of bromocyclopentene 122, the chiral center of the
hydroxy group had to be inverted in the next step using Mitsunobu conditions and
subsequent saponification to yield the inverted cyclopentenol 124. In the last step
a mild bromination following a literature procedure of Diederich et al.[110] lead to
bromocyclopentene 122. Reinversion of the chiral center during the bromination
provided the required diastereomer (scheme 2.17).
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Scheme 2.17. Synthesis of bromocyclopentene 122.[109]
a) PNBA, TPP, DEAD, THF, 55 ◦C, 48 h; b) NaOH, MeOH-H2O 5:1, rt, 18 h, c) Br2, TPP, imidazole,
CH2Cl2, -20 ◦C to rt, 1 h
The synthesis of PreQ1 (58) started from phthalimidoacetaldehyde (125). In a first
step, β-nitroalcohol 126 was synthesized by using the Henry reaction, and the prod-
uct was was dehydrated by reaction with trifluoroacetic anhydride and subsequently
elimination of trifluoroacetate to obtain nitroolefin 127 as the trans isomer exclu-
sively. Michael addition of 2,4-diamino-6-hydroxypyrimidin (90) to the nitroolefin 127
yielded the racemic nitroalkyl compound 128, which was converted to phthalamic
acid 129 by Nef reaction immediately followed by intramolecular cyclyzation. In the
last step the amide was cleaved under acidic conditions to obtain PreQ1 (58) as the























































































































































































Scheme 2.18. Synthesis of preQ1 58.[109]
a) CH3NO2, cat. KOtBu, THF/CH3OH, 0-20◦C, 18 h; b) TFAA, THF, -5 ◦C, 15 min, then TEA, THF,
-10 ◦C, 5 min; c) 90, THF/EtOAc/H2O, 60 ◦C, 4 h; d) NaOH, H2O, 20 ◦C, 5 min, then H+ -5 ◦C to rt,
18 h; e) 6 M HCl, reflux, 6 h
81
2. Stimulation of S. pombe Dnmt2 by the micronutrient queuine
2.5. New synthesis of (1 R,2S,3S)-1-bromo-2,3- O-
isopropylidene-cyclopent-4-ene (122)
In 2012 Gerber and Klebe published a new synthetic route for the synthesis of
queuine (95) (see schemes 2.16, 2.17, 2.18).[109] Although being convergent, short
and concise, as well as good scalable, this route did still carry some disadvan-
tages. The main problems arose from the synthetic part of (1R,2S,3S)-1-bromo-
2,3-O-isopropylidene-cyclopent-4-ene (122) which based on the work of Borchard
et al.[105] (see scheme 2.11). It required some expensive reagents and huge excess
of toxic pyridinium chlorochromate. Additionally, a diastereoselective reduction was
necessary, which provided the exactly wrong diastereomer, due to the already ex-
isting stereochemical environment before the reduction. As a result, two more steps
were necessary to invert the wrong to the right diastereomer. Furthermore, the pu-
rification and storage of the cyclopentenone intermediate 99 was a problem due to
its volatility and poor stability.
The new synthesis was designed based on the route published by Gerber and
Klebe. Herein, PreQ1 (58) and (1R,2S,3S)-1-bromo-2,3-O-isopropylidene-cyclo-
pent-4-ene (122) are the desired building blocks as well. At the same time, the
synthetic route for 122 should be redesigned to avoid the disadvantages of the re-
cent synthesis and to simplify the handling. Thereby, the correct diastereomer has
to be synthesized without formation of chiral centers by stereoselective reactions.
Additionally, intermediates occurring in the new route should be stable, easy to pu-
rify and storable over several weeks. Moreover, all reagents have to be non toxic
and if possible inexpensive. In the end, the new synthetic route should not be longer
than the original one and should be feasible at a gram scale.
The pivotal goal of the new synthesis was to avoid any stereoselective reactions,
which are required to build up chiral centers or to invert diastereomers into each
other. Because of that, a suitable starting material had to be found, which already
possess all required chiral information in the right arrangement. These chiral infor-
mation have to be conserved for the synthetic procedure to avoid any loss of them.
In nature most molecules are chiral compounds, which posses numerous chiral
centers partly. Especially, the classes of pentoses and hexoses consist of a mul-
titude of different diastereomers. The target molecule allylic alcohol 130 shows
82
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three cis arranged hydroxy groups, positioned directly next to each other. From
all pentoses and hexoses, four aldohexoses, one ketohexose and one aldopentose
provide the desired arrangement of chiral centers (scheme 2.19). From these suit-
able sugars only D-galactose and L-arabinose are naturally occurring in reasonable










































































































































D-Allose L-Allose D-Altrose L-Altrose D-Glucose L-Glucose D-Mannose L-Mannose















































D-Psicose L-Psicose D-Fructose L-Fructose D-Sorbsose L-Sorbose D-Tagatose L-Tagatose
CH2OH
O























































































































































Scheme 2.19. Overview of hexoses and pentoses.
Sugars which possess the reacquired chiral information in the right arrangement are highlighted in
blue.
83
2. Stimulation of S. pombe Dnmt2 by the micronutrient queuine
of L-arabinose one of the regarded hydroxy groups is a part of the acetal bond in
the pyranose form. This might cause problems during the synthesis. Moreover,
L-arabinose is roughly ten times more expensive than D-galactose.1 Due to these
facts D-galactose was chosen as the best suited starting material.
Retrosynthetic analysis provided the following steps to convert a hexose into the
desired cyclopentenol building block. 1. glycol cleavage of the 5,6-diol to obtain
the dialdehyde. 2. Wittig olefination at both ends of the dialdehyde to get the di-
ene. 3. Ring-closing-metathesis. 4. Nucleophilic substitution under SN2-conditions





































































































































































Scheme 2.20. Retro synthesis of the bromocyclopentene building block.
To perform the glycol cleavage exclusively regioselective at the 5,6-diol it is nec-
essary to react all other hydroxy groups with suitable protecting groups. Following
a modified protocol developed by Leino et al., α-D-galactose should have been pro-
tected with an isopropylidene group at C3 and C4 and an acetyl group at C2.[111]
In order to achieve this regioselective protection the anomeric hydroxy group had
to be protected as benzylether first. This protecting group can be cleaved selec-
tively by catalytic hydrogenation later on. This first step was done starting from
pentaacetylgalactose (131) by substitution of the anomeric acetyl group with ben-
zyl alcohol in the presence of BF3 in DCM at ambient temperature. Afterwards,
all remaining acetyl groups were cleaved by saponification with sodium methox-
ide in methanol to obtain benzylgalactose 132. To acetylate the hydroxy group
at C2 selectively, the C6 hydroxy group had to be protected with TBDMS tem-
porarily, which gets cleaved in the presence of TBAF later on. The protection
was performed with TBDMSCl in DCM at ambient temperature. To avoid any re-
1The prices are compared from Sigma Aldrich for the 99% pure products.
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action at the C2 hydroxy group, DBU was used as a sterically demanding base
to activate the primary alcohol selectively. TBDMS protected benzylgalactose 133
should have been protected in the next step with 2,2-dimethoxypropane with p-
TsOH as a catalyst to obtain benzyl-3,4-O-isopropylidene-6-O-tertbutyldimethylsilyl-
galactose (134). However, the TBDMS group seemed to be unstable in the presence
of even catalytic amounts of p-TsOH, leading to cleavage and reaction of the C6
hydroxy group with 2,2-dimethoxypropane resulting in benzyl-3,4-O-isopropylidene-
6-methoxyisopropyl-galactose (136) as the only product (scheme 2.21). The suc-
cessful results from Leino et al. could not be reproduced.[111] Not being able to
selectively deprotect both hydroxy groups at C1 and C6 respectively, the following
steps to obtain the C2, C3 and C4 protected galactose derivative 135 could not be































1. BF3 OEt2, BnOH
    4 Å molecular sieves
    DCM, 20 h, rt
2. NaOMe, MeOH
    24 h, rt
54%
TBDMSCl, DBU
DCM, 30 min, rt
65%
2,2-dimethoxypropane,




















































































































































Scheme 2.21. Protecting group strategy to obtain galactose derivative 135.
To avoid the loss of the TBDMS group, the protection with an isopropylidene group
at C3 and C4 should be done before the protection of C6. Although, this strategy
goes along with the disadvantage of C2, C3, C4, and C6 as well as C4 and C6 pro-
tected byproducts, according to Catelani et al. the amount of these byproducts are
below 10%, using camphorsulfonic acid instead of pTsOH.[112]
However, the applicability of this synthetic strategy was not further evaluated.
Instead, a more suitable method for the C5 and C6 cleavage was found in the
zinc-mediated reductive fragmentation.[113] In this process, methyl-6-deoxy-6-iodo-
hexopyranosides are reacted with zinc powder in a THF/water mixture under son-
85
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ication to generate 5,6-dideoxy-hex-5-enoses, which are useful chiral synthons in






























































































































































Scheme 2.22. Zinc mediated reductive fragmentation of methyl-6-deoxy-6-iodo-hexopyranosides.
Murphy et al. published a protocol for the zinc mediated reductive fragmenta-
tion of mannose, followed by Horner Wittig Emmons olefination to obtain a pre-
cursor for C-glycosyl iminosugars.[114] This protocol was adapted with some ad-
justments for the synthesis of 3,4-O-isopropylidene-2-O-tertbutyldimethylsilyl-hex-
5-enal (141). Methyl-galactopyranoside (137) was chosen as the starting material,
which can be synthesized by reaction of galactose with methanol in acetylchlo-
ride, but is also commercially available at a reasonable price.[115] Protected 6-iodo-
galactopyranoside 140 was synthesized in three steps as a precursor for the zinc-













    acetone, 1.5 h, rt
2. I2, TPP, imidazole



























































































































































Scheme 2.23. Iodination and protection of methyl-galactopyranoside (137) to obtain 140.
First, methyl-galactopyranoside (137) was treated with CSA and 2,2-dimethoxypro-
pane in acetone to protect the hydroxy groups at C3 and C4 by an isopropylidene
group. The obtained methyl-4,6-O-isopropylidene-galactopyranoside (138) was io-
dinated with iodine in the presence of TPP and imidazole directly without previous
purification. This reaction is multiple times faster at the primary alcohol compared
to the secondary due to steric reasons. By this effect, the iodination takes place
at C6 exclusively. Methyl-6-iodo-3,4-O-isopropylidene-galactopyranoside (139) was
obtained in reasonable yield over two steps. As mentioned by Catelani et al. a small
amount (below 10%) of methyl-4,6-O-isopropylidene-galactopyranoside was formed
as byproduct during the first reaction step.[112] Following purification, the hydroxy
group at C2 was converted into the TBDMS-ether using TBDMSCl and imidazole in
DCM to obtain methyl-6-iodo-3,4-O-isopropylidene-2-O-tertbutyldimethylsilyl- galac-
topyranoside (140). Protection at C2 is required to avoid racemization after the re-
86
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ductive fragmentation step.
Methyl-6-iodo-3,4-O-isopropylidene-2-O-tertbutyldimethylsilyl-galactopyranoside
(140) was converted into 3,4-O-isopropylidene-2-O-tertbutyldimethylsilyl-hex-5-enal
(141) via zinc-mediated reductive fragmentation with zinc powder in a 1:9 mixture
of water and THF. The reaction was performed under sonication at 40 ◦C and the
product 141 was isolated in almost quantitative yield. α-hydroxy aldehydes are prone
for racemization at the α-carbon due to keto-enol tautomerism. This was prevented
effectively by conversion of the C2 hydroxy group into the silyl ether. Subsequently,
aldehyde 141 should be converted into heptadiene 142 via Wittig olefination. The
reaction was performed with MePPh3Br and n-BuLi in THF at 0 ◦C. Unfortunately,
no desired product was detectable. Only unidentified side products were formed.
The acidity of the α-proton might be problematic in the presence of n-BuLi. To
avoid harsh basic conditions, Wittig olefination was changed to Tebbe olefination,
which was applied with only Tebbe reagent in THF at 0 ◦C. In this case reaction
conditions are only slightly basic and the desired product 4,5-O-isopropylidene-3-
O-tertbutyldimethylsilyl-hepta-1,6-diene (142) was isolated in moderate yield after


















THF, 30 min, 0 °C
67%
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Scheme 2.24. Zinc mediated reductive fragmentation and Tebbe olefination to obtain heptadi-
ene 142.
After conversion of aldehyde 141 into heptadiene 142, the silylether was cleaved
by addition of TBAF in THF at ambient temperature in nearly quantitative yield.
After chromatographic purification, cyclopentenol 130 was formed by ring-closing-
metathesis, following a modified protocol of Smith et al.[116] The ring-closing metathe-
sis has emerged as a powerful and efficient process in the cyclyzation of dienes,
which is also advantageous in carbohydrate chemistry.[117] Using 5 mol% of second
generation Grubb’s catalyst in THF, the reaction was finished after stirring for two
87
2. Stimulation of S. pombe Dnmt2 by the micronutrient queuine






























































































































































Scheme 2.25. Cleavage of the silylether and RCM to obtain cyclopentenol 130.
The last steps were done similar to the queuine synthesis by Gerber and Klebe.[109]
First, the cyclopentenol 130 was converted into cyclopentene bromide 122 by reac-
tion of TPP to the hydroxy group and subsequently nucleophilic substitution under
SN2 conditions. Thereby, the chiral center at the hydroxy group was inverted to ob-
tain enantiomeric pure cyclopentene bromide 122 in fair yield. Finally, queuine was
synthesized by connection of cyclopentene bromide 122 and PreQ1 (58). This was
done again via nucleophilic substitution under SN2 conditions. The primary amine of
PreQ1 (58) was activated by the sterically demanding base DBU and cyclopentene
bromide 122 was added. Chromatographic purification yielded the isopropylidene
protected queuine 144, which was deprotected in refluxing acidic methanol solution




















DCM,45 min, -10 °C
76 % 41 %
HCl/MeOH
3 h, reflux 96 %
PreQ1




















































































































































Scheme 2.26. Bromination of cyclopentenol 130 and connection of building blocks 122 and 58 with
subsequent deprotection to obtain queuine (95).
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2.6. Stimulation of S. pombe Dnmt2 by queuine
In order to quantify the catalytic activity of S. pombe Dnmt2 (spDnmt2) in depen-
dency of queuine containing tRNAAsp, methyltransferase activity assays and bind-
ing affinity assays were performed by Sven Johansson from the Ficner group. A
new system was established, working exclusively outside of S. pombe to prove, that
queuine by itself is able to stimulate the catalytic reaction velocity.[118]
Therefore, unmodified tRNAAsp was converted into queuine containing Q34tRNAAsp
via transglycosylation with human guanine transglycosylase (TGT). Successful trans-
glycosylation was confirmed using a specific electrophoresis band-shift method de-




















































































































































Figure 2.3. Electrophoresis of guanine to queuine transglycosylation in tRNAAsp by TGT.
Samples were taken from the reaction mixture at the indicated time after addition of TGT.
Information provided by S. Johansson.[118]
The methyltransferase assay was performed with an assay kit developed by Dor-
gan et al. Therein, methyltransferase co-product SAH gets degraded by an enzy-
matic cascade, finally producing ureate and hydrogen peroxide. The latter oxidizes
3,5-dichloro-2-hydroxybenzenesulfonic acid, resulting in an increased absorbance
at 515 nm which can be monitored via UV-Vis spectroscopy and is directly related to
the enzyme activity. The measurements were performed independently with increas-
ing tRNAAsp and Q34tRNAAsp concentration respectively. The results are displayed
in figure 2.4.
Comparing the efficiency assays of spDnmt2 with G34tRNAAsp and Q34tRNAAsp
an increased Vmax value and a decreased K0.5 value were observed for Q34tRNAAsp.
Vmax was increased from 1.41 ± 0.01 min−1 to 2.59 ± 0.11 min−1, while K0.5 was de-
creased from 15.59 ± 0.29 µM to 6.88 ± 0.58 µM. These results suggest that gua-
89




















































































































































Figure 2.4. Methyltransferase activity assay.
The activity is plotted as substrate conversion per TAT concentration against G34tRNAAsp and
Q34tRNAAsp concentration respectively. Error bars representing standard deviation. Fitting were
performed applying the Hill equation with a free Hill coefficient.
Information provided by S. Johansson.[118]
nine/queuine exchange at position 34 in tRNAAsp directly increase the catalytic ef-
ficiency of spDnmt2. Moreover, spDnmt2 only poorly follows Michaelis-Menten ki-
netics, but is better described by the Hill equation, with an observed Hill coefficient
n = 1.63± 0.02 and n = 1.19± 0.07 for G34tRNAAsp and Q34tRNAAsp respectively
(figure 2.5).
These data suggest the existence of cooperativity for spDnmt2, although there
are no reports that the enzyme is active as a dimer or multimer. However, in some
monomeric enzymes some kind of cooperativity was observed, which might be due
to several conformations the enzyme takes on while forming the enzyme substrate
complex.[120]
The affinity assay was done by fluorescence anisotropy measurement using a Flu-
oromax III flourimeter (HORIBA JOBIN YVON). G34tRNAAsp and Q34tRNAAsp were
fluorescence labeled with 1 mM fluorescein-5-thiosemicarbazide in 100 mM NaOAc
buffer at pH 5.5. Binding of the fluorescent tRNA’s to spDnmt2 was measured by
florescence anisotropy with increasing spDnmt2 concentration (figure 2.6).
The data show a decrease of Kd from 0.96±0.05 µM for the binding of G34tRNAAsp
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Figure 2.5. Comparison of fitting with the Hill equation (left) and Michaelis-Menten equation (right).
Information provided by S. Johansson.[118]
to 0.67 ± 0.003 µM for the binding of Q34tRNAAsp. These results are in accor-
dance to the data obtained from the activity assay, showing 1.4 fold stronger bind-
ing of queuine incorporated tRNAAsp. However, the increase in binding affinity of





















































































































































Figure 2.6. Fluorescence anisotropy measurement as binding assay.
Information provided by S. Johansson.[118]
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2. Stimulation of S. pombe Dnmt2 by the micronutrient queuine
2.7. Summary
Dnmt2 is a family of RNA methyltransferases, which methylate cytosine 38 in tRNAAsp
at C5. In vivo studies suggest that the methylation is stimulated by incorporation of
the micronutrient queuosine. However, other factors can not be excluded. Establish-
ing of an in vitro method could proof the dependency of Dnmt2 but require significant
amounts of the rare nucleobase queuine.
Although some syntheses for queuine exist, they bear significant disadvantages
like usage of toxic reagents, difficult handling and stereoselective reactions. To im-
prove the queuine synthesis a new synthetic route was developed (scheme 2.27).
Starting from inexpensive α-methyl-galactopyranoside, queuine was obtained in 10
steps with an overall yield of 8%. Key steps in this new synthetic route are zinc medi-
ated reductive fragmentation of methyl-6-iodo-galactopyranoside, Tebbe olefination
and ruthenium catalyzed ring closing metathesis. In the process, the stereochem-
ical arrangement of the galactopyranoside was conserved making stereoselective
reactions expandable.
The synthesized queuine was used in an in vitro essay developed by Dorgan et al.,
proving that queuosine directly stimulates Dnmt2 catalyzed methylation (figure 2.4).
Theese data are supported by fluorescence anisotropy measurement, showing in-
creased binding affinity of queuosine containing tRNAAsp to Dnmt2 compared to
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3.1. General Equipment and Methods
General Reagent Information
All reagents, including anhydrous solvents, were purchased from commercial sup-
pliers (ABCR, Acros-Organics, Alfa Aesar, Fisher Scientific, Merck, Roth, Sigma-
Aldrich, TCI and VWR) without further purification. Technical solvents were distilled
prior to use. Ultrapure water was obtained via purification of demineralized water by
an arium mini water purification system by Sartorius.
Moisture sensitive reactions
Moisture sensitive reactions were performed under an argon (> 99.996%) atmo-
sphere. The gas was dried over P2O5 and KOH prior to use. Glassware was used
after heating in a vacuum und subsequent filling with inert gas. This procedure was
repeated three times.
Chromatography
Reactions were monitored by thin-layer chromatography (TLC) carried out on alu-
minum backed plates of silica gel 60 F254 (layer thickness: 0.20 mm) from Merck.
Spots were detected by fluorescence quenching at 254 nm or dying with KMnO4 so-
lution. Purification by flash chromatography was conducted using Merck Silica Gel
60 (particle size: 40-62 µm).
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3. Experimental section
High Performance Liquid Chromatography (HPLC)
HPLC was performed on the HPLC-system ÄKTA basic 10 by Amersham Phar-
macia Biotech equipped with a P-900 pump system and a UV-900 UV detection
module. It was used an anion exchange column typ Spherisorb SAX OBD 80A 5
250 mm × 19 mm from waters with a particle size of 5 µm. Purification was done at
a flow of 10 mL/min with a linear gradient of eluent A (ultrapure water) and eluent B
(0.5 M TEAA-buffer at pH = 7). Nucleotides were detected at 230 nm, 260 nm and
300 nm if not noted otherwise.
Freeze-Drying
Nucleotide solutions in TEAA buffer were freezed with liquid nitrogen and the
buffer was sublimated under reduced pressure (< 1 mbar) using an Alpha-2-4-LD
plus freeze-dryer from Christ.
3.2. Characterization
Nuclear Magnetic Resonance (NMR)
NMR spectra were recorded at Varian instruments (Mercury 300, Mercury VX 300,
Unity 300, VNMRS-300, Inova-500) and Bruker instruments (Avance III 400, Avance
III HD 400) using chloroform-d, DMSO-d6, methanol-d4 or D2O as the internal stan-
dard at 298 K. Chemical shifts are quoted in ppm and coupling constants in Hz.
Multiplicities are abbreviated as follows: s = singlet, sbr = broad singlet, d = doublet,
dd = doublet of doublets, t = triplet, dt = doublet of triplets, sept = septet, m = multi-
plet. 13C-NMR experiments were recorded with proton decoupling.
Mass Spectrometry
Mass spectrometry was performed using electron spray ionization (ESI). High res-
olution ESI spectra were obtained using microTOF-Q II or maXis ESI-QTOF-MS
instrument from Bruker. The values are given as m/z relation.
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3.3. X-ray diffraction data collection and processing
3.3. X-ray diffraction data collection and processing
Synchrotron X-ray diffraction
The datasets were measured under cryogenic conditions at the Deutsches Elektro-
nen-Synchrotron (DESY) in Hamburg at the PETRA III storage ring beamlines P13
and P14. For data collection, the protein crystals were exposed to maximal 1 MGy.
Data processing and image generation
3D crystal structures were processed using COOT, Jligand and SHELXL. Struc-
ture images were generated using PyMol.
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3. Experimental section





































































































































































To a stirred suspension of uridine (10) (6.0 g, 24.5 mmol, 1.0 eq.) in acetone
(360 mL) H2SO4 (1.5 mL) was added and the resulting solution was stirred at room
temperature for 24 h. The mixture was quenched with NEt3 (4.0 mL) and the solvent
was evaporated in vacuo. The crude product was purified by column chromatogra-
phy on silica gel using DCM/MeOH 9:1. The desired product (11) (6.19 g, 21.8 mmol,
89%) was obtained as a white solid.
1H-NMR (300 MHz, DMSO-d6): δ = 11.38 (sbr, 1 H, NH), 7.78 (d, J = 8.1 Hz, 2 H,
H-6), 5.82 (d, J = 2.7 Hz, 1 H, H-1’), 5.56 (d, J = 8.1 Hz, 1 H, H-5), 4.89 (dd, J = 6.3,
2.7 Hz, 1 H, H-2’), 4.74 (dd, J = 6.3, 3.6 Hz, 1 H, H-3’), 4.08-4.04 (m, 1 H, H-4’),
3.63-3.50 (m, 2 H, H-5’), 1.48 (s, 3 H, CH3), 1.28 (s, 3 H, CH3) ppm.
13C-NMR (125 MHz, DMSO-d6): δ = 163.2 (C-4), 150.4 (C-2), 141.7 (C-6), 113.0
(C(CH3)), 101.8 (C-5), 91.2 (C-1’), 86.5 (C-4’), 83.7 (C-2’), 80.5 (C-3’), 61.3 (C-5’),
27.1 (CH3), 25.2 (CH3) ppm.
MS (ESI): m/z (%) = 307.1 (100) [M+Na]+, 283.1 (100) [M-H]−.
HRMS: m/z calc. for C12H16N2O6Na [M+Na]+: 307.0901, found: 307.0902.
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Under an argon atmosphere, 11 (6.19 g, 21.8 mmol, 1.0 eq.), imidazole (3.7 g,
54.5 mmol, 2.5 eq.) and TBDMSCl (4.92 g, 32.7 mmol, 1.5 eq.) were dissolved
in dry DMF (50 mL) and the solution was stirred at room temperature for 24 h. The
solvent was evaporated in vacuo and the crude product was purified by column chro-
matography on silica gel using DCM/MeOH 95:5. The desired product (12) (8.3 g,
20.9 mmol, 96%) was obtained as a white solid.
1H-NMR (300 MHz, DMSO-d6): δ = 11.33 (sbr, 1 H, NH), 7.68 (d, J = 8.1 Hz,
2 H, H-6), 5.80 (d, J = 2.3 Hz, 1 H, H-1’), 5.57 (d, J = 8.1 Hz, 1 H, H-5), 4.90 (dd,
J = 6.3, 2.3 Hz, 1 H, H-2’), 4.71 (dd, J = 6.3, 3.6 Hz, 1 H, H-3’), 4.13-4.09 (m, 1 H,
H-4’), 3.83-3.71 (m, 2 H, H-5’), 1.48 (s, 3 H, CH3), 1.29 (s, 3 H, CH3), 0.86 (s, 9 H,
SiC(CH3)3), 0.04 (s, 6 H, Si(CH3)2) ppm.
13C-NMR (125 MHz, DMSO-d6): δ = 163.9 (C-4), 150.0 (C-2), 141.6 (C-6), 112.8
(C(CH3)), 101.4 (C-5), 91.6 (C-1’), 86.5 (C-4’), 83.9 (C-2’), 80.3 (C-3’), 63.1 (C-5’),
27.0 (CH3), 25.7 (SiC(CH3)3), 25.2 (CH3), 17.9 (SiC(CH3)3), 5.5 Si(CH3)2 ppm.
MS (ESI): m/z (%) = 399.2 (75) [M+H]+, 421.2 (100) [M+Na]+, 397.2 (100) [M-H]−.











1. LDA, THF, 2 h, -78 °C





























































































































































Under an argon atmosphere, 12 (1.0 g, 2.5 mmol, 1.0 eq.) was dissolved in dry
THF (15 mL) and the solution was cooled to -78 ◦C. LDA solution (2 M in THF,
3.13 mL, 6.25 mmol, 2.5 eq.) was added dropwise. The resulting brownish solution
was stirred at -78 ◦C for 30 min and subsequently CO2 was bubbled trough the so-
lution for 4 h. The mixture was quenched by the addition of HOAc (1 mL) and the
solvent was evaporated in vacuo. The crude product was purified by column chro-
matography on silica gel using DCM/MeOH 4:1. The desired product (13) (811 mg,
1.8 mmol, 72%) was obtained as a white solid.
1H-NMR (300 MHz, DMSO-d6): δ = 6.04 (d, J = 1.1 Hz, 1 H, H-1’), 5.35 (s, 1 H,
H-5), 5.11 (dd, J = 6.4, 1.1 Hz, 1 H, H-2’), 4.70 (dd, J = 6.4, 4.3 Hz, 1 H, H-3’),
3.93-3.85 (m, 1 H, H-4’), 3.78-3.66 (m, 2 H, H-5’), 1.42 (s, 3 H, CH3), 1.26 (s, 3 H,
CH3), 0.85 (s, 9 H, SiC(CH3)3), 0.02 (s, 3 H, Si(CH3)), 0.01 (s, 3 H, Si(CH3)) ppm.
13C-NMR (125 MHz, DMSO-d6): δ = 163.4 (C-4), 163.1 (COOH), 156.3 (C-2),
150.5 (C-6), 112.2 (C(CH3)), 97.2 (C-5), 92.5 (C-1’), 88.6 (C-4’), 84.3 (C-2’), 82.0
(C-3’), 63.8 (C-5’), 27.1 (CH3), 25.8 (SiC(CH3)3), 25.2 (CH3), 18.0 (SiC(CH3)3), -5.2
Si(CH3), -5.3 Si(CH3) ppm.
MS (ESI): m/z (%) = 441.2 (100) [M-H]−.
HRMS: m/z calc. for C19H30N2O8Si [M-H]−: 441.1699, found: 441.1693.
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13 (811 mg, 1.8 mmol, 1.0 eq.) was dissolved in TFA/H2O (50:50 v/v, 15 mL)
and the solution was stirred at ambient temperature for 30 min. The solvents were
evaporated in vacuo. The residue was dissolved in water (5 mL) and washed with
EtOAc (3 × 5 mL). The solvent was evaporated in vacuo. The desired product (14)
(472 mg, 1.64 mmol, 91%) was obtained as a white solid.
1H-NMR (300 MHz, DMSO-d6): δ = 11.09 (s, 1 H, COOH), 8.48 (sbr, 1 H, NH),
5.58 (d, J = 3.8 Hz, 1 H, H-1’), 5.36 (s, 1 H, H-5), 4.49 (dd, J = 6.1, 3.8 Hz, 1 H,
H-2’), 4.08 (t, J = 6.1 Hz, 1 H, H-3’), 3.70-3.39 (m, 3 H, H-4’, H-5’) ppm.
MS (ESI): m/z (%) = 287.1 (100) [M-H]−.












































































































































































Under an argon atmosphere, orotidine (14) (500 mg, 1.73 mmol, 1.0 eq.) was
suspended in dry trimethylphosphate (5 mL) and was cooled to 0 ◦C. Phosphoroxy-
chloride (316 µL, 531 mg 3.47 mmol, 2.0 eq.) was added dropwise and the resulting
solution was stirred at 0 ◦C for 6 h. The mixture was quenched by the addition of
water (1 mL) and the solvent was evaporated in vacuo. The crude product was pu-
rified by ion exchange HPLC using a linear gradient of TEAA in water at pH 7. The
product (1) was obtained as the triethylammonium salt.
1H-NMR (300 MHz, D2O): δ = 5.87 (s, 1 H, H-5), 5.65 (d, J = 3.2 Hz, 1 H, H-1’),
4.88 (dd, J = 6.5, 3.2 Hz, 1 H, H-2’), 4.52 (t, J = 6.5 Hz, 1 H, H-3’), 4.30-4.08 (m,
3 H, H-4’, H-5’) ppm.
13C-NMR (125 MHz, D2O): δ = 167.1 (C-4), 166.2 (COOH), 155.3 (C-2), 151.1
(C-6), 98.7 (C-5), 95.0 (C-1’), 82.5 (C-4’), 71.9 (C-2’), 69.5 (C-3’), 64.6 (C-5’) ppm.
31P-NMR (25 MHz, D2O): δ = 0.46 ppm.
MS (ESI): m/z (%) = 367.0 (100) [M-H]−.
HRMS: m/z calc. for C10H13N2O11P [M-H]−: 367.0184, found: 367.0180.
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6 h, 130 °C



















































































































































Barbituric acid (15) (1.28 g, 10.0 mmol, 1.0 eq.) was suspended in HMDS (30 mL)
and TMSCl (1 mL) was added. The reaction mixture was stirred for 6 h under re-
flux. The resulting solution was cooled to ambient temperature and the solvent was













































































































































































Under an argon atmosphere, 16 (3,45 g, 10.0 mmol, 1.1 eq.) was dissolved in 1,2-
dichloroethan (40 mL) and SnCl4 (1.3 mL, 2.86 g, 11 mmol, 1.25 eq.) was added.
1-O-Acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose (17) (4.4 g, 8.8 mmol, 1.0 eq.) dis-
solved in 1,2-dichloroethan (20 mL) was added dropwise. The resulting solution was
stirred for 6 h at ambient temperature and poured into saturated NaHCO3-solution
(100 mL). The resulting suspension was filtered through a plug of silica gel and the
layers were separated. The organic layer was dried over MgSO4 and the solvent was
evaporated in vacuo. The crude product was purified by column chromatography on
silica gel using DCM/MeOH 9:1. The desired product (18) (2.0 g, 3.5 mmol, 40%)
was obtained as a yellowish solid.
1H-NMR (300 MHz, DMSO-d6): δ = 11.49 (sbr, 1 H, NH), 8.01-7.27 (m, 15 H, Ph-
H), 6.49 (d, J = 1.9 Hz, 1 H, H-1’), 6.15-6.05 (m, 2 H, H-2’, H-3’), 4.72-4.48 (m, 3 H,
H-4’, H-5’), 3.72 (s, 2 H, H-5) ppm.
13C-NMR (125 MHz, DMSO-d6): δ = 165.2 (C-6), 164.5 (C-4), 164.3 (COOPh),
150.7 (C-2), 133.6, 133.4, 133.1, 129.1, 129.0, 128.5, 128.4, 128.2 (C-Ph), 85.1
(C-1’), 77.8 (C-4’), 73.8 (C-2’), 70.1 (C-3’), 63.4 (C-5’), 56.2 (C-5) ppm.
MS (ESI): m/z (%) = 573.2 (28) [M+H]+, 595.1 (100) [M+Na]+, 571.1 (100) [M-H]−.
HRMS: m/z calc. for C30H24N2O10Na [M+Na]+: 595.1323, found 595.1298.
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18 (2.0 g, 3.5 mmol, 1.0 eq.) was dissolved in methanol (40 mL) and NaOMe
(500 mg) was added. The solution was stirred for 20 h at ambient temperature. It
was neutralized with DOWEX 50 W ion exchange resin. After filtration the solvent
was removed in vacuo and the residue was redissolved in water (20 mL). The aque-
ous solution was washed with Et2O (3 × 30 mL). Removal of the solvent in vacuo
yielded the product (19) (720 mg, 2.8 mmol, 80%) as a yellow solid.
1H-NMR (300 MHz, DMSO-d6): δ = 11.35 (sbr, 1 H, NH), 5.88 (d, J = 3.2 Hz, 1 H,
H-1’), 5.12-5.09 (m, 2 H, H-2’, H-3’), 4.05-3.98 (m, 3 H, H-4’, H-5’), 3.66 (s, 2 H, H-5)
ppm.
13C-NMR (125 MHz, DMSO-d6): δ = 166.9 (C-6), 166.2 (C-4), 151.1 (C-2), 88.0
(C-1’), 84.3 (C-4’), 71.6 (C-2’), 70.1 (C-3’), 62.4 (C-5’), 56.2 (C-5) ppm.
MS (ESI): m/z (%) = 283.1 (100) [M+Na]+, 259.1 (100) [M-H]−.














































































































































































Under an argon atmosphere, 19 (220 mg, 846 µmol, 1.0 eq.) was dissolved in dry
trimethylphosphate (3 mL) and was cooled to 0 ◦C. Phosphoroxychloride (154 µL,
259 mg 1.60 mmol, 2.0 eq.) was added dropwise and the resulting solution was
stirred at 0 ◦C for 6 h. The mixture was quenched by the addition of water (1 mL)
and the solvent was evaporated in vacuo. The crude product was purified by ion
exchange HPLC using a linear gradient of 0.5 M TEAA in water at pH 7. The product
(3) was obtained as the triethylammonium salt.
MS (ESI): m/z (%) = 339.0 (100) [M-H]−.
HRMS: m/z calc. for C9H13N2O10P [M-H]−: 339.0235, found 339.0237.
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Under an argon atmosphere, 6-azauridine (20) (400 mg, 1.63 mmol, 1.0 eq.) was
dissolved in dry trimethylphosphate (4 mL) and was cooled to 0 ◦C. Phosphoroxy-
chloride (297 µL, 3.26 mmol, 2.0 eq.) was added dropwise and the resulting reaction
mixture was stirred at 0 ◦C for 6 h. The mixture was quenched by the addition of wa-
ter (1 mL) and the solvent was evaporated in vacuo. The crude product was purified
by ion exchange HPLC using a linear gradient of 0.5 M TEAA in water at pH 7. The
product (4) was obtained as the triethylammonium salt.
MS (ESI): m/z (%) = 324.0 (66) [M-H]−.











1. LDA, THF, 2 h, -78 °C






























































































































































Under an argon atmosphere, 12 (2.15 g, 4.86 mmol, 1.0 eq.) was dissolved in
dry THF (30 mL) and the solution was cooled to -78 ◦C. LDA solution (1.5 M in THF,
8.1 mL, 12.1 mmol, 2.5 eq.) was added dropwise. The resulting brownish solution
was stirred at -78 ◦C for 30 min. ClCOOMe (414 µL, 505.1 mg, 5.35 mmol, 1.1 eq.)
was added dropwise at -78 ◦C, the solution was warmed to ambient temperature and
stirred for 30 min. The mixture was quenched by the addition of HOAc (1 mL) and
the solvent was evaporated in vacuo. The crude product was purified by column
chromatography on silica gel using pentane/EtOAc 1:1. The desired product (21)
(1.4 g, 3.10 mmol, 64%) was obtained as a greenish solid.
1H-NMR (300 MHz, CDCl3): δ = 8.83 (sbr, 1 H, NH), 6.08 (s, 1 H, H-5), 5.90 (d,
J = 2.0 Hz, 1 H, H-1’), 5.18 (dd, J = 6.2, 2.0 Hz, 1 H, H-2’), 4.73 (dd, J = 6.2, 3.1 Hz,
1 H, H-3’), 4.14-4.06 (m, 1 H, H-4’), 3.87-3.71 (m, 2 H, H-5’), 1.54 (s, 3 H, CH3), 1.34
(s, 3 H, CH3), 0.88 (s, 9 H, SiC(CH3)3), 0.05 (s, 6 H, Si(CH3)) ppm.
13C-NMR (125 MHz, CDCl3): δ = 162.4 (C-4), 162.1 (COOMe), 150.1 (C-2), 145.3
(C-6), 114.5 (C(CH3)), 106.1 (C-5), 93.5 (C-1’), 88.8 (C-4’), 84.8 (C-2’), 81.6 (C-
3’), 64.0 (C-5’), 54.5 (COOMe), 27.4 (CH3), 26.1 (SiC(CH3)3), 25.5 (CH3), 18.6
(SiC(CH3)3), -5.2 Si(CH3) ppm.
MS (ESI): m/z (%) = 479.2 (25) [M+Na]+, 455.2 (100) [M-H]−.
HRMS: m/z calc. for C20H32N2O8SiNa [M+Na]+: 479.1820, found: 479.1813.
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7M NH3 in MeOH































































































































































21 (1.41 g, 3.1 mmol, 1.0 eq.) was dissolved in 7 M NH3 methanolic solution
(50 mL) und the solution was stirred at ambient temperature for 20 h. The solvent
was evaporated in vacuo and the crude product was purified by column chromatog-
raphy on silica gel using pentane/EtOAc 1:1. The desired product (22) (838 mg,
1.9 mmol, 61%) was obtained as a white solid.
1H-NMR (300 MHz, CDCl3): δ = 11.62 (sbr, 1 H, NH), 8.44 (s, 1 H, NH2), 8.12 (s,
1 H, NH2), 6.69 (s, 1 H, H-5), 5.66 (d, J = 2.0 Hz, 1 H, H-1’), 5.16 (dd, J = 6.2, 2.0 Hz,
1 H, H-2’), 4.70 (dd, J = 6.2, 3.1 Hz, 1 H, H-3’), 3.98-3.92 (m, 1 H, H-4’), 3.76-3.70
(m, 2 H, H-5’), 1.44 (s, 3 H, CH3), 1.27 (s, 3 H, CH3), 0.85 (s, 9 H, SiC(CH3)3), 0.02
(s, 6 H, Si(CH3)) ppm.
13C-NMR (125 MHz, CDCl3): δ = 163.2 (C-4), 162.5 (COONH2), 150.2 (C-2), 149.7
(C-6), 112.9 (C(CH3)), 101.1 (C-5), 92.5 (C-1’), 88.7 (C-4’), 84.2 (C-2’), 81.8 (C-3’),
63.5 (C-5’), 27.1 (CH3), 25.8 (SiC(CH3)3), 25.2 (CH3), 18.0 (SiC(CH3)3), -5.2 Si(CH3)
ppm.
MS (ESI): m/z (%) = 464.2(100) [M+Na]+.










0.5 M HCl in MeOH































































































































































22 (461 mg, 1.04 mmol, 1.0 eq.) was dissolved in 0.5 M HCl in MeOH (10 mL)
and the solution was stirred at ambient temperature for 30 min. The solvents were
evaporated in vacuo. The desired product (23) (371 mg, 1.04 mmol, quant.) was
obtained a greenish solid.
1H-NMR (300 MHz, CD3OD): δ = 5.77 (s, 1 H, H-5), 5.53 (d, J = 3.1 Hz, 1 H, H-1’),
4.69 (dd, J = 6.2, 3.1 Hz, 1 H, H-2’), 4.28 (dd, J = 6.2, 1.0 Hz, 1 H, H-3’), 3.77-3.68
(m, 3 H, H-4’, H-5’) ppm.
13C-NMR (125 MHz, CD3OD): δ = 166.1 (C-4), 165.2 (COONH2), 152.4 (C-2),
151.1 (C-6), 102.5 (C-5), 96.1 (C-1’), 86.5 (C-4’), 73.5 (C-2’), 71.2 (C-3’), 63.6 (C-5’)
ppm.
MS (ESI): m/z (%) = 310.1 (100) [M+Na]+, 286.1 (80) [M-H]−.
HRMS: m/z calc. for C10H13N3O7Na [M+Na]+: 310.0646, found: 310.0646.
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POCl3 (215 µL, 2.30 mmol, 4.4 eq.) was dissolved in MeCN (1 mL) and the solu-
tion was cooled to 0 ◦C. Pyridine (186 µL, 2.30 mmol, 4.4 eq.) and water (20.7 µL,
1.15 mmol, 2.2 eq.) were added and the solution was stirred at 0 ◦C for 3 min. 23
(150 mg, 522 µmol, 1.0 eq.) was added and the resulting suspension was stirred at
0 ◦C for 20 min. Ice cold water (20 mL) was added and the solution was stirred for
30 min. The solvents were evaporated in vacuo and the crude product was purified
by ion exchange HPLC using a linear gradient of TEAA in water at pH 7. The product
(8) was obtained as the triethylammonium salt.
MS (ESI): m/z (%) = 390.0 (25) [M+Na]+, 366.0 (100) [M-H]−.
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21 (207 mg, 453 µmol, 1.0 eq.) was dissolved in 0.5 M HCl in MeOH (5 mL) and
the solution was stirred at ambient temperature for 30 min. The solvents were evap-
orated in vacuo. The desired product (24) (137 mg, 453 µmol, quant.) was obtained
as a greenish solid.
1H-NMR (300 MHz, CD3OD): δ = 6.00 (s, 1 H, H-5), 5.58 (d, J = 4.0 Hz, 1 H, H-1’),
4.64 (dd, J = 6.5, 4.0 Hz, 1 H, H-2’), 4.19 (t, J = 6.5, 1 H, H-3’), 3.94 (s, 3 H, CH3)
3.98-3.74 (m, 3 H, H-4’, H-5’) ppm.
MS (ESI): m/z (%) = 325.1 (50) [M+Na]+, 301.1 (45) [M-H]−.
HRMS: m/z calc. for C11H14N2O8Na [M+Na]+: 326.0642, found: 326.0642.
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Under an argon atmosphere, uridine (10) (10 g, 41.0 mmol, 1.0 eq.) was dissolved
in dry DMF (15 mL). NIS (11.9 , 49.2 mmol, 1.2 eq.) was added and the solution was
stirred for 20 h, at ambient temperature. The solvent was removed in vacuo and the
resulting crude product was purified by column chromatography on silica gel using
DCM/MeOH 9:1. The desired product (26) (7.6 g, 20.5 mmol, 50%) was obtained
as a white solid.
1H-NMR (300 MHz, DMSO-d6): δ = 11.66 (s, 1 H, NH), 8.47 (s, 1 H, H-6), 5.72 (d,
J = 4.4 Hz, 1 H, H-1’), 5.40 (d, J = 5.2 Hz, 1 H, OH-2’), 5.24 (t, J = 4.6, 1 H, H-2’),
5.05 (d, J = 5.0, 1 H, OH-3’), 4.10-3.93 (m, 2 H, H-3’, H-4’), 3.90-3.34 (m, 3 H, H-5’,
OH-5’) ppm.
MS (ESI): m/z (%) = 393.0 (38) [M+Na]+, 369.0 (100) [M-H]−.




















M: 370.1 g/mol M: 524.4 g/mol
1. acetone, H2SO4
    3 h, rt
2. TBDMSCl, Imidazole,





















































































































































To a stirred suspension of 5-iodouridine (26) (7.6 g, 20.5 mmol, 1.0 eq.) in ace-
tone (350 mL) H2SO4 (1.5 mL) was added and the resulting solution was stirred at
room temperature for 4 h. The resulting solution was quenched with NEt3 (4.0 mL)
and the solvent was evaporated in vacuo. The residue was redissolved in dry DMF
(50 mL). Imidazole (3.4 g, 51.3 mmol, 2.5 eq.) and TBDMSCl (4.63 g, 30.8 mmol,
1.5 eq.) were added and the solution was stirred for 3 h at ambient temperature.
The solvent was evaporated in vacuo and the crude product was purified by column
chromatography on silica gel using pentane/EtOAc 1:1. The desired product (27)
(6.35 g, 12.1 mmol, 59%) was obtained as a white solid.
1H-NMR (300 MHz, CDCl3): δ = 8.76 (s, 1 H, NH), 7.94 (s, 1 H, H-6), 5.86 (d,
J = 2.7 Hz, 1 H, H-1’), 4.76-4.66(m, 2 H, H-2’, H-3’), 4.41-4.36 (m, 1 H, H-4’), 3.92
(dd, J = 11.7 Hz, 2.2 Hz, 1 H, H-5’a), 3.80 (dd, J = 11.6 Hz, 3.0 Hz, 1 H, H-5’b), 1.59
(s, 3 H, CH3), 1.36 (s, 3 H, CH3), 0.91 (s, 9 H, SiC(CH3)3), 0.13 (s, 6 H, Si(CH3)) ppm.
13C-NMR (125 MHz, CDCl3): δ = 159.9 (C-4), 149.7 (C-2), 144.7 (C-6), 114.1
(C(CH3)), 93.1 (C-1’), 86.7 (C-4’), 85.4 (C-2’), 80.7 (C-3’), 68.1 (C-5), 63.4 (C-
5’), 27.2 (CH3), 26.1 (SiC(CH3)3), 25.3 (CH3), 18.5 (SiC(CH3)3), -5.0 Si(CH3), -5.3
Si(CH3) ppm.
MS (ESI): m/z (%) = 525.1 (100) [M+H]+, 523.1 (100) [M-H]−.
HRMS: m/z calc. for C18H30N2O6SiI [M+H]+: 525.0912, found: 525.0911.
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Under an argon atmosphere, 27 (3.0 g, 5,7 mmol, 1.0 eq.) was dissolved in
dry DMF (60 mL). KCN (445 mg, 6.84 mmol, 1.2 eq.) and 18-crown-6 (301 mg,
1.14 mmol, 0.2 eq.) were added and the solution was stirred for 20 h at ambient
temperature. The solvent was evaporated in vacuo and the crude product was puri-
fied by column chromatography on silica gel using pentane/EtOAc 1:1. The desired
product (28) (1.83 g, 4.3 mmol, 75%) was obtained as a white solid.
1H-NMR (300 MHz, CDCl3): δ = 9.37 (s, 1 H, NH), 6.31 (d, J = 2.0 Hz, 1 H, H-5),
6.05 (d, J = 2.3 Hz, 1 H, H-1’), 5.13 (dd, J = 6.7 Hz, 2.3 Hz, 1 H, H-2’), 4.78 (dd,
J = 6.7 Hz, 4.7 Hz, 1 H, H-3’), 4.21-4.07 (m, 1 H, H-4’), 3.89-3.76 (m, 2 H, H-5’), 1.58
(s, 3 H, CH3), 1.35 (s, 3 H, CH3), 0.89 (s, 9 H, SiC(CH3)3), 0.06 (s, 6 H, Si(CH3)) ppm.
13C-NMR (125 MHz, CDCl3): δ = 160.5 (C-4), 148.7 (C-2), 127.9 (C-6), 115.1
(C(CH3)), 113.2 (C-5), 110.9 (CN), 93.8 (C-1’), 88.7 (C-4’), 83.7 (C-2’), 81.4 (C-3’),
63.5 (C-5’), 27.3 (CH3), 26.1 (SiC(CH3)3), 25.5 (CH3), 18.6 (SiC(CH3)3), -5.1 Si(CH3)
ppm.
MS (ESI): m/z (%) = 224.2 (95) [M+H]+, 446.2 (100) [M+Na]+, 422.0 (100) [M-H]−.









































































































































































Under an argon atmosphere, 28 (600 mg, 1.41 mmol, 1.0 eq.) and ZnCl2 (97 mg,
710 µmol, 0.5 eq.) were dissolved in dry THF (15 mL) and the solution was cooled
to 0 ◦C. iPrMgBr (3 M in 2-methyl-THF, 1.42 mL, 7.1 mmol, 3.0 eq.) was added and
the solution was stirred for 3 h at ambient temperature. The reaction was quenched
by addition of saturated NH4Cl solution (15 mL). The layers were separated and the
aqueous layer was extracted with THF (3 × 10 mL). The combined organic layers
were dried over MgSO4 and the solvent was evaporated in vacuo. The crude prod-
uct was purified by column chromatography on silica gel using pentane/EtOAc 2:1.
The desired product (29) (212 mg, 481 µmol, 34%) was obtained as a white solid.
1H-NMR (300 MHz, CDCl3): δ = 9.16 (s, 1 H, NH), 5.80 (s, 1 H, H-5), 5.64 (s, 1 H,
H-1’), 5.19 (d, J = 6.5 Hz, 1 H, H-2’), 4.81 (t, J = 5.1 Hz, 1 H, H-3’), 4.17-4.06 (m,
1 H, H-4’), 3.86-3.78 (m, 2 H, H-5’), 2.97 (sept, J = 6.7 Hz, 1 H, CH(CH3)2), 1.54
(s, 3 H, CH3), 1.33 (s, 3 H, CH3), 1.28 (t, J = 7.7 Hz, 6 H, CH(CH3)2), 0.87 (s, 9 H,
SiC(CH3)3), 0.04 (s, 6 H, Si(CH3)) ppm.
13C-NMR (125 MHz, CDCl3): δ = 163.4 (C-4), 162.7 (C-6), 150.9 (C-2), 113.9
(C(CH3)), 99.1 (C-5), 91.0 (C-1’), 89.6 (C-4’), 84.7 (C-2’), 82.3 (C-3’), 64.4 (C-5’),
29.7 (CH(CH3)2)), 27.4 (CH3), 26.1 (SiC(CH3)3), 25.5 (CH3), 22.2 (CH(CH3)2)), 21.4
(CH(CH3)2)), 18.6 (SiC(CH3)3), -5.1 Si(CH3) ppm.
MS (ESI): m/z (%) = 441.3 (100) [M+H]+, 881.5 (95) [2M+H]+, 439.2 (100) [M-H]−.
HRMS: m/z calc. for C21H37N2O6SiNa [M+Na]+: 441.2415, found: 441.2419.
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29 (212 mg, 481 µmol, 1.0 eq.) was dissolved in 0.5 M HCl in MeOH (5 mL) and
the solution was stirred at ambient temperature for 4 h. The solvent was evaporated
in vacuo. The desired product (30) (138 mg, 481 µmol, quant.) was obtained a white
solid.
1H-NMR (300 MHz, DMSO-d6): δ = 4.86 (d, J = 3.8 Hz, 1 H, H-1’), 4.81 (s, 1 H,
H-5), 3.92 (dd, J = 6.4 Hz, 3.7 Hz, 1 H, H-2’), 3.52 (t, J = 6.3 Hz, 1 H, H-3’), 3.07
(td, J = 6.0 Hz, 2.9 Hz, 1 H, H-4’), 2.95-2.81 (m, 2 H, H-5’), 2.26 (sept, J = 6.7 Hz,
1 H, CH(CH3)2), 0.49 (d, J = 6.7 Hz, 6 H, CH(CH3)2) ppm.
13C-NMR (125 MHz, DMSO-d6): δ = 164.5 (C-4), 163.4 (C-6), 151.3 (C-2), 98.1
(C-5), 91.7 (C-1’), 84.8 (C-4’), 71.7 (C-2’), 70.0 (C-3’), 62.4 (C-5’), 29.4 (CH(CH3)2)),
21.0 (CH(CH3)2)), 20.4 (CH(CH3)2)) ppm.
MS (ESI): m/z (%) = 287.1 (66) [M+H]+, 309.1 (60) [M+Na]+, 573.3 (100) [2M+H]+,
285.1 (57) [M-H]−.










































































































































































POCl3 (189 µL, 2.06 mmol, 4.4 eq.) was dissolved in MeCN (1 mL) and the solu-
tion was cooled to 0 ◦C. Pyridine (186 µL, 2.30 mmol, 4.4 eq.) and water (23.0 µL,
1.30 mmol, 2.2 eq.) were added and the solution was stirred at 0 ◦C for 3 min. 30
(138 mg, 481 µmol, 1.0 eq.) was added and the resulting suspension was stirred
at 0 ◦C for 5 h. Ice cold water (20 mL) was added and the solution was stirred for
30 min. The solvents were evaporated in vacuo and the crude product was purified
by ion exchange HPLC using a linear gradient of TEAA in water at pH 7. The product
(9) was obtained as the triethylammonium salt.
MS (ESI): m/z (%) = 365.1 (100) [M-H]−.
HRMS: m/z calc. for C12H18N2O9P [M-H]−: 365.0755, found: 365.0746.
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1. LDA, THF, 2 h, -78 °C
2. CS2, 30 min, -78   rt































































































































































Under an argon atmosphere, 12 (1.0 g, 2.5 mmol, 1.0 eq.) was dissolved in dry
THF (15 mL) and the solution was cooled to -78 ◦C. LDA solution (2 M in THF,
3.13 mL, 6.25 mmol, 2.5 eq.) was added dropwise. The resulting brownish solution
was stirred at -78 ◦C for 30 min. CS2 (166 µL, 209 mg, 2.75 mmol, 1.1 eq.) was
added dropwise at -78 ◦C and the red solution was stirred for 30 min, while the solu-
tion was warmed to ambient temperature. BnBr (326µL, 470 mg, 2.75 mmol, 1.1 eq.)
was added and the solution was stirred for 30 min. The mixture was quenched by the
addition of HOAc (1 mL) and the solvent was evaporated in vacuo. The crude prod-
uct was purified by column chromatography on silica gel using DCM/MeOH 95:5.
The desired product (35) (1.1 g, 1.95 mmol, 78%) was obtained as an orange solid.
1H-NMR (300 MHz, CD3OD): δ = 7.45-7.16 (m, 5 H, Phenyl-H), 5.64 (s, 1 H, H-5),
5.63 (d, J = 1.3 Hz, 1 H, H-1’), 5.21 (dd, J = 6.4, 1.3 Hz, 1 H, H-2’), 4.76 (dd, J = 6.4,
4.3 Hz, 1 H, H-3’), 4.65 (s, 2 H, CH2), 4.01 (td, J = 6.4, 4.3 Hz, 1 H, H-4’), 3.80
(dd, J = 6.4, 2.0 Hz, 2 H, H-5’), 1.42 (s, 3 H, CH3), 1.30 (s, 3 H, CH3), 0.89 (s, 9 H,
SiC(CH3)3), 0.05 (s, 3 H, Si(CH3)2) ppm.
13C-NMR (125 MHz, CD3OD): δ = 218.8 (CSSR), 164.5 (C-4), 163.2 (COOH),
158.1 (C-2), 151.4 (C-6), 135.1, 130.4, 129.9, 129.2 (Phenyl-C), 114.8 (C(CH3)),
101.5 (C-5), 94.2 (C-1’), 90.9 (C-4’), 85.7 (C-2’), 83.5 (C-3’), 65.3 (C-5’), 42.3
(CH2), 27.6 (CH3), 26.4 (SiC(CH3)3), 25.6 (CH3), 19.2 (SiC(CH3)3), -4.9 Si(CH3),
-5.1 Si(CH3) ppm.




HRMS: m/z calc. for C26H36N2O6S2SiNa [M+Na]+: 587.1676, found: 587.1669.
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35 (696 mg, 1.23 mmol, 1.0 eq.) was dissolved in TFA/H2O (50:50 v/v, 20 mL)
and the solution was stirred at ambient temperature for 30 min. The solvents were
evaporated in vacuo. The desired product (36) (500 mg, 1.21 mmol, 98%) was ob-
tained as an orange solid.
1H-NMR (300 MHz, CD3OD): δ = 7.43-7.27 (m, 5 H, Phenyl-H), 5.64 (s, 1 H, H-
5), 5.46 (d, J = 3.5 Hz, 1 H, H-1’), 4.71 (dd, J = 6.2, 3.5 Hz, 1 H, H-2’), 4.64 (d,
J = 2.2 Hz, 2 H, CH2), 4.33 (t, J = 6.2 Hz, 1 H, H-3’), 3.85-3.60 (m, 3 H, H-4’, H-5’)
ppm.
MS (ESI): m/z (%) = 433.1 (80) [M+Na]+, 409.0 (50) [M-H]−.













































































































































































Under an argon atmosphere, 36 (200 mg, 487 µmol, 1.0 eq.) was suspended
in dry trimethylphosphate (2.5 mL) and was cooled to 0 ◦C. Phosphoroxychloride
(89 µL, 149 mg 974 µmol, 2.0 eq.) was added dropwise and the resulting solution
was stirred at 0 ◦C for 4 h and at ambient temperature for 20 h. The mixture was
quenched by the addition of aqueous NaHCO3 solution (6%, 1 mL) and the solvent
was evaporated in vacuo. The crude product was purified by ion exchange HPLC
using a linear gradient of TEAA in water at pH 7. The product (37) was obtained as
the triethylammonium salt.
MS (ESI): m/z (%) = 489.0 (100) [M-H]−.
HRMS: m/z calc. for C17H19N2O9S2P [M-H]−: 489.0197, found: 489.0196.
122
3.5. Synthesis of queuine
3.5. Synthesis of queuine














    Aceton, 1.5 h, rt
2. I2, TPP, Imidazole
    THF, 4 h, 50 °C




















































































































































To a stirred suspension of methyl α-D-galactopyranoside 137 (25 g, 129 mmol,
1.0 eq.) in acetone (450 mL) 2,2-dimethoxypropane (39,5 mL, 233 mmol, 2.5 eq.)
and camphor sulfonic acid (5 mol%, 1.5 g, 6.45 mmol) were added and the resulting
solution was stirred for 2 h at ambient temperature. After addition of NEt3 (3 mL)
the mixture was evaporated in vacuo and the resulting residue was redissolved in
THF (900 mL). Triphenylphosphine (50.75 g, 194 mmol, 1.5 eq.) and imidazole
(17.6 g, 258 mmol, 2.0 eq.) were added and the solution was heated to 50 ◦C.
Subsequently a solution of iodine (49.2 g, 194 mmol, 1.5 eq.) in THF (180 mL) was
added dropwise and the solution was stirred for 2.5 h at 50 ◦C. The solution was
cooled to ambient temperature and quenched with aqueous Na2S2O3 solution (10%,
600 mL). The layers were separated, and the aqueous layer was extracted with
EtOAc (3 × 200 mL). The combined organic layers were washed with sat. aqueous
NaCl solution (2 × 200 mL), dried over MgSO4 and the solvents were evaporated
in vacuo. The crude product was purified by column chromatography on silica gel
using pentane/EtOAc 1:1. The desired product 139 (27.9 g, 81.1 mmol, 63% over
two steps) was obtained as a white solid.
1H-NMR (300 MHz, CDCl3): δ = 4.68 (d, J = 3.9 Hz, 1 H, H-1), 4.25-4.17 (m, 2 H,
H-3, H-4), 4.08-4.00 (m, 1 H, H-5), 3.81-3.75 (m, 1 H, H-2), 3.43 (s, 3 H, OCH3),
3.30-3.17 (m, 2 H, H-6, H-6’), 1.40 (s, 3 H, C(CH3)2), 1.26 (s, 3 H, C(CH3)2) ppm.
13C-NMR (125 MHz, CDCl3): δ = 109.7 (C(CH3)2), 98.2 (C-1), 75.8 (C-3), 73.5




MS (ESI): m/z (%) = 367.0 (100) [M+Na]+.
HRMS: m/z calc. for C10H17IO5Na [M+Na]+: 367.0013, found 367.0017.
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Under argon atmosphere, iodide 139 (10.0 g, 29.1 mmol, 1.0 eq.), imidazole
(2.38 g, 34.9 mmol, 1.2 eq.) and TBDMSCl (5.26 g, 34.9 mmol, 1.2 eq.) were
dissolved in dry DCM (120 mL) and the solution was stirred for 16 h at ambient
temperature. The reaction was quenched with water (100 mL). The layers were
separated and the organic layer was washed with water (2 × 60 mL) and sat. aque-
ous NaCl solution (60 mL), dried over MgSO4 and the solvents were evaporated in
vacuo. The crude product was purified by column chromatography on silica gel us-
ing pentane/EtOAc 95:5. The desired product 140 (11.35 g, 24.8 mmol, 85%) was
obtained as clear oil.
1H-NMR (300 MHz, CDCl3): δ = 4.59 (d, J = 3.6 Hz, 1 H, H-1), 4.29 (dd, J = 5.7,
2.4 Hz, 1 H, H-4), 4.19-4.08 (m, 2 H, 3 H, H-3), 3.74 (dd, J = 7.2, 3.6 Hz, 1 H,
H-2), 3.44 (s, 3 H, OCH3), 3.41-3.29 (m, 2 H, H-6, H-6’), 1.48 (s, 3 H, C(CH3)2), 1.34
(s, 3 H, C(CH3)2), 0.98 (s, 9 H, SiC(CH3)3), 0.10 (s, 3 H, Si(CH3)2), 0.08 (s, 3 H,
Si(CH3)2) ppm.
13C-NMR (125 MHz, CDCl3): δ = 109.2 (C(CH3)2), 100.2 (C-1), 76.9 (C-3), 74.0
(C-4), 71.2 (C-2), 68.6 (C-5), 55.8 (OCH3), 28.1 (C(CH3)2), 26.2 (C(CH3)2), 25.8
(SiC(CH3)3), 18.1 (SiC(CH3)3), 2.85 (C-6), 0.58 (Si(CH3)2), 0.75 (Si(CH3)2) ppm.
MS (ESI): m/z (%) = 481.1 (100) [M+Na]+.




































































































































































Galactopyranoside 140 (32.6 g, 71.2 mmol, 1.0 eq.) and was dissolved in THF/H2O
(9:1, v/v, 600 mL) and zinc powder (46.5 g, 710 mmol, 10.0 eq.) was added. The
suspension was stirred at 50 ◦C for 6 h. After cooling to ambient temperature, the
suspension was filtered through a silica plug and washed with Et2O (300 mL). The
organic layer was washed with water (200 mL), sat. aqueous NaHCO3 solution
(200 mL) and sat. aqueous NaCl solution (200 mL), dried over MgSO4 and the sol-
vents were evaporated in vacuo to give the desired product 141 (21.2 g, 70.6 mmol,
99%) as yellowish oil.
1H-NMR (300 MHz, CDCl3): δ = 9.67 (d, J = 0.9 Hz, 1 H, CHO), 5.92 (ddd,
J = 17.3, 10.4, 6.8 Hz, 1 H, H-5), 5.35, (dt, J = 17.3, 1.5 Hz, 1 H, H-6), 5.21 (dt,
J = 10.4, 1.5 Hz, 1 H, H-6’), 4.72 (t, J = 6.8 Hz, 1 H, H-4), 4.32 (dd, J = 6.8, 5.3 Hz,
1 H, H-3), 4.07 (dd, J = 5.3, 0.9 Hz, 1 H, H-2), 1.51 (s, 3 H, C(CH3)2), 1.35 (s, 1 H,
C(CH3)2), 0.92 (s, 9 H, SiC(CH3)3), 0.09 (d, J = 1.8 Hz, 6 H, Si(CH3)2) ppm.
13C-NMR (125 MHz, CDCl3): δ = 201.8 (CHO), 133.8 (C-5), 118.9 (C-6), 109.2
(C(CH3)2), 79.1 (C-3), 78.5 (C-4), 77.4 (C-2), 27.1 (C(CH3)2), 25.9 (SiC(CH3)3), 25.2
(C(CH3)2), 18.4 (SiC(CH3)3), -4.4 (Si(CH3)2), -4.7 (Si(CH3)2) ppm.
MS (ESI): m/z (%) = 323.2 (0.5) [M+Na]+.
HRMS: m/z calc. for C15H28O4SiNa [M+Na]+: 323.1649, found 323.1648.
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M: 300.5 g/mol M: 398.5 g/mol
Tebbe reagent


















































































































































Under an argon atmosphere, aldehyde 141 (21.2 g, 70.6 mmol, 1.0 eq.) was dis-
solved in dry THF (200 mL) and the solution was cooled to 0 ◦C. TEBBE REAGENT
(0.5 M in toluene, 200 mL, 100 mmol, 1.4 eq.) was added dropwise and the result-
ing solution was stirred at 0 ◦C for 30 min. Subsequently, Et2O (200 mL) was added
and water (12 mL) was added dropwise. The resulting suspension was dried over
MgSO4, filtered and the residue was washed with Et2O (100 mL). The solvents of
the combined organic layers were evaporated in vacuo and the resulting crude prod-
uct was purified by column chromatography on silica gel using pentane/EtOAc 95:5.
The desired product 142 (14.1 g, 47.1 mmol, 67%) was obtained as an orange oil.
1H-NMR (300 MHz, CDCl3): δ = 6.04-5.80 (m, 2 H, H-2, H-6), 5.41-5.12 (m, 4 H,
H-1, H-7), 4.48-4.41 (m, 1 H, H-5), 4.22-4.14 (m, 1 H, H-4), 4.02-3.95 (m, 1 H, H-
3), 1.50 (s, 3 H, C(CH3)2), 1.35 (C(CH3)2), 0.91 (s, 9 H, SiC(CH3)3), 0.09 (s, 3 H,
Si(CH3)2), 0.07 (s, 3 H, Si(CH3)2) ppm.
13C-NMR (125 MHz, CDCl3): δ = 136.9 (C-2), 134.8 (C-6), 118.7 (C-7), 116.6
(C-1), 108.7 (C(CH3)2), 82.0 (C-4), 79.2 (C-5), 72.7 (C-3), 28.0 (C(CH3)2), 26.0
(SiC(CH3)3), 25.7 (C(CH3)2), 18.6 (SiC(CH3)3), -4.4 (Si(CH3)2), -4.5 (Si(CH3)2) ppm.
MS (ESI): m/z (%) = 321.2 (14) [M+Na]+.































































































































































Under an argon atmosphere, diene 142 (942 mg, 3.10 mmol, 1.0 eq.) and GRUBBS
CATALYST, 1ST GEN. (2.5 mol%, 877.5 µmol, 64 mg) were dissolved in dry DCM
(10 mL) and the solution was stirred under reflux for 4 h. After cooling to ambient
temperature, the solvent was evaporated in vacuo and the resulting crude product
was purified by column chromatography on silica gel using pentane/EtOAc 3:1. The
desired product 145 (587 mg, 2.17 mmol, 70%) was obtained as brown oil.
1H-NMR (300 MHz, CDCl3): δ = 6.00 (d, J = 5.7 Hz, 1 H, H-1), 5.88 (dd, J = 5.7,
2.0 Hz, 1 H, H-4), 5.27 (dd, J = 5.6, 1.0 Hz, 1 H, H-3), 4.76 (s, 1 H, H-2), 4.49 (d,
J = 5.6 Hz, 1 H, H-5), 1.38 (s, 3 H, C(CH3)2), 1.33 (s, 3 H, C(CH3)2), 0.90 (s, 9 H,
SiC(CH3)3), 0.08 (s, 3 H, Si(CH3)2), 0.06 (s, 3 H, Si(CH3)2) ppm.
13C-NMR (125 MHz, CDCl3): δ = 135.5 (C-5), 134.8 (C-4), 111.8 (C(CH3)2), 86.0
(C-3), 84.4 (C-2), 81.1 (C-1), 27.4 (C(CH3)2), 25.8 (C(CH3)2), 18.6 (SiC(CH3)3), -4.4
(Si(CH3)2), -4.5 (Si(CH3)2) ppm.
MS (ESI): m/z (%) = 315.2 (4) [M+HCOO]−.
HRMS: m/z calc. for C14H26O3SiHCOOa [M+HCOO]−: 315.1640, found 315.1633.
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Diene 142 (13.6 g, 45.6 mmol, 1.0 eq.) was dissolved in THF (500 mL) and a
solution of TBAF·3 H2O (28.8 g, 91.2 mmol, 2.0 eq.) in THF (100 mL) was added
dropwise. The solution was stirred for 2.5 h at ambient temperature. The solvent
was evaporated in vacuo and the resulting crude product was purified by column
chromatography on silica gel using pentane/EtOAc 5:1. The desired product 143
(8.12 g, 44.1 mmol, 97%) was obtained as yellow oil.
1H-NMR (300 MHz, CDCl3): δ = 6.07-5.93 (m, 1 H, H-2), 5.90-5.77 (m, 1 H, H-6),
5.44-5.17 (m, 4 H, H-1, H-7), 4.63-4.55 (m, 1 H, H5), 4.16-4.04 (m, 2 H, H-4, H-3),
1.52 (s, 3 H, C(CH3)2), 1.38 (s, 3 H, C(CH3)2) ppm.
13C-NMR (125 MHz, CDCl3): δ = 136.8 (C-2), 134.1 (C-6), 119.5 (C-7), 117.2
(C-1), 108.1 (C(CH3)2), 80.8 (C-4), 79.7 (C-5), 70.7 (C-3), 27.5 (C(CH3)2), 25.1
(C(CH3)2) ppm.
MS (ESI): m/z (%) = 207.1 (7) [M+Na]+.









M: 184.2 g/mol M: 156.2 g/mol
Grubbs 2nd gen.
catalyst, DCM




















































































































































Under an argon atmosphere, diene 143 (8.12 g, 44.1 mmol, 1.0 eq.) and GRUBBS
CATALYST, 2ND GEN. (2.3 mol%, 848 mg, 1.0 eq.) were dissolved in dry DCM
(200 mL) and the solution was stirred under reflux for 1 h. After cooling to ambient
temperature, the solvent was evaporated in vacuo and the resulting crude product
was purified by column chromatography on silica gel using pentane/EtOAc 2:1. The
desired product 130 (5.2 g, 32.7 mmol, 74%) was obtained as brown oil.
1H-NMR (300 MHz, CDCl3): δ = 6.00 (d, J = 5.7 Hz, 1 H, H-1), 5.88 (dd, J = 5.7,
2.0 Hz, 1 H, H-4), 5.27 (dd, J = 5.6, 1.0 Hz, 1 H, H-3), 4.76 (s, 1 H, H-2), 4.49 (d,
J = 5.6 Hz, 1 H, H-5), 1.38 (s, 3 H, C(CH3)2), 1.33 (s, 3 H, C(CH3)2) ppm.
13C-NMR (125 MHz, CDCl3): δ = 135.5 (C-5), 134.8 (C-4), 111.8 (C(CH3)2), 86.0
(C-3), 84.4 (C-2), 81.1 (C-1), 27.4 (C(CH3)2), 25.8 (C(CH3)2) ppm.
MS (ESI): m/z (%) = 179.1 (4) [M+Na]+.
HRMS: m/z calc. for C8H12O3Na [M+Na]+: 179.0679, found 179.0678.
130
3.5. Synthesis of queuine
3.5.8. (1R,2S,3S)-1-Bromo-2,3- O-isopropylidene-cyclopent-4-
ene (122)
O O O O
76%
M: 156.2 g/mol M: 219.1 g/mol
Br2, TPP, imidazole




















































































































































Triphenylphosphine (16.1 g, 61.4 mmol, 2.0 eq.) was dissolved in DCM (300 mL)
and cooled to -10 ◦C. A solution of bromine (3.1 mL, 61.4 mmol, 2.0 eq.) in DCM
(20 mL) was added dropwise. The resulting solution was added slowly to a solu-
tion of alcohol 130 (4.8 g, 30.7 mmol, 1.0 eq.) and imidazole (2.3 g, 33.8 mmol,
1.1 eq.) in DCM (150 mL) at -10 ◦C. The reaction mixture was stirred at -10 ◦C for
45 min, then allowed to reach ambient temperature and Et2O (300 mL) was added.
The resulting organic solution was washed with water (2 × 300 mL) and sat. aque-
ous NaCl solution (300 mL), dried over MgSO4 and the solvents were evaporated
in vacuo. The residue was dissolved in DCM (10 mL) and hexane (500 mL) was
added. The resulting suspension was filtered, and the filtrate was concentrated in
vacuo. The residue was suspended in hexane (150 mL) and filtered. The filtrate
was concentrated in vacuo and the resulting crude product purified by column chro-
matography on silica gel using pentane/EtOAc 95:5. The desired product 122 (5.1 g,
23.3 mmol, 76%) was obtained as colorless oil.
1H-NMR (300 MHz, CDCl3): δ = 6.01-5.97 (m, 1 H, H-5), 5.97-5.93 (m, 1 H, H-4),
5.32 (d, J = 5.4 Hz, 1 H, H-3), 4.96 (d, J = 5.4 Hz, 1 H, H-2), 4.86-4.82 (m, 1 H,
H-1), 1.38 (s, 3 H, C(CH3)2), 1.34 (s, 3 H, C(CH3)2) ppm.
13C-NMR (125 MHz, CDCl3): δ = 135.1 (C-5), 134.2 (C-4), 112.2 (C(CH3)2), 86.0
(C-3), 84.1 (C-2), 54.5 (C-1), 27.5 (C(CH3)2), 26.3 (C(CH3)2) ppm.
MS (ESI): m/z (%) = 241.0 (7) [M+Na]+.






M: 219.1 g/mol M: 317.3 g/mol
preQ1, DBU, DMF


























































































































































Under an argon atmosphere, preQ1 (58) (1.0 g, 4.0 mmol, 1.0 eq.) was dissolved
in DMF (15 mL). DBU (6.0 mL, 40.0 mmol, 10.0 eq.) was added and the solu-
tion was stirred at 50 ◦C for 15 min. A solution of bromocyclopentene 122 (1.1 g,
4.8 mmol, 1.2 eq.) in DMF (3 mL) was added dropwise and the solution was stirred
at 50 ◦C for 5 h. After cooling to ambient temperature, the solvent was evaporated
in vacuo and the residue was purified by column chromatography on silica gel using
EtOAc/MeOH/NEt3 3:1:0.1. The resulting crude product was suspended in CHCl3
(100 mL) and stirred for 10 min. The solid components were separated by filtration
and suspended in methanol (30 mL). The suspension was filtered, and the filtrate
was concentrated in vacuo to yield the desired product 144 (581 mg, 1.64 mmol,
41%) as a slightly yellow solid.
1H-NMR (300 MHz, CD3OD): δ = 6.90 (s, 1 H, H-8), 6.30 (dt, J = 5.9, 1.7 Hz,
1 H, H-5’), 6.01 (d, J = 5.9 Hz, 1 H, H-4’), 5.36 (d, J = 5.8 Hz, 1 H, H-3’), 4.94 (d,
J = 5.7 Hz, 1 H, H-2), 4.49-4.29 (m, 3 H, H-1’, H2-10), 1.37 (s, 3 H, C(CH3)2), 1.36
(s, 3 H, C(CH3)2) ppm.
MS (ESI): m/z (%) = 318.2 (100) [M+H]+, 340.2 (4) [M+Na]+.
HRMS: m/z calc. for C15H20N5O3Na [M+Na]+: 318.1561, found 318.1562.
132
3.5. Synthesis of queuine
3.5.10. Queuine (95)
96%



































































































































































2’,3’-O-Isopropylidene-queuine (144) (581 mg, 1.64 mmol, 1.0 eq.) was dissolved
in methanol (60 mL) and conc. HCl solution (5 mL) was added. The solution was
stirred under reflux for 2 h. After cooling to ambient temperature, the resulting sus-
pension was concentrated in vacuo to yield queuine (95) (544 mg, 1.57 mmol, 96%)
as a slightly yellow solid.
1H-NMR (300 MHz, CD3OD): δ = 7.04 (s, 1 H, H-8), 6.28 (dt, J = 6.3, 2.2 Hz, 1 H,
H-5’), 6.10 (dd, J = 6.3, 1.7 Hz, 1 H, H-4’), 4.71-4.65 (m, 1 H, H-3’), 4.55-4.25 (m,
4 H, H-2’, H-1’, H2-10) ppm.
13C-NMR (125 MHz, CD3OD): δ = 161.8 (C-6), 152.6 (C-2), 146.6 (C-4), 138.9
(C-4’), 129.8 (C-5’), 121.0 (C-7), 109.8 (C-8), 99.9 (C-5), 74.7 (C-3’), 74.0 (C-2’),
87.8 (C-1’), 42.6 (C-10) ppm.
MS (ESI): m/z (%) = 278.1 (95) [M+H]+, 276.1 (100) [M-H]−, 312.1 (75) [M+Cl]−.
HRMS: m/z calc. for C12H15N5O3Na [M+Na]+: 300.1067, found 300.1063.
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3. Experimental section












M: 390.3 g/mol M: 270.3 g/mol
1. BF3  OEt2
    BnOH, molecular sieves
    DCM, 20 h, rt
2. NaOMe, MeOH




















































































































































β-D-Galactose-pentaacetate (131) (10.0 g, 25.4 mmol, 1.0 eq.) was dissolved in
DCM (100 mL) and benzylalcohol (3.5 mL, 33.2 mmol, 1.3 eq.) and molecular sieves
(4 Å, 10.0 g) were added. Subsequently, BF3·OEt2 (6.5 mL, 51.0 mmol, 2.0 eq.) was
added dropwise at 0 ◦C. The solution was stirred for 20 h at ambient temperature
and neutralized with NEt3. The organic solution was washed with water (3 × 70 mL)
dried over MgSO4 and the solvent was evaporated in vacuo. The crude residue
was redissolved in methanol (300 mL) and NaOMe (2.0 g) was added. The solution
was stirred for 20 h at ambient temperature and neutralized with DOWEX 50 W. The
solids were filtered off and the solvent was evaporated in vacuo. The resulting crude
product was purified by column chromatography on silica gel using DCM/MeOH 9:1.
The desired product 132 (3.72 g, 13.8 mmol, 54%) was obtained as an orange resin.
1H-NMR (300 MHz, DMSO-d6): δ = 7.43-7.20 (m, 5 H, Ph), 4.82 (d, J = 12.3 Hz,
1 H, CH2Ph), 4.85 (d, J = 12.3 Hz, 1 H, CH2Ph), 4.21 (d, J = 7.5 Hz, 1 H, H-1), 3.68
(d, J = 3.2 Hz, 1 H, H-4), 3.58 (d, J = 2.2 Hz, 1 H, H-6a), 3.56 (d, J = 2.2 Hz, 1 H,
H-6b), 3.45-3.27 (m, 3 H, H-5, H-3, H-2) ppm.
13C-NMR (125 MHz, DMSO-d6): δ = 138.3, 128.2, 127.2, 127.4 (Ph), 102.8 (C-1),
75.4 (C-3), 73.6 (C-2), 70.8 (C-5), 69.6 (CH2Ph), 68.3 (C-4), 60.7 (C-6) ppm.
MS (ESI): m/z (%) = 293.2 (100) [M+Na]+.
HRMS: m/z calc. for C13H18O6Na [M+Na]+: 293.0996, found 293.0996.
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132 (3.72 g, 13.8 mmol, 1.0 eq.) and TBDMSCl (2,29 g, 15.2 mmol, 1.1 eq.)
were suspended in DCM (90 mL) and stirred for 30 min at ambient temperature.
The suspension was cooled to 0 ◦C and DBU (2.7 mL, 15.2 mmol, 1.1 eq.) in DCM
(15 mL) was added dropwise. The resulting solution was stirred for 20 h at ambient
temperature. The solvent was evaporated in vacuo and the resulting crude product
was purified by column chromatography on silica gel using DCM/MeOH 95:5. The
desired product 133 (3.46 g, 9.01 mmol, 65%) was obtained as a white sticky solid.
1H-NMR (300 MHz, CDCl3): δ = 7.37-7.21 (m, 5 H, Ph), 4.85 (d, J = 11.7 Hz, 1 H,
CH2Ph), 4.56 (d, J = 11.7 Hz, 1 H, CH2Ph), 4.23 (d, J = 7.8 Hz, 1 H, H-1), 3.90-3.77
(m, J = 3.2 Hz, 2 H, H-4, H-6a), 3.69 (dd, J = 9.6, 7.8 Hz, 1 H, H-6b), 3.47-3.31 (m,
3 H, H-5, H-3, H-2), 0.89 (s, 9 H, C(CH3)2), 0.07 (s, 6 H, Si(CH3)2) ppm.
13C-NMR (125 MHz, CDCl3): δ = 137.2, 128.6, 128.5, 128.0 (Ph), 102.0 (C-
1), 75.0 (C-3), 73.8 (C-2), 71.8 (C-5), 70.9 (CH2Ph), 69.1 (C-4), 62.7 (C-6), 26.0
(C(CH3)3), 18.4 (C(CH3)3), -5.2 (Si(CH3)2), -5.2 (Si(CH3)2) ppm.
MS (ESI): m/z (%) = 407.3 (100) [M+H]+.
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Dnmt Desoxyribonucleic acid methyltransferase






hOMPD Human orotidine-5’-monophosphate decarboxylase domain.
HPLC High performance liquid chromatography
















































B. Crystal data collection and refinement data
B. Crystal data collection and refinement data
’
Data collection of hOMPDwt crystals in complex with BMP
Wavelength (Å) 0.7563
Resolution range (Å) 30.3 - 0.95 (0.984 - 0.95)
Space group C2221
Unit cell (Å) / (◦) 77.896 116.425 61.968 / 90 90 90
Total reflections 619037 (52593)
Unique reflections 171326 (17215)
Multiplicity 3.6 (3.1)
Completeness (%) 97.14 (98.27)









Model refinement of hOMPDwt-BMP-complex data
Reflections used in refinement 171183 (17204)












Ramachandran favored (%) 98.81
Ramachandran allowed (%) 1.19
Ramachandran outliers (%) 0.00







B. Crystal data collection and refinement data
Data collection of hOMPDwt crystals in complex with 6-aza-UMP
Wavelength (Å) 0.7293
Resolution range (Å) 42.46 - 1.0 (1.036 - 1.0)
Space group C2221
Unit cell (Å) / (◦) 77.67 116.572 61.97 / 90 90 90
Total reflections 568265 (56287)
Unique reflections 147558 (14770)
Multiplicity 3.9 (3.8)
Completeness (%) 97.69 (98.79)









Model refinement of hOMPDwt-6-aza-UMP-complex data
Reflections used in refinement 147554 (14767)












Ramachandran favored (%) 98.81
Ramachandran allowed (%) 1.19
Ramachandran outliers (%) 0.00







B. Crystal data collection and refinement data
Data collection of hOMPDwt crystals in complex with 6-amido-UMP
Wavelength (Å) 0.9763
Resolution range (Å) 42.47 - 1.2 (1.243 - 1.2)
Space group C2221
Unit cell (Å) / (◦) 77.735 116.302 62.174 / 90 90 90
Total reflections 569885 (46920)
Unique reflections 85218 (7891)
Multiplicity 6.7 (5.9)
Completeness (%) 96.80 (90.55)









Model refinement of hOMPDwt-6-amido-UMP-complex data
Reflections used in refinement 85217 (7891)












Ramachandran favored (%) 98.41
Ramachandran allowed (%) 1.59
Ramachandran outliers (%) 0.00







B. Crystal data collection and refinement data
Data collection of hOMPDwt crystals in complex with 6-thioamido-UMP
Wavelength (Å) 0.9763
Resolution range (Å) 42.42 - 1.124 (1.164 - 1.124)
Space group C2221
Unit cell (Å) / (◦) 77.461 116.105 62.13 / 90 90 90
Total reflections 636400 (26827)
Unique reflections 102727 (7283)
Multiplicity 6.2 (3.7)
Completeness (%) 96.66 (69.28)









Model refinement of hOMPDwt-6-thioamido-UMP-complex data
Reflections used in refinement 102725 (7283)












Ramachandran favored (%) 98.81
Ramachandran allowed (%) 1.19
Ramachandran outliers (%) 0.00







B. Crystal data collection and refinement data
Data collection of hOMPDwt crystals in complex with 6-methyl-UMP
Wavelength (Å)
Resolution range (Å) 42.5 - 1.122 (1.162 - 1.122)
Space group C2221
Unit cell (Å) / (◦) 77.375 116.687 62.027 / 90 90 90
Total reflections 618960 (24690)
Unique reflections 104066 (7617)
Multiplicity 5.9 (3.2)
Completeness (%) 97.07 (71.93)









Model refinement of hOMPDwt-6-methyl-UMP-complex data
Reflections used in refinement 104065 (7617)












Ramachandran favored (%) 98.81
Ramachandran allowed (%) 1.19
Ramachandran outliers (%) 0.00







B. Crystal data collection and refinement data
Data collection of hOMPDwt crystals in complex with 6-isopropyl-UMP
Wavelength (Å) 0.9763
Resolution range (Å) 64.52 - 1.3 (1.346 - 1.3)
Space group C2221
Unit cell (Å) / (◦) 77.562 116.28 62.075 / 90 90 90
Total reflections 447839 (44961)
Unique reflections 69057 (6840)
Multiplicity 6.5 (6.6)
Completeness (%) 99.75 (99.50)









Model refinement of hOMPDwt-6-isopropyl-UMP-complex data
Reflections used in refinement 69056 (6821)












Ramachandran favored (%) 98.01
Ramachandran allowed (%) 1.99
Ramachandran outliers (%) 0.00







B. Crystal data collection and refinement data
Data collection of hOMPDwt crystals in complex with 6-isopropenyl-UMP
Resolution range (Å) 44.97 - 1.15 (1.191 - 1.15)
Space group P1211
Unit cell (Å) / (◦) 70.772 61.972 69.464 / 90 112.578 90
Total reflections 668931 (66385)
Unique reflections 192202 (19047)
Multiplicity 3.5 (3.5)
Completeness (%) 97.86 (97.51)









Model refinement of hOMPDwt-6-isopropenyl-UMP-complex data
Reflections used in refinement 192186 (19047)












Ramachandran favored (%) 97.82
Ramachandran allowed (%) 2.18
Ramachandran outliers (%) 0.00







B. Crystal data collection and refinement data
Data collection of hOMPD314AcK crystals in complex with OMP
Wavelength (Å) 0.8266
Resolution range (Å) 44.67 - 1.2 (1.243 - 1.2)
Space group C2221
Unit cell (Å) / (◦) 77.285 116.819 61.951 / 90 90 90
Total reflections 596481 (59213)
Unique reflections 87507 (8673)
Multiplicity 6.8 (6.8)
Completeness (%) 99.85 (99.88)









Model refinement of hOMPD314AcK-OMP-complex data
Reflections used in refinement 87501 (8672)












Ramachandran favored (%) 98.79
Ramachandran allowed (%) 1.21
Ramachandran outliers (%) 0.00







B. Crystal data collection and refinement data
Data collection of hOMPD314AcK crystals in complex with BMP
Wavelength (Å)
Resolution range (Å) 44.72 - 1.1 (1.139 - 1.1)
Space group C2221
Unit cell (Å) / (◦) 77.386 116.838 62.036 / 90 90 90
Total reflections 766064 (74211)
Unique reflections 113656 (11263)
Multiplicity 6.7 (6.6)
Completeness (%) 99.88 (99.90)









Model refinement of hOMPD314AcK-BMP-complex data
Reflections used in refinement 113650 (11261)












Ramachandran favored (%) 98.79
Ramachandran allowed (%) 1.21
Ramachandran outliers (%) 0.00








First and foremost I would like to thank Prof. Dr. Ulf Diederichsen for giving me
the opportunity to work on these highly interesting research topics at the interface
of organic chemistry and biology. Thank you for the academic freedom and all the
great support.
Thank you to Prof. Dr. Kai Tittmann for being part of the thesis committee and
acting as second referee. Your knowledge in the field of enzymology and crystallog-
raphy were very helpful and I enjoyed our discussion on the sometimes confusing
data.
Moreover, I would like to thank the further members of the examination board
Prof. Dr. Manuel Alcarazo, Prof. Dr. Claudia Steinem, Dr. Sebastian Kruss and Dr.
Michael John.
Sören thank you for the close cooperation on the OMPD project. You made it al-
ways possible to measure new inhibitor samples even on the tightest schedules and
the structure resolution was always impressing. Sven thank you for your patience
during the queuine synthesis.
I thank my Bachelor student Marcel and my lab intern Isabelle for the support on
the inhibitor synthesis. You did excellent work.
Thank you to the Central Analytics team for the measurement of a multitude of
mass spectra and to the NMR facility for the acquisition of NMR spectra.
To all members of the Diederichsen group, especially to my colleagues from lab
106, Patrick Menzel, Dr. Stephen Middel, Nils Frederik Meyer, Lina Kopp, Lucas
Hensen, Simon Pottgießer and Manuel Müller, thank you for the great time. I al-
ways enjoyed being part of this group, the kicker competitions and our funny coffee
breaks. To Patrick, Tobi, Pira and Markus, you made fantasy football great again.
A big thank you goes to the proofreaders of this thesis. Mike, Patrick, Tobi and
Pira your comments were highly appreciated.
Furthermore, I would like to thank Angela Heinemann and Aiofe Neville for all the
organizational support. The office was always a helpful place. And to "Mrs. Heine-
mann" thank you for a little "kick in the ass" when necessary.
Most notably I would like to thank my parents for all their moral and financial sup-
port from the start of my Bachelor studies to the last line of this thesis. Without you
none of this would have been achievable.
Carina you helped me through the hardest times of this work and built me up,
when I wanted to quit. You make my life brighter and I am glad your are always by
my side.
And last but not least I would like to thank all my family and friends for the great
time. I am fortunate to have you around me.
